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Abstract 
 
Oncolytic adenoviral mutants have demonstrated good safety profiles but, despite some 
encouraging clinical results, efficacy as a single agent was limited. Combinations with 
conventional chemo- or radiotherapy significantly enhanced the anti-tumour effect.  
 
We investigated the possibility of enhancing prostate cancer (PCa) cell killing using 
adenovirus type 5 (Ad5) with phytochemicals. Phytochemicals are chemopreventive and can 
modulate intracellular signalling pathways, including the mitogen-activated protein kinase 
(MAPK) pathway which regulates the expression of the coxsackie-adenovirus receptor (CAR).  
 
Equol and resveratrol synergistically enhanced cell death in both androgen receptor (AR)-
positive and AR-negative PCa cell lines. On the other hand, curcumin, epigallocatechin-gallate 
(EGCG) and genistein had either synergistic and antagonistic responses with Ad5, depending 
on the dose and timing of addition. We therefore decided not to pursue the use of these 
compounds.  
 
Although we found that equol and resveratrol increased adenoviral receptor expression and 
viral uptake, this was not paralleled by enhanced viral replication. Treatment of DU145 and 
PC-3 cells with equol or resveratrol decreased viral titres, but did not block cell cycle 
progression. E1A expression in these cells was lower at 18h post-infection, but levels were 
normal by 72h. The exact mechanism behind the repression of adenovirus replication remains 
unclear.  
 
Equol and resveratrol induced moderate apoptotic responses. Mitochondrial membrane 
depolarization and caspase-3 activation were further increased by the addition of Ad5 in 
DU145 and PC-3 cells, but was reduced in 22Rv-1 cells. Caspase inhibition could not prevent 
sensitisation of 22Rv-1 cells to combination-induced cell death. The involvement of additional 
cell death mechanisms was therefore considered. Equol and resveratrol triggered autophagy 
while Ad5 acted as an autophagy repressor. Modulation of autophagy using pharmacological 
inducers and repressors indicates that autophagy may play a protective role in AR-negative 
cell lines.  
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1 Introduction 
1.1 Prostate cancer 
1.1.1 Etiology 
Prostate cancer (PCa) is the most common cancer in men worldwide after lung cancer (Ferley 
et al., 2004). Around 30,000 cases are diagnosed in the UK each year and a third of all patients 
die from it. Prostate cancer incidence increases with age. Prevalence among men in their 50’s 
is 30% but this increases to 80% among those in their 70’s (Breslow et al., 1977). Prostate 
cancer can often be detected by autopsy in elderly men having died of other causes. This 
reflects the disease’s slow progression and demonstrates its high prevalence in Western 
countries.    
 
The incidence and mortality for prostate cancer vary widely across different regions of the 
world (Damber & Aus, 2008). Incidence is lowest in Asia, whereas it is high in Europe and 
North America. Autopsy studies have revealed that the incidence of ‘latent’ carcinoma does 
not differ significantly from country to country. Although the frequency and accuracy of 
diagnosis may vary across the globe, it is thought that the differences in PCa incidence do not 
reflect differences in initiation but rather differences in exposure to environmental factors that 
affect the conversion of histopathologically apparent lesions to clinically-relevant tumours 
(Dewailly et al., 2003). The worldwide variation in PCa incidence is also linked to individual 
genetic background that render men more or less susceptible to protective or risk factors. The 
Multiethnic Cohort (MEC) Study found that the risk of PCa is approximately double in 
African-American men compared to their Caucasian counterparts (Kolonel et al., 2004). 
Prostate cancer susceptibility has recently been linked to genetic variants on chromosome 
8q24, although the genes encoded by this region are currently unknown (Gudmundsson et al., 
2007).  
 
Apart from age and ethnic background, the only other well-established risk factor for PCa is 
family history. Almost a quarter of prostate cancers occurs in family clusters, so men with a 
first degree relative affected by prostate cancer are twice to three times as likely to suffer from 
the disease. About 9% PCa cases can be attributed to hereditary PCa and segregation analyses 
suggest that this is at least partly due to the inheritance of an autosomal dominant 
susceptibility trait (Shand & Gelmann, 2006). Genetic polymorphisms have also been reported 
in several genes such as those encoding the androgen receptor (AR), 5α-reductase and steroid 
hydroxylase, which are involved in androgen metabolism.  
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Environmental factors also contribute to PCa initiation. This is supported by the observation 
that Japanese men living in the USA have a higher risk of developing PCa compared to their 
counterparts living in Japan, a country which traditionally has very low rates of PCa, although 
the numbers are increasing as lifestyles become more ‘Westernised’ (Sim & Cheng, 2005). A 
high intake of saturated fats has been correlated with an increased risk of PCa, which may 
account for the high incidence in Western countries, where people consume more food 
products rich in saturated fats. Other risk factors are vitamin D deficiency and high plasma 
levels of insulin-like growth factor-1 (IGF-1). Protective habits include a high soy intake, 
which is part of the traditional Asian diet, and a diet rich in tomatoes, which are a source of 
lycopene (Kurahashi et al., 2007; Sonn et al., 2005).  
 
1.1.2 Diagnosis 
In many Western countries, including the USA, screening programmes are in place for men 
above 50 to detect PCa at the earliest possible stage. Screening is usually done by determining 
serum levels of prostate-specific antigen (PSA), which is a biomarker for PCa progression. In 
the UK, patients with a family history of PCa can be offered a PSA test, and symptomatic 
patients can also be diagnosed by digital rectal examination (DRE) to determine local staging 
(T staging) and enable estimation of the presence of extracapsular extension of the tumour.  
 
Following a positive PSA test (usually PSA > 4ng/ml), patients may be advised to undergo a 
biopsy to evaluate the cancer grade (Damber & Aus, 2008). The most commonly used system 
is the Gleason score. The score of a tumour is the sum of the two most common histological 
patterns (grades 1-5) of tumour growth and can range from 2 (least aggressive) to 10 (most 
aggressive). 
 
If the patient does not suffer from additional symptoms and is in the ‘low risk’ group (PSA 
<10ng/ml, Gleason score < 5, disease stage T1c-2a) or if the patient’s natural life expectancy 
<10 years, the recommended cancer management strategy is commonly ‘active surveillance’. 
This simply involves close monitoring for any further increases in PSA levels or prostate size, 
as, at this stage, the risks of surgery or radiation out-weigh the benefits.  
 
1.1.3 Treatment of locally-restricted PCa 
Men with poorly differentiated tumours and short PSA doubling-time, especially those with a 
longer life expectancy, are offered treatment with a curative intent. Prostatectomy is highly 
effective for locally restricted cancer and reduces PSA to non-detectable levels. Alternatively, 
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radiotherapy is also effective in reducing PSA levels. Novel delivery routes have been 
developed to minimise damage to surrounding tissue, including Intensity-Modulated Radiation 
Therapy (IMRT), Image-Guided Radiation Therapy (IGRT) and brachytherapy.  
 
Patients with extracapsular extensions of the tumour can be offered high-dose radiotherapy, 
often in combination with hormonal therapy, but are less likely to benefit from radical 
prostatectomy due to the difficulties in obtaining a disease-free margin of resection. 
 
1.1.4 Treatment of advanced hormone-responsive PCa 
If the cancer is not detected during its early stage, it commonly metastasizes to the lymph 
nodes and then to the vertebrae, pelvis or ribs, causing acute bone pain, requiring second-line 
treatment. Therapy for advanced, metastatic PCa initially involves hormonal treatment, 
followed by combinations of radiotherapy and/or chemotherapy. Patients whose PSA levels 
continue to rise after primary surgery and/or radiotherapy are also give hormone therapy, 
although if there are no symptoms and the rise in PSA occurs more than a year after initiation 
of treatment with a long PSA doubling-time, providing that the cancer was not aggressive on 
presentation (Gleason score < 8), active surveillance may offer the best quality of life. All 
treatments cause significant side effects and choice of therapy therefore depends on prognosis, 
patient life expectancy and their general health. 
 
Effective treatment for metastatic cancer by ‘chemical castration’ was developed in the 1950s 
by Charles Huggins, using the xenoestrogen diethylstilbestrol (DES) to inhibit the synthesis of 
androgens via inhibition of the hypothalmamic-pituitary axis.  
 
The theory behind hormonal treatment is based on the requirement of prostate cells for 
androgen stimulation via the androgen receptor (AR), without which these cells stop 
proliferating and die. Androgens are secreted by the testes, the adrenal glands and the prostate 
itself. The main androgen hormone is testosterone, which can be converted by 5-α-reductase to 
dihydrotestosterone (DHT) in prostate cells. DHT has a higher affinity for the AR than 
testosterone and is more potent.  
 
Androgen production is regulated by endocrine stimulation from the hypothalamus via the 
pituitary gland (Figure 1). Gonadotrophin releasing hormone (GnRH) is normally released in 
pulses from the hypothalamus, stimulating pulsatile release of follicle-stimulating hormone 
(FSH) and luteinising hormone (LH), the latter stimulating production of testosterone by the 
Leydig cells in the testes.  
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In order to abort prostate cancer growth, GnRH agonists (eg: goserelin, leuprolide) can be used 
to inhibit downstream stimulation of testosterone production (Hellerstedt & Pienta, 2002; 
Miyamoto et al., 2004). These drugs initially trigger a surge in FSH and LH (the ‘flare effect’), 
but the long-term result is a down-regulation of the GnRH receptor in the pituitary, reduced 
FSH and LH, and a concomitant decrease in testosterone production. The flare effect can be 
avoided using GnRH antagonists (eg: abarelix) to directly inhibit GnRH. The hormonal loop 
can also be interrupted with nonsteroidal antiandrogens (eg: flutamide, bicalutamide) which 
interact directly with the AR and competitively inhibit binding by androgens. However, 10% 
of circulating testosterone remains if antiandrogens are used as monotherapy, due to the 
conversion of adrenal steroids to testosterone. It is therefore common to treat patients with 
combined androgen blockade (CAB) with a GnRH agonist plus a nonsteroidal antiandrogen, 
although this is associated with more significant side-effects. If the patient experiences spinal 
cord compression and bone pain, they may be offered orchidectomy to abolish circulating 
testosterone levels as quickly as possible. Androgen ablation therapy may also be prescribed 
before (neoadjuvant) or after (adjuvant) prostatectomy or radiotherapy (Miller et al., 2009).  
 
 
Figure 1 Androgen hormonal feedback 
Stimulation shown by arrows, negative feedback represented by dashed lines. Hormones shown in 
green, gonadotrophin releasing-hormone (GnRH), luteinising hormone (LH), follicle-stimulating hormone 
(FSH), adrenocorticotrophic hormone (ACTH). Hormone ablation drugs shown in pink.  
 
Hormone ablation therapy causes various side-effects including loss of libido, cardiovascular 
events, hot flushes, osteoporosis, impotence, gynecomastia, weight gain, fatigue, anaemia, 
muscle atrophy and loss of cognitive function (Hellerstedt & Pienta, 2002). The combination 
of an oestrogen with a GnRH agonist may reduce these effects. Antiandrogens are associated 
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with rare but occasionally fatal hepatotoxicity and patients with pre-existing liver conditions 
should therefore be carefully monitored. 
 
1.1.5 Progression to androgen-resistance 
In around 15% of patients, mostly those with high-grade metastatic tumours, hormone ablation 
therapy does not produce any clinically meaningful response (Hamdy & Thomas, 2001). In 
responsive patients, androgen blockade results in a rapid inhibition of growth, followed by 
tumour regression. Serum PSA levels are rapidly reduced and cancer-related symptoms are 
decreased. However, the selection pressure of androgen starvation results in clonal expansion 
of androgen resistant cells from the initial heterogenous cancer cell population (Craft et al., 
1999; Tso et al., 2000). This inevitable progression to hormone-refractory prostate cancer 
(HRPC) occurs within 18 – 24 months after beginning hormone therapy.  
 
The most common hypothesis postulated to explain this is that a pre-existing abnormal AR is 
clonally selected. An equally valid hypothesis is that cancer treatments create conditions 
favouring the development of AR mutations which provide a survival advantage to the PCa 
cells, allowing their propagation. These explanations are not mutually exclusive. In addition, 
PCa cells develop AR-independent stimulatory pathways involving stimulation by growth 
factors and anti-apoptotic feedback, weaning the cells off the need for androgen stimulation 
(Figure 2).  
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Figure 2 Androgen-dependent and –independent pathways involved in PCa progression 
In androgen-dependent PCa, the tumour cells depend on androgen stimulation for growth. At this stage, 
androgen deprivation and hormonal treatment are therefore effective. However, androgen-resistance 
develops as the cells acquire growth stimulation from abnormal AR signalling and other pathways 
bypassing the AR.  
 
The androgen receptor is a transcription factor belonging to the nuclear receptor superfamily. 
Although it normally resides in the cytoplasm, it homodimerises and translocates to the 
nucleus upon ligand binding. There, it mediates transcription of target genes containing 
androgen-response elements (ARE). Activation of the AR in the cytoplasm is kept in check by 
phosphorylating kinases and its transcriptional effect in the nucleus is modulated by 
coregulators (Heinlein & Chang, 2002). 
 
A proposed mechanism for AR hyperactivation is AR gene amplification. This has been 
observed in a third of androgen-independent tumours (Linja et al., 2001; Visakorpi et al., 
1995). In these studies, none of the samples collected prior to hormone ablation therapy from 
the same patients showed AR gene amplification. This implies the androgen blockade has a 
causative role. 
 
Other studies have found that 50% of advanced PCa samples exhibit mutations in the AR gene 
(Marcelli et al., 2000a; Suzuki et al., 1993; Taplin et al., 1999). Most mutations appear in the 
ligand-binding domain of the receptor, causing decreased receptor affinity and sensitivity. This 
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results in a ‘promiscuous’ receptor that can be activated by non-specific ligands such as 
estrogens, progestins and even anti-androgens. The growth of prostate cells is thus triggered by 
inappropriate stimuli. Mutations may also render the AR constitutively active and androgen-
independent. 
 
Another abnormality detected in androgen-resistant prostate cancer tissue samples is the 
overexpression of AR coactivators, such as steroid receptor coactivator-1 (SRC-1) and 
transcriptional intermediary factor-2 (TIF-2) (Fujimoto et al., 2001; Gregory et al., 2001). 
Receptor coactivators function by enhancing the transcriptional activity of activated AR, or by 
lowering the AR activation threshold.  
 
AR activity can also be deregulated by the abnormal functioning of AR corepressors. 
Corepressors are proteins that reduce target gene transcription without altering basal 
transcription rates. For example, Hey1 is a downstream mediator of Notch signalling that 
directly interacts with SRC1 and AR to specifically repress transcription from AR-dependent 
promoters. Immunohistochemical analysis of cancer samples has demonstrated that Hey1 is 
often excluded from the nucleus in PCa (Belandia et al., 2005). 
 
Mutations in other genes, such as the tumour suppressor Phosphatase and Tensin Homologue 
(PTEN), can also affect AR activity. PTEN is a tumour suppressor which interrupts PI3K 
activation of Akt, thereby decreasing the overall flux through the PI3K pathway. PTEN has 
been shown to repress the transcriptional activity of AR (Li et al., 2001). It is often lost in 
advanced PCa and this correlates with higher Gleason score and clinical stage (Cairns et al., 
1997).  
 
In addition to abnormalities involving the AR, other growth-stimulating mechanisms may play 
a role in androgen-resistant PCa. For example, survival proteins are often abnormally active 
due to over-expression or mutations. The insulin-like growth factor (IGF) pathway is 
commonly hyperactive in androgen-independent tumours. In normal cells, the pathway is ‘off’ 
as IGF-1 is bound by insulin-like growth factor binding protein -3 (IGFBP-3). However, in 
PCa, IGFBP-3 is down-regulated such that unbound IGF-1 triggers downstream Mitogen-
Activated Protein Kinase (MAPK) and phosphatidyl-inositol-3-OH kinase (PI3K) pathways, 
preventing apoptosis and promoting survival (Meinbach & Lokeshwar, 2006). IGF signalling 
has also been shown to affect AR cellular localization and stimulate transcriptional activity 
(Wu et al., 2006). 
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Similarly, fibroblast growth factors (FGFs) and their receptors (FGFR) have been found to be 
overexpressed in prostate tumours with high Gleason grade (Gowardhan et al., 2005). 
Fibroblast growth factor signalling induces the MAPK pathway, enabling cell survival, 
proliferation and angiogenesis. Also, increased expression of the epidermal growth factor 
receptor ErbB1 has recently been correlated with progression to androgen resistance (Shah et 
al., 2006).  
 
Advanced PCa also exhibit deregulated apoptotic responses that arise in response to hormone 
ablation treatment. Bcl2 inhibits cell death and contributes to hormone ablation resistance 
(Raffo et al., 1995). The overexpression of the anti-apoptotic protein Bcl-xL correlates with 
onset of androgen-resistance and is associated with higher Gleason scores (Castilla et al., 
2006). Bcl-xL exerts its anti-apoptotic effect by binding to and inhibiting the effect of the pro-
apoptotic protein Bax. Another anti-apoptotic protein, clusterin, has also been show to be 
instrumental in androgen resistance and many efforts are being made to develop a therapeutic 
anti-sense oligonucleotide targeting this protein (Miyake et al., 2006). Heat shock protein-27 
(Hsp27) modulates Signal Transducer and Activator of Transcription-3 (STAT-3)-mediated 
apoptosis after metastasis and is another potential therapeutic target (Rocchi et al., 2005).  
 
Finally, neuroendocrine differentiation (NED) provides PCa cells with another source of 
growth stimulatory signals. The normal benign epithelial prostate compartment includes 
neuron-like neuroendocrine (NE) cells. In high grade and high stage tumours, the number of 
these cells increases, especially in hormonally-treated, androgen-independent tumours. The NE 
cells secrete neuropeptides, such as chromogranin, which act in a paracrine fashion on 
neighbouring non-NE tumour cells to stimulate their survival and proliferation. The PI3K-Akt-
mTOR pathway has recently been shown to be critically involved in NED (Wu & Huang, 
2006).  
 
1.1.6 Management of androgen resistant cancers 
PCa is considered androgen-resistant when patients have >25% increase in PSA levels to a 
value of ≥ 5ng/ml despite castration levels of testosterone (<50ng/ml). The estimated median 
survival ranges from 24 – 68 months, depending on the presence of skeletal metastases which 
is associated with poor prognosis (Oefelein et al., 2004).  
 
Patients with HRPC have limited treatment options beyond the addition of other 
antiandrogens. Chemotherapy has generally been ineffective in providing a survival advantage 
or in alleviating symptoms, so HRPC is usually considered a chemoresistant disease. 
  19 
Mitoxantrone and docetaxel are now commonly used because, although survival benefits of 
monotherapy are not significant, the chemotherapeutic drugs can reduce the duration and 
intensity of pain associated with HRPC. A number of clinical trials have shown stabilization of 
disease and decreased PSA levels by combinations of docetaxel or mitoxantrone with 
estramustine, prednisolone, dexamethasone (Chang & Kibel, 2009). Novel targeted 
therapeutics currently in clinical trials include calcitriol (the biologically active form of 
vitamin D), bevacizumab (an anti-angiogenic monoclonal antibody against vascular 
endothelial growth factor) and thalidomide (an anti-angiogenic agent which inhibits platelet-
derived growth factor and TNF).  
 
In conclusion, androgen deprivation is usually initially a very successful treatment that leads to 
tumour size reduction. However, PCa inevitably progresses to androgen-independence via the 
acquisition of various abnormal characteristics including mutations of the AR, co-regulators, 
tumour suppressors, growth factors and survival factors. Androgen-insensitive cancers are 
currently incurable since resistance to other treatments such as chemotherapy and radiotherapy 
also develops. Consequently, innovative therapies need to be developed to treat patients 
suffering from advanced, androgen-independent, and metastatic forms of the disease. Novel 
treatments curtailing cancer progression to the androgen-resistant state, or reversing the 
process, would also be of immense value. These goals require greater in-depth understanding 
of the mechanisms of PCa in order to design targeted therapies. 
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1.2 Adenovirus type 5 
1.2.1 Adenovirus structure 
Adenoviruses (Ad) are icosahedral, double-stranded DNA viruses first isolated in 1953 which 
can infect humans and animals (Shenk, 2001). With a diameter of 60-90nm, they are the 
largest non-enveloped viruses able to infect cells via the endosome, and not requiring 
membrane fusion. Adenoviral particles consist of the viral genome encapsulated by a protein 
shell (Figure 3). The main components of the capsid are the 240 hexon homotrimers and 12 
pentameric penton bases at the apices (Russell, 2009). Trimeric fibres, consisting of a tail, 
shaft and knob region, extend from each penton. Penton is also associated with five copies of 
polypeptide IIIa at its base. Proteins VI and VIII are minor capsid proteins which bind hexon 
on the inner side of the capsid, while IX is located externally and acts to ‘cement’ and stabilise 
the capsid. The 36kb linear viral genome is contained within the capsid together with the viral 
protease, and is packaged by the core proteins, mu, IVa2, V and VII, which ensure its 
availability for transcription and subsequent packaging. The 5’ DNA termini are bound by two 
terminal proteins (pTPs) which act as protein primers during replication. 
 
 
 
Figure 3 Adenovirus structure 
Adenoviral structure has been studied by electron microscopy and crystallography. The locations of 
capsid and minor components have been determined but the disposition of core proteins is unknown. Not 
to scale. Based on a figure shown in (Russell, 2009). 
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1.2.2 Adenovirus classification 
Adenoviruses are classified into six groups (A-F) based on their ability to agglutinate red 
blood cells and their biological and DNA sequence similarities (Table 1). There are 51 
serotypes of human adenoviruses which were originally classified based on their expression of 
antigens and their neutralising-susceptibility to specific animal antisera. 
 
Only a third of adenoviral serotypes cause symptomatic infections in humans (Lenaerts et al., 
2008). Usually, these are limited to a mild, self-resolving infection with flu-like symptoms. 
Some serotypes are responsible for viral gasteroenteritis which affects young children, acute 
respiratory disease (ARD), for example, among military recruits who live in crowded and 
physically challenging conditions, and keratoconjunctivitis which can have long-term 
consequences. Additional population groups at risk of serious consequences from adenoviral 
infection are immunocompromised individuals, such as those who are HIV-positive, or organ 
transplant recipients on immunosuppressive therapy. The most widely studied adenoviruses 
are the Group C serotypes 2 and 5 (Ad2, Ad5) which cause only mild, self-limited respiratory 
symptoms.   
 
Table 1 Classification of human adenoviral serotypes 
Group Serotypes Tropism Diseases 
A 12, 18, 31 Intestine Mainly asymptomatic 
B 3, 7, 11, 14, 16, 21, 34, 
35, 50 
Lung, urinary tract Respiratory and ocular 
diseases 
C 1, 2, 5, 6 Upper respiratory tract, 
(liver) 
Respiratory diseases 
D 8, 9, 10, 13, 15, 17, 19, 
20, 22-30, 32, 33, 36-39, 
42-49, 51 
Eye, (intestine) Ocular diseases 
E 4 Respiratory tract Respiratory and ocular 
diseases 
F 40, 41 Intestine  Gasteroenteritis  
Human adenovirus serotypes are classified based on biological and physiochemical properties which 
generally coincide with viral tropism and the diseases they can cause. In brackets are sites of infection 
which may affect immunocompromised individuals. 
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1.2.3 Adenovirus lifecycle 
1.2.3.1  Attachment 
The lifecycle of adenoviruses begins with the infection of target cells (Figure 4). Group C 
adenoviruses are transmitted between host organisms via aerosol droplets. The tropism of 
adenoviruses is mainly the epithelia of the airways and gastro-intestinal tract that express the 
Coxsackie and Adenovirus Receptor (CAR), although Group B adenoviruses and Ad37 (Group 
D) instead use CD46, CD80 or CD86 as cellular receptors. Ad37 has been reported to use 
sialic acid (Burmeister et al., 2004). 
 
CAR is bound by the virus via the AB surface loop on the side of the fibre knob protein 
(Bergelson et al., 1997; Bewley et al., 1999). One fibre molecule interacts with three CAR 
proteins, resulting in a high affinity interaction that allows viral docking to the cell. The AB 
loop is conserved amongst adenoviral serotypes which use CAR as a receptor while it is absent 
in serotypes which use alternative receptors.  
 
It has been shown that docking of some serotypes onto host cells can take place in the absence 
of CAR via heparan sulphate glycosaminoglycans (HS-GAGs) which are widely expressed on 
cell surfaces and within the extracellular matrix (ECM) (Dechecchi et al., 2000; Zhang & 
Bergelson, 2005). Binding to HS-GAGs requires a lysine-lysine-threonine-lysine (KKTK) 
motif on the fibre shaft and is thought to allow viral access to high affinity receptors, CAR or 
CD46, HS-GAGs thus acting as co-receptors (Tuve et al., 2008).  
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Figure 4 Schematic of the adenoviral lifecycle 
Ad5 attaches to host cells via the coxsackie adenovirus receptor (CAR), or alternatively, via heparan 
sulfate glycoproteins (HS-GAGs). Internalization is mediated by an interaction with integrins αVβ3 and 
αVβ5 which induces endocytosis. The viral capsid is partly dismantled in the endosome, from which the 
virus escapes before the environment becomes too acidic. The viral protein VI is key in this process. Ad5 
binds to dynein motors which facilitate viral translocation along microtubule tracks to the nucleus. Here 
Ad5 docks with the nuclear pore complex and the viral genome enters the nucleus. Transcription of the 
viral genome begins from the constitutively-active E1A promoter. E1A transactivates other viral genes 
whose products cooperate to establish a favourable enviroment for viral replication. The viral genome is 
replicated by the viral polymerase in association with the DNA-binding protein (DBP). Genome copies are 
packaged into newly-assembled caspid shells. Virions accumulate, eventually causing cell lysis, 
releasing progeny virus particles in the extracellular matrix and allowing a new replication cycle to begin. 
 
1.2.3.2  Internalization 
After attachment, internalization is initiated by the binding of viral penton protein to integrins 
αVβ3 or αVβ5 in a quick and efficient process that is completed within 15min (Wickham et al., 
1993). Integrins are heterodimeric cell membrane proteins involved in cell adhesion, cell 
migration, differentation and proliferation. The penton base protein contains a consensus 
arginine-glycine-aspartic acid (RGD) motif on five flexible surface loops which fit into the 
groove between the αV and β integrin subunits. Structural models have shown that the 
arrangement of the loops on the penton base and the position of the fibre prevent binding by 
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neutralising antibodies, whilst enabling clustering of integrins in a ring pattern around the 
penton base (Nemerow et al., 2009).  
 
Binding to integrins via the RGD penton motif triggers down-stream intracellular signalling 
and endocytosis via clathrin-coated vesicles. Viral uptake requires and induces activation of 
the PI3K pathway, which, in turn, stimulates downstream targets including rac1 and cdc42 
GTPase (Li et al., 1998; Nemerow & Stewart, 1999). These events catalyses actin 
polymerization and facilitate endosomal vesicular trafficking and functioning.   
 
The endosome matures as proton pumping causes the environment within it to become acidic. 
At pH 6.0, conformational changes enable the virus to escape into the cytoplasm before the 
formation of a lysosome. It is thought that free fibre protein, released by viral protease, might 
act as a pH sensor, thus coordinating the timing of viral exit from the endosome. Vertex 
components of the capsid, including the fibre, penton base, peripentonal hexons, polypeptides 
IIIa2 and VI are released. The latter protein has recently been shown to possess lytic activity, 
enabling disruption of the endosomal membrane (Wiethoff et al., 2005).  
 
1.2.3.3  Intracellular traff ick ing 
Having entered the cell and escaped the endosome successfully, the virus then encounters the 
viscous, crowded cytoplasm through which passive diffusion to the nucleus is not possible. 
The adenoviral capsid must be translocated to the nucleus along microtubule tracks by dynein 
motors (Kelkar et al., 2004). The exact mechanism behind this interaction remains unknown 
but it is thought that adenoviral translocation uses the same mechanism as adeno-associated 
virus (AAV), since trafficking of these two viruses is mutually exclusive (Kelkar et al., 2006). 
Adenovirus traffic can also be interrupted by microtubule depolymerisation and function-
inhibiting antibodies against dynein (Leopold et al., 2000).  
 
The movement of viral particles towards the nucleus is induced by the protein kinase A 
pathway, which is activated by integrin binding (Suomalainen et al., 2001). Movement 
towards the periphery of the cell is inhibited by p38/MAPK signalling such that the net speed 
of adenovirus towards the nucleus is around 0.6µm/s (Leopold et al., 1998; Suomalainen et al., 
2001).  
 
The viral particles are unloaded at the microtubule organizing center (MTOC) located next to 
the nucleus by the nuclear export factor CRM1 (Strunze et al., 2005). The partially dismantled 
adenoviral capsid binds to the CAN/Nup214 protein of the nuclear pore complexes (NPC), and 
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possibly also interacts with nuclear histone H1 (Campbell & Hope, 2005). The capsid 
components are sequentially dismantled before transit of the viral genome, complexed with 
protein VII, through the NPC.  
 
1.2.3.4  Init iation of v iral gene expression 
Upon entry in the cell nucleus, E1A is the first gene to be transcribed from its constitutively 
active promoter (Figure 5) (Berk, 2005). E1A induces the transcription of the other viral genes, 
which leads to the expression of various adenoviral proteins (Table 2). Alternative RNA 
splicing yields two main E1A proteins: 12S (243 residues) and 13S (289 residues). The larger 
protein is produced during the early stages of infection after which there is a switch in splice 
selection such that the smaller E1A protein in produced during the late phase. Three additional 
E1A mRNA species also accumulate during the late stage of the infection.  
 
Comparison of E1A amino acid sequences from different adenoviral serotypes revealed the 
presence of four conserved regions (CR1-4) in E1A. These and the N-terminal region of E1A 
are the interaction sites for most E1A-interacting proteins.  
 
E1A-CR3 is present only in the larger 13S and binds proteins involved in transcriptional 
activation, including the TATA binding protein, Mediator 23 (Med23) and transcription 
factors. This promotes the assembly of preinitiation complexes (PICs) with RNA polymerase 
II to the early adenovirus promoters, trans-initiating transcription of the other viral genes. 
E1A-CR3 interaction with Med23 also enables sufficienctly high rates of transcription 
reinitiation to support viral replication. 
 
Another role of E1A is to induce cellular progression to S phase to enable viral genome 
replication. The ability of E1A to counter senescence is often referred to as its 
‘immortalization’ function, as E1A with viral E1B or activated Ras can transform mammalian 
cells to an oncogenic phenotype. E1A-CR2 binds to Rb family proteins (pRb, p107 and p130) 
on a motif which is also the binding site for E2F transcription factors. This frees E2F, enabling 
its activation of genes required for entry into S phase, such as those coding for CDK2 and 
cyclins E and A.  
 
E1A-CR1 also functions to induce cell cycle progression by interacting with cellular proteins 
involved in the control of chromatin structure (Frisch & Mymryk, 2002). Most notably, E1A-
CR1 binds to and inhibits the activity of the structurally related proteins p300 and CREB-
binding protein (CBP). Both are multidomain proteins which function as histone-
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acetyltransferases (HATs). CBP and p300 activate transcription by acetylating histone tails or 
target lysines in transcription factors which control cellular differentiation and the cell cycle. 
Depletion of p300 allows the activation of cyclin E and A and leads to the expression of c-myc 
and c-jun.  
 
E1A-CR4 competitively binds and inhibits a cellular transcriptional corepressor, C-terminal 
binding protein (CtBP), which is recruited to promoters where it engages histone deacetylases 
(HDACs) and heterochromatin-interacting protein Polycomb-2. Target genes of CtBP include 
pro-apoptotic and genes involved in differentiation. 
  
 
Figure 5 Simplified transcriptional organisation of the adenoviral genome 
Transcription begins from the constitutively-active promoter of E1A. E1A transactivates transcription of 
the other early (E1B, E2A, E2B, E3 and E4) genes. The late genes (L1-5) are transcribed from the Major 
Late Promoter (MLP). Proteins IX and IVa2 have their own promoter. VA RNAs are transcribed but not 
translated. The functions of the proteins transcribed from these regions are described in Table 2. Not to 
scale. cM: centimorgans. Based on a figure in (Akusjärvi, 1986) 
 
 
Table 2 The products of Ad5 genes and their functions 
Gene Product Function 
E1A 12S and 13S Transactivators of other viral genes.  
Bind to cellular pRb, TBP, p300/CPB. 
Activate p53. 
19kD Bcl-2 homolog. 
Inhibits apoptotis by sequestering proapoptotic Bak and Bax. 
E1B 
55kD Inhibits apoptosis by binding to p53 and preventing its activity. 
Blocks cellular but enables viral mRNA accumulation, with E4-orf6. 
Polymerase Contains 5’-3’ polymerase and 3’-5’ exonuclease activity. E2A 
DNA-binding protein 
(DBP) 
Binds DNA and separates strands, allowing replication. 
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E2B Pre-terminal protein 
(pTP) 
Core protein covalently bound to 5’ ends of the viral genome. 
Acts as a primer for viral transcription. 
Adenovirus death 
protein (11.6K) 
Accumulates in the cell during the late stage of infection. 
Triggers cell death. 
10.4, 14.5, 14.7K  
(E3B proteins) 
Inhibit activation of phospholipase A2, preventing TNFα-induced 
cytolysis. 
Block proapoptotic activities of FAS and FIP proteins. 
E3 
gp19K Inhibits antigen processing and recognition of infected cells by 
cytotoxic T lymphocytes by binding MHC class I molecules and 
sequestering them in the endoplasmic reticulum.  
orf4 Stimulates release of viral progeny during the late stage of infection. 
Binds protein phosphatates 2A. 
E4 
orf6/7 Cooperates with E1B-55k in the nuclear export of viral mRNAs. 
Shuts off cellular mRNA processing. 
L1 IIIa Structural protein interacting with penton and bridging the core and 
capsid. 
III Structural protein associating pentamers to form the penton base. 
V Core protein associated with VI, VII and viral DNA. Bridges core and 
capsid. 
L2 
VII Abundant histone-like core protein around which viral DNA is 
wrapped. 
II Associates in trimers to form the hexon capsomere. 
Protease Processes structural proteins to produce mature proteins.  
Cleaves cytokeratin component of the cytoskeleton at the end of 
infection to aid cell lysis 
L3 
VI Structural protein located on the inner side of the capsid beneath 
hexon. Instrumental in viral escape from the endosome. 
L4 100k Stimulates late viral gene transcription. 
 VIII Structural protein stabilising hexon-hexon interactions. 
L5 IV Fibre protein which associates in trimers. 
Mediates attachment to the host cell via primary receptors. 
VA 
RNA 
VA1 and VA2 Virus-associated RNAs. Protect the cell from interferon-α and -β. 
IX Structural protein on the external side of the capsid, confers stability. 
Mu (protein X) Core protein. 
Delayed early gene IVa2 Structural protein involved in encapsidation and regulation of late 
transcription. 
Based on information in (Berk, 2005; Russell, 2009; Shenk, 2001) 
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1.2.3.5  Counteracting the induction of  apoptosis  
The natural host response to viral induction of S phase is cellular apoptosis mediated by 
activation of p53, which is stabilised by E1A. E1A expression also results in the proteosomal 
degradation of anti-apoptotic Bcl-2 family member Myeloid Cell Leukaemia (MCL)-1, which 
usually binds to and represses proapoptotic Bak. The DNA-damage response is also triggered 
by the presence of foreign DNA.  
 
In order to prevent apoptosis-induced degradation of both cellular and viral DNA and 
premature cell death, which would limit viral replication, adenoviruses possess antiapoptotic 
proteins (Berk, 2005). These are mainly transcribed from E1B. E1B-19K is a Bcl-2 homolog 
which sequesters Bak and Bax (Cuconati et al., 2002). This interaction represses their ability 
to form a mitochondrial transmembrane pore which would otherwise lead to the leakage of 
cytochrome c and the activation of downstream effectors such as caspases -9 and -3. E1B-55K 
blocks p53 activity by binding to its activation domain, acting as a repression domain, and 
causes p53 to aggregate at the microtubule organising centres (MTOCs) before being degraded 
by proteosomes. Furthermore, E1B-55K and E4-orf6 form a ubiquitin ligase complex which 
targets p53 and the cellular MRE11-RAD50-NBS-1 (MRN) complex for degradation. MRN 
initiates non-homologous end-joining DNA double-stranded break repair which results in the 
concatanation of viral DNA if allowed to proceed and would consequently prevent viral DNA 
replication. 
 
1.2.3.6  Countering the cellular  immune response to Ad5 
The host response to adenoviral infection is a rapid induction of both arms of the immune 
system. The innate response to adenoviral infection involves upregulation of the transcription 
factor NFκB, which regulates the expression of immunomodulatory genes, and the production 
of interferons. The immune response efficiently eliminates transduced cells, thus limiting viral 
spread. Adenoviruses have therefore evolved strategies to avoid immune recognition and 
counteract pro-inflammatory signalling.  
 
E3-10.4K and -14.5K, also known as the receptor internalisation and degradation (RID)-α/β 
complex, prevent tumour necrosis factor (TNF) and Fas-induced cell death by triggering the 
internalization and degradation of death domain receptors via the lysosome, blocking 
arachidonic acid release and inhibiting phospholipase A2 translocation to the cellular 
membrane (Braithwaite & Russell, 2001; Horwitz, 2004; Zhao et al., 2007). Fas-induced 
apoptosis is also prevented by the interaction of E3-14.7K with FLICE (caspase-8) and other 
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pro-apoptotic proteins. The activity of NFκB, which is induced by Toll-Like Receptors (TLR) 
or TNF signalling, is also inhibited by E3-10.4K/14.5K which blocks its nuclear import and 
inactivates Iκ-kinase (IKK). This downregulates chemokine expression and pro-inflammatory 
stimuli.  Pro-apoptotic signals that are triggered by NFκB or TNF-related apoptosis-inducing 
ligand (TRAIL) are inhibited by E1B-19K with E3gp19K. The latter protein also prevents the 
presentation of viral antigens to cytotoxic T-lymphocytes (CTLs) by inhibiting the transport of 
viral antigens from the endoplasmic reticulum (ER) to the cell membrane with the class I 
major histocompatibility complex (MHC).  
 
1.2.3.7  Viral genome replication  
Having established optimal conditions, replication of the viral genome can proceed. This 
requires E2-encoded viral polymerase, DNA-binding protein (DBP) and terminal protein 
(pTP) (Shenk, 2001). Synthesis is initiated from one strand at either terminus of the viral 
DNA. The viral polymerase contains 5’-3’-polymerase activity and 3’-5’-exonuclease proof-
reading ability and uses pTP as a primer. The pTP-polymerase complex is stabilised by 
cellular nuclear factors (NF) I and II. NFII also cooperates with the viral DBP to allow chain 
elongation and to maintain strand separation.  
 
1.2.3.8  Virion assembly and release 
After the initiation of viral DNA replication, gene expression is initiated from the major late 
promoter (MLP) which controls transcription of the late genes, L1-L5. These genes code for 
structural proteins (fibre, hexon etc.) involved in assembly of the capsids and packaging of 
replicated viral DNA into these shells.  
 
During viral replication, E1B-55K and E4orf6 block cytoplasmic accumulation of cellular 
mRNA whilst enabling efficient cytoplasmic export of viral mRNAs. E1B-55K has an intrinsic 
RNA binding ability and binds E4orf6 which contains a nuclear export sequence and shuttles 
between the nucleus and the cytoplasm. The complex also interacts with cellular transport 
partners, redirecting them to viral transcription centres.  
 
In the cytoplasm, viral mRNAs are preferentially translated over host mRNAs. Viral 
antagonist (VA) RNAs inhibit protein kinase R (PKR) which would otherwise phosphorylate 
eukaryotic initiation factor (eIF)-2α and block translation. The L4 100K protein (L4-100K) 
also inhibits eIF-4E phosphorylation and activation, preventing cellular cap-dependent mRNA 
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translation. Late viral mRNAs are exempt from this block because they contain a non-coding 
5’ tripartite leader sequence which enables them to be translated by ribosome shunting. This 
method allows loading of the small ribosomal subunit (40S) to the capped 5’ end of viral 
mRNAs followed by direct translocation to the downsteam initiation site, directed by the 
tripartite leader ‘shunting elements’. L4-100K contains an RNA-binding domain and a 
tripartite-specific mRNA binding domain which enables it to promote the initiation of 
translation by ribosome shunting (Xi et al., 2005).   
 
Assembly begins with the formation of the capsid, starting with hexon capsomeres, followed 
by penton bases and trimeric fibres, L4-100K functioning as a scaffold. Once formed, the viral 
genome enters the empty capsid. This requires the packaging sequence located on the 5’ end of 
the viral genome to mediate the DNA-capsid interaction. The particles are then rendered 
infectious by processing of VI, VII, VIII and pTP by the L3 protease (Ostapchuk & Hearing, 
2005).  
 
The viral protease is also instrumental in viral exit from the cell, as it cleaves cytokeratins K18 
and K7 which are components of the cellular intermediate filament network. Coupled with the 
inhibition of protein translation, the cell is unable to replace degraded subunits of the 
cytoskeleton, resulting in compromised structural integrity and the characteristic phenotype of 
viral cytopathic effect (CPE): cell rounding, clumping and detachment (Zhang & Schneider, 
1994). This, together with initiation of cell death by the adenovirus death protein (ADP), 
causes cell lysis and releases progeny virions, completing the viral cycle (Tollefson et al., 
1996).  
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1.3 Optimization of adenoviruses for oncolytic therapy 
Oncolytic viruses were first considered for use in cancer therapy in the 1950s when doctors 
noticed that cancer patients suffering from non-related viral infections or those having been 
recently administered with a virus-based vaccine had better outcomes. With the advent of 
genetic engineering, many oncolytic viruses have been designed in the past 15 years.  
 
Ad5 is an attractive vector for use in cancer therapy as it is a human pathogen that naturally 
only causes minor illness. Ad5 is a well-studied virus and the functions of the majority of its 
genes are known. The virus can easily be genetically modified for tumour-selectivity or armed 
with suicide genes. Non-essential genes can be deleted from the genome to accommodate 
desired genes or modulate the specificity of the virus. The natural genome size (36kD) can be 
exceeded by up to 5% without hampering genome packaging. Furthermore, Ad5 does not 
integrate in the human genome, avoiding problems associated with insertional mutagenesis. It 
can infect and replicate in non-cycling epithelial cells and has a rapid lytic lifecycle that is 
completed within 18-24h. The viral load is amplified 1000 to 10,000-fold in a single 
replicative cycle, increasing the potency of the viral load delivered to the tumour, and it can be 
produced to high titres of up to 1012 particles (pt)/ml in the laboratory.  
 
1.3.1 Tumour selectivity 
Initially, only replication-deficient adenoviruses were designed for clinical evaluation due to 
safety concerns. However, it was soon apparent that the cancer-killing ability of these viruses 
was not potent enough (McCormick, 2001). The expression level of tumour suppressor genes 
inserted into the adenoviral genome was limited due to low viral transduction of tumour cells. 
Cancer growth still exceeded cell death so the overall anti-cancer effect was not sufficient to 
eradicate the cancer. Research therefore turned to the design of replication-selective viruses in 
order to benefit from dose amplification by viral replication and intratumoural spread.  
 
Since adenoviruses target most epithelial cells and not only cancer cells, tumour selectivity 
needs to be engineered for their use as an oncolytic virus. The most common method to 
engineer tumour-selectivity into oncolytic adenoviruses is to delete viral genes that are 
expendable in tumour cells but not in normal cells (Figure 6). Since cellular processes such as 
the cell cycle and apoptosis are often deregulated in cancer, adenoviral proteins subverting 
these mechanisms are not necessary in tumour cells. The viral genes encoding these proteins 
can be deleted without preventing viral replication in cancer cells. However, in normal cells 
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where the pathways function normally, viral replication will be restricted. ‘Complementation 
mutations’ can thus render viruses tumour-selective.  
 
 
Figure 6 Tumour selectivity of viral mutants 
Conditionally-replicating viral muatants contain gene deletions that restrict their replication to tumour 
cells, although both normal and cancer cells can be infected by the mutant. The infection of normal cells 
by the tumour-selective mutant is non-productive as it lacks essential complementation proteins. 
However, in the tumour cell, replication of the viral mutant is facilitated by deregulated apoptotic and cell 
cycle pathways which complement the gene deletion, enabling progeny production and further viral 
spread within the tumour.  
 
The first Ad5 complementation mutant to be genetically engineered was Onyx-015 (also 
known as dl1520) (Bischoff et al., 1996). This modified adenovirus lacks the E1B-55K gene 
whose protein product binds p53 to prevent apoptosis, as described in Section 1.2.3.5. Onyx-
015 was predicted to be tumour-selective due to the inactivation of the p53 pathway in most 
cancer cells, which would allow viral replication to proceed unchecked. However, in normal 
cells functional p53 is present and would trigger apoptosis before Onyx-015 could replicate 
and spread.  
 
Clinical studies showed variability in patient response to Onyx-015 treatment. It was later 
shown that the tumour-selectivity of Onyx-015 was not only dependent on non-functional p53 
status but also on the cellular host-protein shut-off and mRNA export functions mediated by 
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E1B-55K and the L4-100K viral protein(Geoerger et al., 2002; O'Shea et al., 2004). Tumour 
cells which support Onyx-015 replication can complement the absence of these E1B-55K-
mediated late functions. However, not all tumour cells have this ability, so overall Onyx-015 
replication is severely attenuated.  
 
Non-permissive tumour cells can be induced to support Onyx-015 replication by triggering a 
heat-shock response which mimics the effect of E1B-55K (O'Shea et al., 2005b). During heat 
shock, molecular chaperone heat-shock proteins, such as Hsp70, are selectively exported from 
the nucleus and translated in the endoplasmic reticulum, while expression of other cellular 
proteins is repressed (to prevent aggregation of mis-folded proteins). This selectivity is 
mediated by the special 5’-UTR of heat shock protein mRNAs which distinguishes them from 
other cellular mRNAs. The 5’UTR of 100K bears homology with the 5’UTR region of Hsp70, 
suggesting that both mRNAs might be translated via the same mechanism. Heat shock proteins 
are commonly over-expressed and deregulated in tumours (Jolly & Morimoto, 2000), while 
normal cells cannot be rendered sensitive to Onyx-015 even by heat shock induction. This is 
thought to be due to a differential heat shock response in primary cells. Details of the exact 
mechanism behind this are of high interest but remain to be elucidated.  
 
Currently, deletion mutants with improved cancer selectivity are being constructed and 
evaluated preclinically. These mutants have small regions of E1A deleted, whilst the essential 
functions for viral replication are preserved. This renders the mutants selective for tumour cells 
which can complement the deleted function of E1A. For example, the dl922-947 mutant has a 
seven amino-acid deletion in the CR2 domain of E1A which impairs binding to pRb (Heise et 
al., 2000a). This mutant therefore has a reduced ability to induce S-phase such that its 
replication is severely attenuated in non-proliferating cells.  
 
Another approach to achieve tumour selectivity is to place the E1A gene under the control of a 
tumour- or tissue-specific promoter, instead of its native promoter. For example, in CV706, 
which has the PSA promoter upstream of E1A, viral replication can only take place in prostate 
cells (DeWeese et al., 2001). Similarly, CV787 has the E1A gene under the control of the 
prostate-specific probasin promoter and the E1B gene under the control of the human prostate-
specific antigen enhancer promoter (PSE), conferring high prostate selectivity to the virus (Yu 
et al., 1999).  
  
Metastatic PCa has also been targeted using the conditionally replicating Ad-OC-E1A mutant 
(Matsubara et al., 2001). This virus has the bone matrix protein osteocalcin (OC) promoter 
driving E1A. This restricts viral replication to OC-expressing cells such as the tumour 
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epithelia, prostate and bone stroma. This strategy has the advantage of targeting both the PCa 
cells and the stromal compartment which support the primary tumour and metastases to the 
bone. OC is normally expressed in maturing osteoblasts during bone mineralization where it 
negatively regulates bone formation. Transgenic OC knockout mice exhibit increased bone 
mass rather than any damage to the skeleton.  
 
1.3.2 Improving viral potency  
1.3.2.1  Arming vectors with suicide genes 
Another method to augment the cancer-killing capacity of replication-selective adenoviruses is 
to insert a gene coding for a non-mammalian pro-drug converting enzyme into the viral 
genome (Greco & Dachs, 2001; Kirn et al., 2002). The patients receive the virus which 
selectively infects and expresses the enzyme in tumour cells. The non-toxic pro-drug is then 
administered and, although it is taken up by all cells, it is only converted to its cytotoxic form 
by the enzyme in infected cancer cells, thus achieving tumour selectivity. The toxic metabolite 
kills the infected cell and diffuses throughout the tumour via gap junctions. This is known as 
the ‘bystander effect’ and is a major advantage of ‘suicide’ gene therapy propagated by viral 
vectors. The potency of antitumour effects by suicide virotherapies varies in different systems. 
It is thought that differences may be due to differing levels of enzyme within tumours. Crucial 
factors affecting this are viral uptake efficiency, suicide gene expression and the numbers of 
gap junctions in different tissues (Elshami et al., 1996).  
 
A phase I/II trial has been conducted to evaluate the replication-selective mutant Ad-OC-TK 
for metastatic PCa treatment (Hinata et al., 2006). This virus carries the herpes simplex virus 
(HSV) enzyme thymidine kinase (tk) under the control of the OC promoter. Expression is 
induced in OC-expressing cells, where HSV-tk converts the prodrug ganciclovir (GCV), or 
structurally-related prodrugs such as valaciclovir, to cytotoxic deoxyguanosine triphosphate 
(dGTP) analogues. This nucleotide becomes incorporated in DNA, terminating elongation and 
resulting in cell death. None of the three patients suffered serious adverse events and one 
showed partial response to the therapy. Further trials are ongoing with higher doses of the 
virus.   
 
The Ad5-CD/TKrep provides another suicide gene therapy approach (Freytag et al., 1998). 
This mutant has wild type E1A, so it is replication-competent, and it has a pro-drug enzyme 
expression cassette under the control of the CMV promoter in the E1B region. It is rendered 
replication-selective by the mutation of E1B-55K although it expresses E1B-19K. Ad5-
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CD/TKrep expresses a fusion protein composed of the Escherichia coli cytosine deaminase 
(CD) enzyme as well as the HSV-tk enzyme described above. Cytosine deaminase converts the 
prodrug 5-fluorocytosine (5-FC) to the cytotoxic analog 5-fluorouracil (5-FU). This product is 
further metabolized by cellular enzymes to analogues that inhibit thymidylate synthase, 
resulting in double-stranded DNA breaks, cell cycle redistribution and cell death. These 
cytotoxic analogues also become incorporated into DNA and RNA strands, inhibiting 
nucleotide synthesis as well as DNA repair (Aghi et al., 2000).  
 
Initial studies showed that combining Ad5-CD/TKrep with suicide therapy was associated with 
low toxicity and PSA declined in half of the patients (Freytag et al., 2002). A five-year follow-
up of the trial demonstrated that PSA doubling time (PSADT) increased significantly and 
resulted in an average delay to hormone therapy initiation of two years (Freytag et al., 2007). 
The investigators suggest that selected patients can benefit from this type of treatment, while 
those with a PSADT of less than six months, who are more likely to have subclinical 
metastases and die from PCa, should be offered more aggressive therapies such as hormone 
ablation treatment in combination with chemotherapy and/or gene therapy.  
 
1.3.2.2  Combination therapies 
Despite transient, local tumour killing, adenoviruses as single agent therapies have limitations, 
particularly insufficient infection of target cells, restricted viral spread and rapid elimination 
from the body (Chu et al., 2004; Kirn, 2001). However, a combination of treatment types that 
target different cellular mechanisms can prevent the development of resistance to 
chemotherapeutic drugs and radiotherapy and enhances the adenoviral anti-cancer effect.  
 
Initial in vitro and in vivo studies of oncolytic viruses with chemotherapeutic drugs 
demonstrated the efficiency of combination strategies. The overall effects of combination 
treatments targeting cancer may be dependent upon the sequence of administration of each 
agent and the dose. In vivo experiments showed that administration of Onyx-015 prior to, or 
simultaneously with, chemotherapy caused superior killing of xenograft tumours to 
chemotherapy followed by Onxy-015 (Heise et al., 2000b). Premature dosing with cytotoxic 
drug induces early cell death, curtailing viral replication and spread, and so does not benefit 
combination therapies with adenoviral mutants. In vitro and in vivo evaluation of CV787 
showed that subtoxic doses of paclitaxel or docetaxel acted synergistically to kill LNCaP cells 
(Yu et al., 2001).  
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The exact mechanism underlying the synergy between chemotherapeutic agents and oncolytic 
viruses remains unknown. Hypotheses include enhancement of viral replication by the 
chemotherapeutic drugs, altered structure of tumours due to chemotherapeutic drug treatment, 
allowing greater diffusion and infection of tumour cells, or viral potentiation of drug-induced 
cytotoxicity, perhaps due to sensatisation of cells to apoptosis by E1A (Kruyt & Curiel, 2002).  
 
Combinations of radiotherapy with adenoviruses have also shown promising results. For 
example, combination of the prostate-specific CV706 with 10Gy radiation resulted in greater 
cell killing in vitro and synergistic inhibition of tumour growth in vivo with increased necrosis 
and apoptosis and decreased tumour blood supply (Chen et al., 2001). Crucially, the toxic 
effect in vivo was no higher than radiation alone, and viral replication was actually increased 
when combined with radiation treatment, possibly due to the activation of the cellular DNA 
synthesis machinery caused by irradiation damage. Combination of double suicide therapy of 
Ad5-CD/TKrep with radiotherapy for PCa has demonstrated promising results without 
exacerbating toxic side effects (Freytag et al., 2003).  
 
1.3.2.3  Delivery of v iral vectors  
The safety of Onyx-015 has been tested in around 15 clinical trials involving more than 250 
patients (Kirn, 2001). In 2006, an E1B-55K-deleted mutant known as H101 (the equivalent of 
Onyx-015) was approved for use in head and neck cancer patients by China’s State Food and 
Drug Administration (Garber, 2006; Xia et al., 2004). Despite this success, therapeutic 
adenoviruses face a number of hurdles in vivo which reduce their potency.  
 
In a staged clinical research and development approach, safety was first evaluated in clinical 
trials with the intra-tumoral (i.t.) delivery of Onyx-015 in patients suffering from recurrent 
head and neck carcinomas (Kirn, 2001). These patients benefited from the palliative effect of 
the virus and some had prolonged survival without the maximum tolerated doses being 
reached. Intra-peritoneal (i.p.) administration in ovarian cancer patients caused only mild side 
effects (local swelling and flu-like symptoms) with feasible doses up to 1013 particles. 
However, no objective responses could be demonstrated. Complete regression of tumours was 
observed, although rarely (Nemunaitis et al., 2000). The limited efficacy in these trials was 
probably due to insufficient viral transduction of tumour cells, such that tumour growth 
exceeded tumour cell killing.  
 
Investigators began to consider intravenous (i.v.) delivery in order to reach inoperable sites 
and target metastases. However, use of the i.v. route has been met with some obstacles and 
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concerns particularly over significant transient increases in liver transaminases which indicate 
liver damage (Reid et al., 2002). The toxicity to the liver is due to viral transduction of liver 
parenchymal cells and Kupffer cells. Kuffer cells are liver-specific macrophages of the 
reticuloendothelial system which break down erythrocytes by phagocytosis. Ad5 has recently 
been shown to bind human red blood cells via CAR and complement receptor (CR)-1, as well 
as blood coagulation factors, especially Factor X (Baker et al., 2007; Carlisle et al., 2009; 
Parker et al., 2006; Waddington et al., 2008). It would appear that humans have therefore 
evolved a very efficient protective mechanism for sequestering Ad5 in the blood and clearing 
the virus by the liver. This effect is detrimental in gene therapy as it reduces the circulating 
viral dose and therefore requires high viral doses to target tumour cells.  
 
Despite the challenges of viral delivery, clinical trials did demonstrate the feasibility of 
adenoviral cancer therapy (Lin & Nemunaitis, 2004). Evidence of viral replication was 
obtained from continuous detection of viral elements by qPCR 15 days after i.p. injection of 
Onyx-015 in advanced ovarian cancer patients. Onyx-015 was found to be present at 
metastatic sites in two trials following i.v. delivery, although no significant tumour regression 
was observed (Kirn, 2001). No sign of replication nor toxicity was found in normal tissue. 
Clinical evaluation of i.t. delivery of dl1520 with cisplatin and 5-fluorouracil or gemcitabine 
showed no additional toxicity and higher response rates in tumours supporting viral replication 
(head and neck, and colorectal), but not in those resistant to viral replication (pancreatic).  
 
1.3.2.4  Retargeting adenoviral vectors 
A novel strategy to improve infection rates of tumour cells involves the modification of 
adenoviral envelope proteins to ‘retarget’ the virus. For example, in AdΔ24-RGD, the integrin-
binding arginine-glycine-aspartate (RGD) motif has been engineered into the HI-loop of the 
fibre protein of Ad5 with the E1A gene lacking the pRb-binding site (CR2). This mutant binds 
primarily to the widely expressed integrins, instead of CAR which is often downregulated in 
cancer cells, confering an amplified tropism to the virus and enhancing its oncolytic potency 
(Cripe et al., 2001).  
 
Another possibility is the substitution of fibre protein on Ad5 with those of other Ad serotypes. 
For example, Ad5/3 carries the Ad3 fibre knob, and displays targeting to the Ad3 receptors 
CD80 and CD86 (Kawakami et al., 2003; Short et al., 2004). This tropism is beneficial for 
ovarian cancer cells which express these proteins to higher densities than CAR. Furthermore, 
Kawakami et al. showed that not only are Ad5/3 infection rates superior, but also additional 
steps in the viral lifecycle, including nuclear translocation, E1A transcription, transgene 
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expression and oncolysis. Another mutant, Ad5.Ad3.SH.luc1, carries the Ad3 fibre shaft and 
the Ad5 fibre knob and exhibited much lower liver tropism in vivo (Breidenbach et al., 2004).  
 
In order to reduce interactions of Ad5 with blood components, ‘stealth’ viruses have been 
designed by shielding the viral capsid with a polymer coat such as poly-ethylene glycol (PEG) 
or poly-N-(2-hydroxypropyl) methacrylamide (HPMA) (Green et al., 2008; Subr et al., 2009). 
Additional ligands can also be covalently attached to the polymer coat to redirect the virus to 
tumour cells. These cloaked viruses have shown promising results in murine models and in 
vitro with human blood components (Kreppel & Kochanek, 2008). 
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1.4 Phytochemicals 
 
Phytochemicals are chemical compounds found in plants commonly consumed by humans. 
Phytochemicals can be classified according to their sources and chemical structures (Table 3). 
These natural substances are not considered ‘nutrients’ as such because their deficiency does 
not directly cause adverse effects, although they are beneficial to human health. For example, 
they can affect the immune system, promote good functioning of various organs and prevent 
cancerous and cardiovascular diseases. This has traditionally been attributed to their 
antioxidant properties since they can act as free radical scavengers using their hydroxyl groups 
to donate hydrogens/electrons. Increased production of reactive oxygen species (ROS) had 
been linked to PCa initiation and progression (Kumar et al., 2008). Exogenous ROS can result 
from exposure to UV, radiation, chemotherapeutic drugs, environmental toxins and cytokines. 
ROS are also produced intracellularly by cytosolic NADPH oxidases and by complex III in the 
mitochondria (Finkel & Holbrook, 2000). Premature ‘leakage’ from the electron transport 
chain can cause the production of superoxide anions (O2-), hydrogen peroxide (H2O2) and 
hydroxyl radicals (-OH). ROS can damage DNA, proteins and lipids, requiring the 
maintenance of homeostasis by cellular enzymes which prevent the excessive formation and 
accumulation of ROS. These enzymes include superoxide dismutase (SOD), catalase, 
glutathione peroxidase and glutathione S-transferases. Oxidative stress can also be neutralised 
by antioxidant metabolites synthesised by the cell, such as glutathione, or obtained from the 
diet.  
 
Phytochemicals have attracted attention in recent years as scientists and clinicians realise the 
grossly untapped pharmaceutical potential of these compounds. This is especially true in light 
of the shortcomings of ‘conventional’ drugs which are commonly associated with dose-
limiting side-effects. Phytochemicals have been consumed by humans since the beginning of 
time, demonstrating their inherent lack of toxicity (at least to dermal and oral exposure). As 
the incidence and significance of resistance against conventional therapies increase, 
therapeutic use of phytochemicals will probably become even more attractive. Resistance to 
phytochemicals is less likely to develop since, in contrast to traditional drugs, these bioactive 
compounds have multiple molecular targets and function via more than one mechanism.  
 
Nearly 30 years ago, an average of 35% cancer mortality was estimated to be attributable to 
diet (Doll & Peto, 1981). Since then, epidemiological data and some clinical studies have 
supported the notion that the consumption of fruits and vegetables containing phytochemicals 
is beneficial and may be cancer-preventive (Research, 2007; Surh, 2003; Wiseman, 2008). 
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Amongst others, soya and soy products have been shown to protect against stomach and 
prostate cancer. This could explain, perhaps at least in part, the low PCa incidence in Asian 
countries where soy consumption is high. Foods containing lycopene and selenium have also 
been found to decrease the risk of prostate cancer (Nelson & Montgomery, 2003). 
 
Some discrepancies between epidemiological observations, the results of in vitro experiments 
and clinical trials has been attributed in part to the extensive metabolism that phytochemicals 
undergo in the human body (Russo, 2007). Polyphenols are usually present in the gut as 
glycosyl-derivatives. The sugar moiety is removed by glycosidases before the compounds can 
be absorbed through the small intestine, resulting in an aglycone, which can subsequently be 
conjugated by methylation and/or sulfation, glucuronidation. Compounds which reach target 
cells may therefore be quite different structurally from their parent compound and may thus 
have different effects. Another possible explanation for discrepancies could also be the 
phytochemical concentration range used in vitro which is often higher than measured plasma 
and tissue concentrations. Additionally, while epidemiological studies indicate beneficial food 
intakes, phytochemicals in clinical trials are usually evaluated as single agents, not as 
interacting mixtures of compounds which may act synergistically (Meyskens & Szabo, 2005). 
These problems are of course quite complex, and, furthermore, since mouse and human 
metabolism differ greatly, the insights to be gained from animal experiments remain limited. 
 
Table 3 The major classes of phytochemicals with biological activity 
Phytochemical class Chemical structure Examples and plant sources 
Carotenoids 40-carbon skeleton of isoprene units. 
Responsible for the colours of plants, 
fruits, flowers, etc. 
β-carotene (carrots), lycopene 
(tomatoes) 
Organosulphur 
compounds 
Organic compounds containing sulphur. 
Often give off potent smells/taste. 
Diallyl sulphide (garlic), 
isothiocyanate (mustard oil), 
sulfopharane (broccoli) 
Polyphenols Compounds containing one or more 
benzene rings. Includes 
phenylpropanoids, tannins, flavonoids. 
Catechins (tea), quercetin (capers, 
apples, berries) 
Based on information in (Liu, 2004) 
 
In the first stage of this project, a literature review was conducted and five polyphenolic 
phytochemicals were selected for study with Ad5. Some of the effects of these phytochemicals 
are shown in Table 4 and they are described in Sections 1.4.1 and 1.4.2. The rationale for their 
use with Ad5 is discussed in Section 1.4.3. 
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Table 4 Effects of five selected polyphenolic phytochemicals 
 Curcumin EGCG Equol Gensitein Resveratrol 
Source Turmeric in curry Green tea Intestinal 
metabolite of 
daidzein from 
soy  
Soy Grapes, mulberries, 
etc. 
Effect on 
hormonal 
pathways 
 AR  AR expression  5α-reductase 
 DHT 
 
ERα agonist 
ERβ affinity ¼ 
genistein’s 
 AR 
 5α-reductase 
 
SERM 
 ERα, ERβ 
ERβ agonist 
 AR via 
Raf/MEK/ERK. 
 
Effect on GF 
pathways 
  EGFR 
  ERK1/2 
  JNK, IκK, NF-κB 
 
 
  VEGFR1/2 
  EGFR 
  IGF 
  Akt 
  ERK 
 
 
 NF-κB  
 TNFα  
 
 
 EGFR 
  IGF-1R 
 ERK, p38 MAPK 
 IκB , NF-κB  
 PTEN 
  AP-1 
 
  ERK  
 p38 MAPK  
  NF-κB, AP-1, 
Egr-1  
 
 
 
Effect on 
cell cycle 
Arrest in G2/M 
  p53 
 Cyclin A and E 
 p21WAF1/CIP1  
 p27Kip1 
 CDK1 
 
Arrest in G1 
  pRb 
 Cyclin D and E 
 p16INK4A 
 p21WAF1/CIP1 
 p27Kip1 
Arrest in G0/G1 Arrest in G2/M 
(LNCaP cells 
arrested in G0/G1) 
  c-fos  
 Cyclin B 
 p21WAF1/CIP1  
 p27Kip1 
 cdc25C 
  cdc2 
Arrest in S phase 
  p53 
  cyclin D and E 
  CDK2  
 p21WAF1/CIP1   
 p27Kip1 
  Sir2 
Effect on 
apoptosis 
  caspase-3, -7, -8, -9 
 ΨM 
  Cox2, P450 
  caspase-3,-8, -9 
  Cox2 
Unknown   caspase-3 
 topoisomerase II 
 Bax 
 Bcl-2, Bcl-XL 
 Bax 
 Cox-2 
 Bcl-2 
Effect on 
metastasis and 
angiogenesis 
 MMP-9, MMP-2 
 
 MMP-2, -9 
 HIF-1α 
 VEGF, 
VEGFR1/2 
 uPA 
  MDA cell 
invasion in vivo 
 MMP-2, -9,  
 uPA 
 VEGF 
 HIF-1α 
 VEGF 
 FGF 
Synergy 
with 
other 
therapies 
Radiation, TRAIL, 
doxorubicin, cisplatin, 
genistein. 
5-FU, taxol, 
tamoxifen, curcumin 
Unknown TSA, tamoxifen, 5-
FU, radiation 
Cisplatin, 
doxorubicin. 
 upregulation  downregulation  inhibition  activation. Abbreviations see page 4. 
References: general (Dorai & Aggarwal, 2004; Meeran & Katiyar, 2008; Ramos, 2008; Russo, 2007); 
curcumin (Chendil et al., 2004; Deeb et al., 2004; Mukhopadhyay et al., 2001); EGCG (Siddiqui et al., 
2006; Yang et al., 2006); equol (Hedlund et al., 2003; Setchell et al., 2002), genistein (Banerjee et al., 
2008; Gao et al., 2004; Huang et al., 2005; Takahashi et al., 2006; Wang et al., 2006); resveratrol (Kundu 
& Surh, 2004; Signorelli & Ghidoni, 2005; Ulrich et al., 2005). 
 
1.4.1 Phytochemicals selected for initial study 
1.4.1.1  Curcumin  
Curcumin is the principal curcuminoid present in turmeric (Curcuma longa) (Figure 7). It is 
widely used in Indian cuisine, giving curries their distinctive colour and taste. Turmeric is used 
in Chinese medicine and is also known as jiang huang. Curcumin is a strong antioxidant, with 
an oxygen-scavenging activity comparable to vitamin C and E. It is also a potent 
immunomodulatory compound and has been shown to decrease the production of pro-
inflammatory cytokines Tumour Necrosis Factor (TNF)-α and IL-1β (Maheshwari et al., 
2006). Curcumin has been shown to induce apoptosis in DU145 and LNCaP cells by 
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suppressing NFκB and AP-1 growth-promoting transcription factors (Mukhopadhyay et al., 
2001). Another reported target of curcumin is Toll-Like Receptor (TLR)-4 which is involved 
in the innate immune response to bacterial pathogens (Youn et al., 2006).  
 
Curcumin has recently been evaluated in Phase II clinical trials as a chemopreventive agent for 
colorectal and pancreatic cancers (Dhillon et al., 2008; Thomasset et al., 2007). A number of 
patients showed positive responses and stable disease, despite its limited absorption.  
 
 
Figure 7 The chemical structure of curcumin 
Curcumin is composed of two aromatic rings connected by a diketone.  
 
1.4.1.2  Epigallocatechin-gallate (EGCG) 
EGCG is a polyphenol found in the leaves of minimally oxidised Camellia sinensis (green tea) 
(Figure 8). EGCG has been observed to inhibit cancer growth in multiple in vitro and in vivo 
models. It inhibited Insulin-like Growth Factor (IGF) signalling and the PI3K/Akt pathway in 
both androgen-responsive and -nonresponsive cell lines, resulting in apoptosis (Khan et al., 
2006). In Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice, EGCG 
prevented carcinogenesis and prolonged survival. The molecular mechanism behind these 
effects could be linked to the irreversible arrest of cells in G1 via increased protein expression 
of p21 (Gupta et al., 2003). Several studies have also shown IκK and NFκB inactivation by 
EGCG. 
 
Numerous clinical trials have been conducted to determine the benefits of EGCG in humans. A 
phase II trial in patients with prostate intra-epithelial neoplasia showed decreased progression 
of the disease, although another trial did not find any improvements in patients with advanced 
hormone-independent PCa (Thomasset et al., 2007).  
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Figure 8 The chemical structure of epigallocatechin-gallate (EGCG) 
EGCG is contains a galloyl group linked to a skeleton of two benzene rings linked by a heterocyclic 
pyrane ring. 
 
1.4.1.3  Genistein 
Genistein is the most abundant isoflavone derived from soy (Glycine max). It occurs naturally 
as a glucosidic conjugate, genistin, and is hydrolysed to the active aglycone form, genistein, by 
intestinal enzymes. The structure of genistein contains two benzene rings linked by a 
heterocyclic pyrane ring (Figure 9). Genistein has structural similarity to oestrogen (Figure 
14), and has a strong binding affinity for estrogen receptor (ER)-β (Kuiper et al., 1998). In 
addition to its hormonal effects, genistein can modulate various intracellular signalling 
pathways involved in proliferation, apoptosis and cell cycle progression via the inhibition of 
DNA topoisomerases and tyrosine kinases (Table 4).  
 
Two chemopreventive phase II clinical trials with genistein have been conducted for breast 
and pancreatic cancer. A phase II clinical trial in PCa patients showed that soy 
supplementation containing genistein could inhibit PSA increases in both androgen-sensitive 
and -insensitive patient populations (Banerjee et al., 2008).  
 
 
Figure 9 The chemical structure of genistein 
Genistein is composed of two benzene rings linked by a heterocyclic pyrane ring 
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1.4.2 Additional phytochemicals selected for in-depth study 
1.4.2.1  Equol 
Equol is not strictly a phytochemical as it exists exclusively as an intestinal metabolite of 
daidzein which is present in soy. Equol is optically active due to its unique chiral centre and 
exists in R- and S-forms. Metabolism of daidzein by the intestinal bacterial flora results in the 
formation of the S-enantiomer. Two bacterial species, Adlercreutzia equolifaciens and Slackia 
isoflavoniconvertens, have recently been identified for their ability to convert daidzein to equol 
(Maruo et al., 2008; Matthies et al., 2009). Only about 30-50% of soy-consuming adults have 
the ability to produce equol, depending on their intestinal microflora (Yuan et al., 2007). The 
ability to produce equol is thought to be closely related to the lower incidence of PCa. Plasma 
and prostatic fluid concentrations of equol are higher in men from Hong Kong, who 
traditionally consume higher quantities of soy-based foods, compared to men from the UK or 
Portugal, whose diets do not usually include soy.  
 
Fewer studies have been conducted with equol due to its high cost and limited availability, 
although it has attracted more attention since it was shown to be more biologically active than 
its parent compound, daidzein, in terms of antioxidant and antiproliferative effects. Equol, like 
genistein, is a phytoestrogen. Equol has a high binding affinity for ERβ while genistein is less 
potent, with only a modest affinity for ERβ and little or no affinity for ERα (Setchell et al., 
2005). Equol inhibited cell growth in PCa cell lines by inducing cell cycle arrest in G1 
(Hedlund et al., 2003). The antiproliferative effect has been shown to hold true also in vivo 
(Lund et al., 2004). Equol’s anti-PCa effects are most probably due to its ability to act as a 
potent androgen antagonist, thus preventing growth stimulation through the AR (Lund et al., 
2004). 
 
Equol is typically present at concentrated levels in prostatic fluid compared to plasma levels, 
although the mechanism for its concentration has not been described (Hedlund et al., 2005). 
Equol is currently being assessed in a phase I and II clinical trial for the prevention of 
recurrent cancer in patients who have undergone surgery for stage II PCa.  
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Figure 10 The chemical structure of equol 
Equol is structurally similar to genistein but it lacks a hydroxyl and an oxygen group. 
 
1.4.2.2  Resveratrol 
Resveratrol (3,4’,5-tri-hydroxystilbene) is a polyphenol comprising two aromatic rings 
connected by an ethylene bridge (Figure 11). Resveratrol is a phytoalexin produced by various 
plants, including grapes (Vitis vinifera) and berries of the Vaccinium species, in response to 
fungal infection (de la Lastra & Villegas, 2005). The resveratrol concentration of red wine is 
double that of grape juice as resveratrol is released by the wine-making process. Resveratrol 
content of wines varies with the grape cultivar and its exposure to fungal infection, 
geographical origin and fermentation time. 
 
Resveratrol was first isolated in 1940, but therapeutic interest only developed after 1992 when 
resveratrol was postulated to explain some of the cardioprotective effects of red wine and the 
so-called ’French paradox’ (the low incidence of heart disease in France, despite diets high in 
saturated fats) (Fitzpatrick et al., 1993). Resveratrol can decrease platelet aggregation and lipid 
peroxidation, promote vasorelaxation and improve serum cholesterol and triglycerides 
concentrations (Baur & Sinclair, 2006). 
 
In 1997, a study showing the anticancer effects of resveratrol promoted the possibility of using 
the compound for chemoprevention and cancer therapy (Jang et al., 1997). Since then, there 
have been numerous reports of the anticancer effects of resveratrol in different models 
including PCa (Athar et al., 2007). Resveratrol in the diet decreased cancer progression in 
TRAMP mice and inhibited IGF-1 and ERK signalling (Harper et al., 2007). 
 
More recently, resveratrol has attracted attention as it has been shown to extend the lifespan of 
flies, worms, small vertebrate fish and even mice (Baur et al., 2006). This effect is thought to 
be due to resveratrol’s ability to enhance the activity of the nictotinamide adenine dinucleotide 
(NAD)+-dependent deacetylase silent information regulator-2 (SIR2) and the human homolog 
Sirt1 which belong to the sirtuin class III histone deacetylase family (Brown et al., 2009; 
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Howitz et al., 2003). These proteins are evolutionarily conserved and are thought to play a role 
in genomic stability, DNA repair and ageing (Michishita et al., 2005; Wang et al., 2008a).  
 
The pharmacokinetics of resveratrol have been investigated in a phase I clinical trial which 
demonstrated that oral doses up to 5g of resveratrol could be taken without any significant 
side-effects (Udenigwe et al., 2008). Resveratrol in the body has a short half-life and is rapidly 
converted to metabolites which remain present for much longer and may retain biological 
activity. The chemopreventive potential of resveratrol for colon cancer is being tested in a 
phase I clinical trial and its therapeutic efficiency is being tested in phase I-II trials for 
colorectal cancers. 
 
 
Figure 11 The chemical structure of resveratrol 
Resveratrol is composed of two benzene rings linked by a styrene double bond. 
 
1.4.3 Rationale for combining phytochemicals with Ad5 
1.4.3.1  Enhancing Ad5 infectabil ity 
Many studies have shown that oncolytic efficiency can be enhanced by combining viral 
treatment with chemotherapy (see Section 1.2.3.3). Phytochemicals have been found to affect 
various signalling pathways and they could therefore also act in synergy with viruses.  
 
The five phytochemicals were selected based on their modulatory effects on the MAPK 
pathway which has been implicated in the regulation of the adenoviral receptor CAR (Anders 
et al., 2003a). The cell surface expression levels of adenoviral receptors on target cells are 
crucial for efficient adenoviral-mediated oncolysis. The susceptibility of cells with low cell 
surface expression of CAR to Ad5 infection can be improved by ectopic expression of CAR 
(Douglas et al., 2001; Kaner et al., 1999). Thus, if phytochemicals could increase CAR 
expression levels, adenoviral potency might be enhanced.  
 
Adenoviral transgene expression has previously been shown to be increased by treatment of 
cells with agents such as etoposide, topotecan and FR901228, and that this correlated with 
  47 
enhanced CAR expression (Hemminki et al., 2003). Adenoviral transgene expression was 
increased in vivo, up to 11.2-fold by FR901228. A modified version of the TRAMP mouse 
which expressed CAR under the control of the PSA promoter also demonstrated enhanced 
expression of an adenoviral reporter transgene (Bao et al., 2005).  
 
CAR is a 46kDa transmembrane immunoglobulin-like protein which localizes to basolateral 
cell-cell adhesions and tight junctions of epithelial cells (Cohen et al., 2001). CAR co-localises 
with zonula occludens-1 (ZO-1), a protein central to tight juction structure which serves not 
only as a scaffold protein but also mediates downstream intracellular signalling (Coyne & 
Bergelson, 2005). CAR is most highly expressed in the heart, brain and pancreas, with 
significant expression in the testis and prostate (Tomko et al., 1997). 
 
Although human adult prostate cells have moderate levels of CAR, it is often decreased in PCa 
(Rauen et al., 2002). Forced expression of CAR in ovarian, cervical and PCa cell lines 
prevented cell migration so it is thought that CAR could act as a tumour inhibitor at this stage 
(Bruning & Runnebaum, 2004; Okegawa et al., 2000). Similarly, in gastric cancer cell lines, 
RNAi-mediated knock-down of CAR increased proliferation, migration and invasion, whereas 
ectopic expression of CAR had the opposite effect (Anders et al., 2009). Loss of CAR was 
also correlated with decreased tumour differentiation, the presence of distant metastases and 
reduced survival.  
 
It has also been shown that the spatial distribution of CAR within the cell is important in 
determining cellular susceptibility to adenoviral infection (Anders et al., 2003b). In normal 
human breast tissue, CAR was expressed at the cell membrane, particularly at the lateral cell 
surface where tight junctions are located. When CAR is participating in cell-cell adhesion 
complexes, it seems to be physically inaccessible and unavailable for binding by Ad5, 
rendering normal cells in intact tissue resistant to adenoviral infection. Early stage ductal 
carcinoma in situ (DCIS) samples exhibited even expression of CAR at the membrane and low 
cytoplasmic expression and their equivalent cell line in 3D culture lacked polarity and tissue 
organisation. This was associated with enhanced CAR expression and good infectability by 
Ad5. In contrast, infiltrating breast cancer samples showed weak, diffuse cytoplasmic staining 
or complete loss of CAR expression.  
 
Surprisingly, after metastasis, PCa cells have been found to re-express CAR to levels 
comparable to those found in normal tissue (Rauen et al., 2002). At this stage, CAR might act 
as an oncogene, enabling the attachment of metastatic cells to new sites or mediates survival 
signals that enhance proliferation.  
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Epigenetic studies of CAR have shown that CAR is transcribed from three exons downstream 
of a 5’-regulatory region containing potential binding sites for transcription factors including 
E2F, Sp1, Ets and c-Jun (Pong et al., 2003). The number of methylated CpG islands did not 
differ between CAR-positive and CAR-negative urogenital cancer cell lines, indicating that 
methylation does not regulate the CAR gene promoter. However, histone acetylation seems to 
play a role in the modulation of CAR expression as the chromatin structure surrounding the 
CAR gene promoter was maintained in an “open” conformation by the association with 
acetylated histone H4 and this was enhanced by the histone deacetylase (HDAC) inhibitor 
FR901228 which increased viral uptake. Other studies have also described CAR gene 
transcription up-regulation by HDAC inhibitors (Hemminki et al., 2003; Kitazono et al., 2001; 
Pong et al., 2003; Sachs et al., 2004). A recent study demonstrated that genistein can 
synergistically enhance the inhibition of HDAC activity and the level of acetylated H4 on the 
CAR promoter induced by FR901228, although genistein alone did not inhibit HDAC activity 
(Pong et al., 2006). 
 
Various signalling pathways have been implicated in CAR regulation. TGF-β treatment of 
pancreatic Panc-1 cells induced a mesenchymal phenotype, accompanied by loss of cell 
surface CAR, which could be reversed by the TGF-β inhibitor LY2109761 (Lacher et al., 
2006). TGF-β and the anti-inflammatory drug dexamethasone also decreased CAR expression 
in ovarian cancer cells, and pre-treatment with either agent reduced adenoviral gene transfer 
efficiencies (Bruning & Runnebaum, 2003). 
 
CAR has also been shown to be upregulated by the inhibition of the Raf-MEK-ERK pathway 
(Anders et al., 2003a). Inhibition of MEK in SW480, a colon cancer cell line, increased CAR 
at the mRNA level as well as the protein level, but that the inhibition of the PI3K pathway, 
which is also downstream of Ras, caused the opposite effect and decreased CAR expression. 
This might indicate that the level of CAR expression in a given cell line may be dictated by the 
balance between PI3K and MAPK signalling activities. 
 
1.4.3.2  Enhancing Ad5-induced tumour cell death 
As mentioned previously (Section 1.3.2.2), adenoviruses have been reported to increase the 
anti-cancer effects of a number of conventional chemotherapeutic drugs. This is thought to be 
mediated via the enhancement of viral replication and/or the induction of apoptosis by E1A. 
We hypothesised that, in addition to possible effects on viral uptake, the phytochemicals might 
also enhance cell death in combination with Ad5. Phytochemicals have been reported to 
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induce apoptotic and non-apoptotic cell death in various different models (Choi et al., 2009; 
Gatz & Wiesmuller, 2008; Li et al., 2007; Siddiqui et al., 2006; Singletary & Milner, 2008; 
Trincheri et al., 2008). We therefore sought to harness the ability of the phytochemicals to 
modulate signalling cascades synergistically to induce cell death with Ad5, whilst benefiting 
from their low systemic toxicity profiles. 
 
1.4.3.2.1 Apoptosis 
Apoptosis is a form of programmed cell death (PCD) during which the cell is dismantled by 
executioner cysteine proteases (caspases), resulting in the controlled fragmentation of DNA 
and the formation of apoptotic bodies which are engulfed and cleared up by macrophages 
(Taylor et al., 2008). Apoptosis can be induced extrinsically, via death receptor signalling and 
caspase-8, or intrinsically via pro-apoptoic proteins, such as Bad and Bid, and caspase-9 
(Figure 12).  
 
 
Figure 12 Apoptosis signalling 
Apoptosis can be induced by the binding of extracellular death ligands, such as TRAIL, to 
transmembrane death recptors, which induce downstream activation of caspase-8. Alternatively, 
apoptosis can be induced by the intrinsic pathway where cell stress or damage activate pro-apoptotic 
proteins such as Bid, Bim and Bad. These proteins promote the assembly of Bak-Bax in the 
mitochondrial outer membrane. This causes the release of cytochrome c into the cytosol, triggering 
caspase-9 activation. The extrinsic and intrinsic pathways converge at the activation of effector 
caspases-3 and -7 which mediate proteolysis and controlled dismantling of the cell into apoptotic bodies. 
These are subsequently engulfed by phagocytes. Based on figures in (Taylor et al., 2008). 
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High doses of phytochemicals have been reported to induce apoptosis and also sensitise cells 
to cytotoxic agents. Curcumin has been shown to be pro-apoptotic by downregulating anti-
apoptotic genes such as Bcl-XL and c-myc (Mukhopadhyay et al., 2001). This effect is 
mediated by its inhibition of IκB phosphorylation which prevents translocation of the 
transcription factor NFκB to the nucleus, so anti-apoptotic genes under its control are not 
transcribed. Curcumin sensitised PCa cells to TRAIL-, TNF- and radiation-induced cell death 
via this pathway (Chendil et al., 2004; Deeb et al., 2004). EGCG arrests PCa cells in G1, 
resulting in apoptosis, by modulating p21/WAF1, Bax and Bcl-2 (Hastak et al., 2003). 
Genistein is capable of inducing apoptosis by inhibiting DNA topoisomerase II (Markovits et 
al., 1989; Salti et al., 2000). Genistein was also found to synergistically enhance cell death 
with cisplatin, docetaxel and doxorubicin via the inhibition of NFκB (Li et al., 2005). Fewer 
studies have been conducted with equol, but it has been reported to induce cytochrome c 
release in breast cancer cells and trigger apoptosis via caspase-9 (Choi et al., 2009). 
Resveratrol can induce apoptosis in PCa cells directly and can sensitise these cells to apoptosis 
induced by death receptor-mediated apoptosis by TRAIL, Fas and TNFα (Gill et al., 2007; 
Shankar et al., 2007).  
 
It is possible that by combining phytochemicals with Ad5 cell death could be enhanced by 
decreasing the apoptotic threshold of cells. The adenoviral protein E1A can sensitise infected 
cells to TNFα-, TRAIL- and radiation-induced apoptosis (Brader et al., 1997; Sanchez-Prieto 
et al., 1996). The apoptotic-inducing effect of E1A can be enhanced by the deletion of E1B-
19K which is a Bcl-2 homolog and functions to block apoptosis (see Section 1.2.3.5) (White et 
al., 1991). We have recently shown that a replication-competent, E1B-19K-deleted adenoviral 
mutant enhances cell death in pancreatic cancer cells in combination with the DNA damage-
inducing chemotherapeutic drug gemcitabine (Leitner et al., 2009). 
 
1.4.3.2.2 Autophagy 
Although individual adenoviral proteins can induce apoptosis, adenovirus-mediated cell death 
is generally recognised to be non-apoptotic. The exact mechanism is still unknown but has 
been observed to be a ‘necrosis-like’ form of PCD (Abou El Hassan et al., 2004). A 
replication-selective mutant containing E1A under the control of the human telomerase reverse 
transcriptase promoter (hTERT-Ad) has also been shown to induce autophagic cell death of 
malignant glioma cell lines in vitro and in vivo (Ito et al., 2006). Similarly, Δ24-RGD (an 
adenoviral mutant deleted in E1A-CR2 with enhanced infectability via additional RGD motif 
in the fibre HI loop) also induces autophagy in glioma cells (Alonso et al., 2008). This type of 
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cell death may be cell type-specific, since infected ovarian cancer cells showed induced 
autophagy but it was not required for cell death (Baird et al., 2008).  
 
Autophagy is an evolutionarily conserved cellular process by which long-lived proteins and 
bulk cytosplasmic material are sequestered within a double-membrane vesicle, known as the 
autophagosome, and delivered to the lysosome for degradation and recycling of amino acids 
(Degterev & Yuan, 2008). Autophagy occurs at a basal rate as a ‘quality-control’ mechanism 
to eliminate damaged or aggregated proteins and maintaining cellular homeostasis. 
Misfunctioning of the pathway been implicated in a number of pathological conditions 
including Alzheimer’s and Crohn’s diseases (Levine & Kroemer, 2008). 
 
Autophagy is increased in response to nutrient starvation, withdrawal of growth factors, and 
external triggers such as infection or radiation. Under these types of stressful conditions, 
autophagy allows cells to recycle nutrients, maintaining protein synthesis and energy 
production. Autophagy therefore gives cells time to adapt and survive, or it can eventually lead 
to type II (autophagic) PCD, although this has yet to be demonstrated in mammals in vivo 
(Scarlatti et al., 2009).  
 
The main modulator of autophagy is the mammalian target of rapamycin (mTOR) which 
integrates growth-factor induced signals and represses autophagy (Figure 13) (Pattingre et al., 
2008). mTOR negatively regulates the  induction of autophagy by phosphorylating autophagy 
protein-13 (Atg13). Atg13 complexes with Atg1 and Atg17 and initiates autophagosome 
formation by activating vacuolar protein sorting-34 (Vps34), a class III PI3K. Vps34 usually 
exists in its inactive form as it is repressed by leucine, the principal indicator of amino acid 
supply in mammalian cells. Upon stimulation, Vps34 complexes with Beclin-1 and stimulates 
the formation of the autophagosome. 
 
Autophagy induction is controlled by upstream sensors that detect the nutritional status and 
stress levels of the cell. Class I PI3K signalling is enhanced by nitrogen sources and amino 
acids, acting as a sensor of the nutritional status of the cell (Codogno & Meijer, 2005). Active 
Class I PI3K negatively regulates autophagy via the serine threonine kinase Akt, which 
activates mTOR and downstream protein translation regulators p70S6K and eukaryotic 
initiation factor 4E (eIF-4E)-binding protein 1. Autophagy can also be inhibited by PTEN, 
which blocks Class I PI3K signalling and is often lost in advanced PCa. Conversely, oncogenic 
Ras downregulates autophagy via activation of Class I PI3K. The level of activation of the 
different branches of the PI3K pathway, as well as Ras status, affects the sensitivity of cell 
lines to the modulation of autophagy. The PI3K/Akt/mTOR signalling cascade is often 
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hyperactive in tumour cells and has been implicated in PCa progression (Gao et al., 2003; 
Murillo et al., 2001; Wu & Huang, 2006). Another important modulator of autophagy is the 
anti-apoptotic protein Bcl-2 which inhibits autophagy by binding to Beclin-1 (Pattingre et al., 
2005). This blocks the interaction of Beclin-1 and Vps34, inhibiting the assembly of the 
autophagosome, providing a link between apoptosis and autophagy. 
 
 
 
Figure 13 Autophagy signalling 
Autophagy is induced by nutrient starvation via the energy sensor AMPK and mTOR. mTOR also 
regulates protein translation by inducing p70S6K and inhibiting 4E-BP1. Inactivation of mTOR allows the 
formation of the Atg13-Atg1-Atg17 complex which stimulates Beclin-1 binding with the class III PI3K, 
Vps34 protein. In turn, this stimulates downstream Atg proteins and initiates authophagosome formation. 
The LC3 protein is a component of the double membrane of the autophagosome. The autophagosome 
eventually fuses with the lysosome, allowing degradation of proteins and recycling of amino acids. 
Growth factor stimulus signals through class I PI3K and negatively regulates autophagy. Cross-talk 
between autophagy and apoptosis occurs via Bcl-2 which blocks autophagy.  
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Autophagy defects and gene mutations have been detected in mouse models of breast, ovarian 
and prostate cancer (Kang et al., 2009; Qu et al., 2003). However, understanding whether the 
therapeutic goal should be to induce or repress autophagy is complicated by several 
observations indicating that autophagy might play differing roles depending on the stage of 
cancer progression (Kondo et al., 2005). Autophagy seems to act as a tumour suppressive 
mechanism during the development of cancer, but later it can provide a survival advantage to 
oxygen-restricted and nutrient-starved tumour cells. Autophagy may also function as a 
resistance mechanism against chemotherapeutic drug treatment, although, on the other hand, 
autophagy has been shown to crosstalk with, and in some cases be required for, apoptosis and 
other forms of cell death (Mathew et al., 2007). 
 
A number of chemotherapeutic agents have been shown to induce autophagic cell death. The 
antiestrogen tamoxifen induces autophagic cell death via downregulation of Akt and ceramide-
dependent induced expression of Beclin-1 in breast cancer cells (Bursch et al., 1996; Scarlatti 
et al., 2004). Temozolomide, a DNA alkylating agent, caused type II cell death in glioma cells 
and its anticancer effect was enhanced by inhibition of autophagy, depending on where in the 
autophagy pathway the inhibitor acted (Kanzawa et al., 2004). The Class III PI3K inhibitor 3-
methyladenine (3-MA) prevented temozolomide-induced cell death, while bafilomycin-A1, 
which prevents the fusion of autophagosomes with lysosomes, increased cell death and 
activated caspase-3. Radiotherapy has also been shown to induce autophagy in malignant 
breast, colon and prostate cells. Derivatives of the mTOR inhibitor and autophagy inducer 
rapamycin, CCI-779 and RAD001, are currently being developed as anticancer agents. These 
agents may have increased anti-tumour efficacy in combination with γ-irradiation therapy or 
chemotherapeutic agents (Kondo et al., 2005). 
 
Genistein has been reported to induce autophagy in ovarian cancer cells, by inhibiting glucose 
uptake and Akt phosphorylation (Gossner et al., 2007). Similarly, resveratrol downregulated 
glycolysis and blocked Akt phosphorylation and downstream signalling in ovarian cancer cells 
via mTOR and p70S6K which was proposed to explain the induction of autophagy (Kueck et 
al., 2007). Ovarian cancers have increased glycolytic activity and often over-express the Glut1 
glucose transporter, and may therefore be more sensitive to the restriction of glucose 
metabolism. Resveratrol has also been shown to induce autophagy in colorectal cancer cells 
(Trincheri et al., 2008). This effect was reversible but lead to apoptosis if allowed to proceed. 
Both the genetic inactivation of autophagy and the pharmacological inhibition of apoptosis 
prevented resveratrol-induced cytotoxicity. Interestingly, these examples demonstrate that 
autophagy and apoptosis are not mutually exclusive. Indeed, the cross-talk between the two 
pathways is beginning to emerge (Maiuri et al., 2007).  
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1.4.3.3  Restricting cancer growth-promoting pathways 
The inhibition of growth factor signalling pathways by phytochemicals could also break the 
endocrine loop in PCa required for androgen-resistant growth. The ERK1/2 signalling cascade 
has been implicated in PCa progression (Oka et al., 2005; Papatsoris et al., 2007). Hormone-
responsiveness could be restored by the phytochemicals. Genistein has a biphasic effect on 
human prostate epithelial cell proliferation: at low concentrations, believed to be 
physiologically achievable by soy-rich diets (<12.5µM), genistein decreases cell proliferation 
and ERK1/2 and MEK activity (Wang et al., 2006). At concentrations of 50-100µM, genistein 
has the opposite effect. Cell proliferation induced by low doses could be inhibited by the 
MEK1 inhibitor PD098059 and the antioestrogen ICI 182,780, indicating that the effect of 
genistein may be mediated via ER-dependent pathways.  
 
Genistein has been been shown to downregulate AR in LNCaP cells at the transcriptional level 
using doses as low as 0.1-1.0µM and this occurs via ERβ (Bektic et al., 2004). Equol and 
genistein are known as ‘phytoestrogens’ as they are structurally similar to 17β-oestradiol 
although they possess much lower estrogenic activity (Rosenberg Zand et al., 2002). Equol 
and genistein have higher affinity for ERβ than ERα, the former isoform being the 
predominant ER in the adult prostate gland (Kuiper et al., 1998; Prins & Korach, 2008). 
Ligand bound ERβ has been shown to protect against PCa while signalling through ERα is 
associated with increased hyperplasia and squamous cell metaplasia of the prostate. Equol and 
genistein also share common chemical features with other steroid hormones, such as 
testosterone and progesterone, and synthetic inhibitors including tamoxifen (Figure 14). They 
have been classified as natural selective ER modulators (SERMs) as they can act as estrogen 
agonists or antagonists in different tissues, depending on the concentrations of endogenous 
estrogen and the distribution of ER (Hwang et al., 2006).  
 
Resveratrol is also structurally related to oestrodiol. Resveratrol has been shown to compete 
for ER binding, leading to the expression of estrogen-responsive genes, and that this effect can 
be inhibited by estrogen antagonists (Gehm et al., 1997). In addition, resveratrol can decrease 
AR and PSA expression levels in LNCaP cells (Mitchell et al., 1999) 
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Figure 14 Structure of isoflavone phytoestrogens and related compounds 
Adapted from (Dixon & Ferreira, 2002) 
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1.5 Project aims 
• To identify phytochemicals that interact synergistically on cell death with Ad5 in PCa 
cell lines. 
• To select the most promising phytochemicals for in-depth study. 
• To determine the optimal sequence of administration of each combination of 
phytochemical and Ad5. 
• To determine the effects of equol and resveratrol on the viral lifecycle 
– Effects on the infectability of PCa cell lines 
– Effects on viral replication. 
• To determine the effects of equol and resveratrol on cellular processes with and 
without Ad5 on 
– Cell cycle progression 
– Apoptosis induction 
– Autophagy induction. 
• To confirm the synergistic enhancement of cell death by equol and resveratrol with 
replication-selective Ad5 mutants designed in our lab.
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2 Methods 
2.1 Reagents 
Curcumin and epigallocatechin gallate (EGCG) were obtained from Merck Biosciences 
(Nottingham, UK). Equol and genistein were from Apin Chemicals (Adington, UK). 
Resveratrol, 3-methyladenine (3-MA), rapamycin and bafilomycin-A1 were from Sigma (St. 
Louis, MO, USA). The phytochemicals were reconstituted in dimethyl sulphoxide (DMSO) 
(Fisher Scientific, Loughborough, UK) to give a stock concentration of 50mM. Bafilomycin-
A1, rapamycin and the pan-caspase inhibitor zVAD-FMK (Calbiochem, La Jolla, CA, USA) 
were also dissolved in DMSO to stocks of 5µM, 100µM and 5mM respectively. 3-
methyladenine (3-MA) was diluted in sterile distilled water to a stock concentration of 
100mM. Trichostatin-A was obtained from Calbiochem and diluted in DMSO to 1mM. All 
chemicals were aliquoted and stored at -20°C for use up to a year after reconstitution as it was 
noted that EC50 values for the phytochemicals decreased over time after storage for around 8 
months under these conditions.  
 
2.2 Cell culture 
The PCa cell lines 22Rv-1, LNCaP, DU145 and PC-3 were obtained from Cancer Research 
UK Cell Services (Clare Hall, Middlesex, UK). Characteristics of the cell lines are shown in 
Table 5. JH293 cells used for TCID50 assays are a sub-clone of the E1-transformed human 
embryonic kidney (HEK) 293 cell line, both obtained from Cancer Research UK Cell Services, 
as well as A549 human lung carcinoma cells used for primary viral expansions. Cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf 
serum (FCS), 100 units/ml penicillin, 100mg/L streptomycin and 584mg/L L-glutamine. Viral 
infections were done in 0% FCS DMEM medium for 2h and 2% FCS DMEM medium was 
used for culturing cells in 96- or 6-well plates. All experiments were done with cells between 
passages 5-25. Cells were subcultured every 3-4 days using 0.25% trypsin in versene to detach 
monolayers and generate single cells. Cells were incubated at 37°C in a humidified 
atmosphere with 5% CO2. Aliquots of 1×106 cells/ml were frozen in 10% DMSO, 20% FCS 
DMEM and stored in liquid nitrogen. All cell culture reagents were obtained from Cancer 
Research UK Cell Services. 
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Table 5 Characteristics of human PCa cell lines used in this project 
Characteristic 22Rv-1 DU145 LNCaP PC-3 
Year established 1999 1977 1980 1978 
Origin Primary tumour 
from CRW22Rv 
xenograft 
serially-passaged 
in mice. 
Carcinoma brain 
metastasis. 
Carcinoma 
supraclavicular 
lymph node 
metastasis. 
Grade IV 
adenocarcinoma 
bone metastasis. 
Androgen 
dependency 
Mutated androgen 
receptor. 
Androgen 
independent but 
responsive. 
Independent (no 
androgen receptor 
protein nor 
mRNA). 
Androgen 
responsive, 
promiscuous 
androgen receptor 
binding. 
Androgen 
independent (no 
androgen receptor 
protein nor 
mRNA). 
p53 status Wild type Mutated + - 
PTEN status + + - - 
Bcl-2 status ++ - + + 
(Skjoth & Issinger, 2006; Webber et al., 1997) 
 
2.3 Viruses 
2.3.1 Adenoviral mutants 
The majority of the experiments described in this thesis were done using wild-type adenovirus 
type 5 (Ad5). Synergy assays were also carried out using adenoviral mutants constructed in 
our laboratory based on the Ad5 backbone (Table 6). The identity of the viral mutants was 
confirmed by PCR using specific primers described in Section 2.3.5. 
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Table 6 Adenoviral vectors and their deletions 
Virus Deletion Insertions Reference 
Ad5 − −  
dl312 ΔE1A, ΔE3B − (Jones & Shenk, 1979) 
Ad5-Hey1 ΔE1, ΔE3 Hey1 under the control of the CMV 
promoter replacing E1A 
S. Cheong (manuscript 
in preparation) 
AdE1A-12S ΔE1, ΔE3 E1A-12S under the control of the CMV 
promoter replacing E1A 
E. Miranda (manuscript 
in preparation) 
Ad5-GFP ΔE1 GFP under the control of the CMV 
promoter replacing E1A 
Prof. Nick Lemoine’s 
lab 
Ad5-GFP 
REP 
ΔE3 GFP under the control of the Major Late 
Promoter region 
(Jin et al., 2005) 
Ad5tg None (wild type Ad5 generated from pTG3602) (Chartier et al., 1996) 
AdΔΔ ΔE1A-CR2, 
ΔE1B-19K 
− D. Oberg (submitted) 
AdΔE1B-19K ΔE1B-19K − (Leitner et al., 2009) 
AdΔCR2 ΔE1A-CR2 − D. Oberg (submitted) 
 
2.3.2 Viral production 
Viruses were produced and characterised by Jennelle Francis and Katrina Sweeney (scientific 
officers, Viral Gene Therapy group, Centre for Molecular Oncology and Imaging). Primary 
viral expansions were made using 30µl viral stock to infect a subconfluent T175 culture flask 
of A549 cells in 30ml 2% FSC medium. Cells and medium were harvested after the 
appearance of cytopathic effect (CPE) 48-72h post-infection, freeze-thawed three times and 
stored at -80°C. The primary expansion was used to infect HEK293 cells grown to 80% 
confluency in 10% FCS medium in ten-layer cell factories (CF-10, Fisher Scientific) in 2% 
FCS medium for 72h or until signs of CPE and detachment were observed, followed by routine 
viral isolation procedures (Wold, 1998). Briefly, cells and media were collected and 
centrifuged for 10min at 2000rpm at 4°C in a Sigma 6K15 centrifuge (Sigma, Germany). Cells 
were resuspended in 15ml cold PBS, centrifuged for 10min at 1000rpm and finally 
resuspended in 12ml cold 10mM Tris-HCl (pH8). Viral suspensions were freeze-thawed three 
times to release viral particles and centrifuged for 10min at 6000rpm. The supernatants were 
layered onto CsCl gradients prepared in 3.5” ultracentrifuge tubes (Beckman, UK) with 10ml 
1.25g/ml CsCl underlayed with 7.6ml 1.4g/ml CsCl solution. The virus preparation was 
centrifuged for 2h at 25,000rpm at 15°C in a Beckman SW28 swing-out rotor in an Optima 
LE-80K ultracentrifuge. After centrifugation, using a 19G needle, the bottom band of virus 
was extracted in a minimum amount of CsCl, discarding the top band of cell debris and the 
second band of empty viral particles. The virus suspension was layered onto 2.5ml 1.35g/ml 
CsCl solution in 2” ultracentrifuge tubes (Beckman) and centrifuged for 15h at 40,000rpm at 
15°C in a Beckman SW55Ti swing-out rotor in an Optima LE-80K ultracentrifuge. The 
purified virus band was collected using a 19G needle and the volume made up to 12ml with 
 60 
TSG buffer containing 96mM NaCl, 0.5mM Na2HPO4, 2.8mM KCl, 0.3mM MgCl2, 0.5mM 
CaCl2 and 30% (v/v) glycerol adjusted to pH7.5. The suspension was dialysed using a 3-12ml 
Slide-a-Lyser (Pierce Biotechnology, Rockford, IL, USA) against a buffer containing 10mM 
Tris-HCl (pH7.5), 1mM MgCl2, 150mM NaCl and 10% (v/v) glycerol for 24h at 4°C. The 
purified virus was removed from the dialysis chamber, aliquoted and stored at −80°C. An 
aliquot was used to determine viral particle and plaque-forming unit (pfu) titres as described 
below. 
 
2.3.3 Determination of viral particle titres 
To determine the particle count of purified virus, two viral samples were prepared: 
 
Sample 1. 100µl virus + 100µl dialysis buffer + 200µl lysis buffer 
Sample 2. 200µl virus + 200µl lysis buffer.  
 
The dialysis buffer was prepared as described in Section 2.3.2 and the lysis buffer contained 
1% SDS, 0.04M Tris-HCl in ddH2O. The samples were vortexed and heated for 10min at 
56°C, vortexed, allowed to cool for 10min and made up to 1ml with sterile H2O. The 
absorbance of each sample was measured at 260nm (OD260) with a Beckman DU520 
spectrophotometer. The viral particle count for each sample was determined according to 
Equation 1.  
 
Equation 1 Determination of viral particle counts by optical density 
Viral particles (vp)/ml = OD260 × dilution factor × extinction coefficient at 260nm wavelength 
(ε260) 
Where the dilution factor for Sample 1 = 10 and for Sample 2 = 5 
And purified adenovirus ε260 = 1.12×1012  vp/absorbance unit 
 
ε260 is the molar extinction coefficient of one vp/ml/absorbance unit, based on the assumption 
that 87% total dry weight of Ad5 is protein and that the molecular mass of a viral particle is 
2.3×107 Da (Maizel et al., 1968; Mittereder et al., 1996).  
 
Alternatively, viral particles were measured by determining DNA content using the Quanti-iT 
Pico Green dsDNA Assay Kit (Invitrogen, OR, USA). Viral stocks were diluted 1:6 and 1:10 
in Tris-EDTA (TE) buffer containing 10mM Tris-HCl (pH8), 1mM EDTA and 1% SDS and 
assayed in triplicate in 96-well plates. The Pico Green reagent was diluted 200-fold and 100µl 
added to each well. A standard curve was made using Lambda DNA (provided with the kit). 
  61 
Emission was read at 535nm after excitation at 485nm using Magellan Software version 6.3 
and a Tecan Infinite F200 plate-reader (Mannedorf, Switzerland). Viral particles/ml were 
calculated from the standard curve, assuming that 2.7×1010 viral particles contain 1µg DNA. 
 
2.3.4 Determination of viral activity 
Viral replication was determined by limiting dilution tissue culture infectious dose (TCID)50 
assay. JH293 cells were seeded in 96-well plates at a density of 1×104cells/well in 200µl/well 
in 10% FCS medium. The following day, purified virus was diluted to 1×10-7 and used to 
infect the top row of duplicate or triplicate plates (20µl/well) and serially diluted down the 
plate by transferring 22µl/well from each row down to the following row, leaving the last row 
uninfected as controls. Plates were incubated for 10 days after which each well was scored for 
signs of cytopathic effect (CPE). Wells where the monolayer had plaques of clear areas or 
where cells were rounded up were counted as positive. The titre of each sample was calculated 
in plaque-forming units (pfu)/ml using the Reed and Muench method (O'Reilly et al., 1994) 
(Equation 2). All viruses used in this thesis had a particle/pfu ratio between 10-50.  
 
Equation 2 Calculation to determine viral replication units 
TCID50 = 10 L - d (s - 0.5)  
TCID50/ml = TCID50 × v  
 
L = lowest dilution with CPE 
d = log difference between dilution steps 
s = Σ proportion of CPE-positive wells in each row 
v = infection volume = 0.02ml 
 
pfu/ml = Log TCID50 × µ 
Where µ = −ln p = 0.69 
 
According to the Poisson distribution:  
µ is the mean concentration of infectious particles at a given dose  
p is the proportion of cultures remaining uninfected, = 0.5 
 
2.3.5 Confirmation of viral identity 
The identity of each viral mutant was confirmed by PCR using specific primers. Viral DNA 
was extracted from 200µl dialysed virus using purification columns from a DNA Blood Mini 
Kit (Qiagen, West Sussex, UK) following the manufacturer’s protocol. PCR reactions were set 
up with 8 primer sets shown in Table 7 using the Advantage 2 PCR Kit (Clontech, CA, USA). 
Each reaction contained 50ng purified viral DNA, 1µl of forward and reverse primers (10µM), 
3µl 10X PCR buffer, 1µl dNTP (10mM), 1µl DNA mix and 20µl dH2O to make a final volume 
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of 30µl. DNA was amplified by 35 cycles (94°C 40s, 62°C 60s, 72°C 90s) in a Gene Amp 
PCR System 9700 (Applied Biosystems, CA, USA). PCR samples were separated on a 1.5% 
agarose gel with a DNA Hyper ladder IV (Bioline, UK) to determine the size of amplified 
DNA fragments. The expected sizes were calculated from known sizes of each sequence and 
the deletions made (Table 8). An example of a typical PCR identity gel is shown in Figure 15.  
 
Table 7 PCR primers used to determine viral identity 
Primer set Direction Sequence 
5’ forward CCCGGTGAGATTCCTCAAGAGGCCAC 1 
3’ reverse CCGGACCCAAGGCTCTCTGCTCTCCGGCTGCTCGGGC 
5’ forward GTAATGTTGGCGGTGCAGGAAGGGATTG 2 
3’ reverse GGGTCCCCCGTATTCCTCCGGTGATAATGAC 
5’ forward GTGTTCGCTTTGCTATATGAGGACCTGTGGC 3 
3’ reverse CCTCGATACATTCCACAGCCTGGCGACGCCCACC 
5’ forward CCTGTGATTGCGTGTGTGG 4 
3’ reverse GACAACAGTAGCAGGCGATTC 
5’ forward GCATCTGTGGAGAGCGGTTGTGAGACAC 5 
3’ reverse GCGCCAGCAGATCAAGCTCATTAGCGC 
5’ forward GCTTAATGACCAGACACCGTCCTGAGTG 6 
3’ reverse GCACCAAGTGATCGGGCCTCAGCTCC 
5’ forward CACCCTCACGCTCATCTGCAGCCTCATCACTGTGG 7 
3’ reverse CTTCAGACGGTCTTGCGCGCTTCATCTGC 
5’ forward CGCTGGGGTCGCCACCCAAGATGATTAGG 8 
3’ reverse GAGTAGGGTACAGACCAAAGCGAGCACTG 
 
Table 8 Expected size of DNA fragments generated by PCR primer sets 
Primer set 5’ binding site 3’ binding site Target sequence Expected Ad5 size (bp) 
1 476 853 E1A start 377 
2 767 1029 E1A-CR2 262 
3 1069 1453 E1A end 384 
4 1554 2086 E1B-19K 532 
5 2073 2440 E1B-55K 367 
6 2383 3434 E1B-55K 1051 
7 29915 31038 E3B 1123 
8 28715 29135 E3-gp19K 420 
5’ and 3’ binding sites refer to the Ad5 genome sequence base pairs (NCBI Reference Sequence: 
AC_000008.1) (Chroboczek et al., 1992) 
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Figure 15 Verification of viral identity for Ad5ΔE1B-19K 
The sizes of 8 regions of the viral genome were determined by PCR using primer sets shown in Table 7 
as detailed in Methods Section 2.3.5. The first lane in each set represents amplified DNA from Ad5 wild-
type, the second lanes are from the mutant, Ad5ΔE1B-19K in this case. Fragment sizes were estimated 
using the DNA ladders on either side of the gel, and compared to expected sizes (Table 8). Primer set 4, 
detecting E1B-19K, amplified a smaller (390bp) DNA region in the Ad5Δ19K mutant (right lane) 
compared to wild type Ad5 (left lane) which shows amplification of the full-length 532bp region. 
 
2.4 Cell viability and synergy 
2.4.1 MTS assay 
Cells were seeded in 96-well plates in 200µl/well of 10% FCS medium at a density of 
1×104cells/well (DU145, PC-3) or 2×104 cells/well (22Rv-1 and LNCaP) in triplicate plates. 
After allowing cells to adhere overnight, the seeding medium was replaced with 2% FCS 
medium to a total volume of 100µl/well. Ad5 and phytochemicals were diluted in serum-free 
medium and added to the wells at 10-fold higher concentration after serial dilution (5-fold 
dilutions, 10µl/well). Viability was assessed 6 days post-treatment (7 days after seeding) using 
the MTS viability assay performed according to the manufacturer’s instructions (Promega, WI, 
USA). The tetrazolium salt MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-
(4-sulphophenyl)-2H-tetrazolium) is converted by mitochondrial dehydrogenases in 
metabolically active cells to a soluble formazan compound which absorbs light at 490nm. The 
product of the reaction is directly proportional to the relative number of live cells. After 
incubation at 37°C for 3h (DU145 and PC-3), 4h (LNCaP) or 7h (22Rv-1), the plates were 
read using a microplate reader (Opsys MR, Dynex Technologies) at a wavelength of 495nm. 
Values were corrected against the blank wells containing media without cells and expressed as 
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percentage cell death compared to untreated control cells. Sigmoidal dose-response curves 
were generated by non-linear regression analysis using GraphPad Prism version 4.0c for 
Macintosh (GraphPad Software, San Diego California, USA) to determine the effective 
concentration (EC)50 values (dose required to kill 50% cells) for each agent or combination of 
agents in each cell line. 
 
2.4.2 Synergistic interactions between Ad5 and phytochemicals 
Drug combinations have been used empirically since the earliest days to cure diseases and 
alleviate symptoms. For example, Chinese herbal medicine is based on the interaction of 
mixtures of plant-based compounds. A number of stategies to evaluate these interactions 
mathematically have been proposed. This is of particular interest in oncolytic drug 
development where the mechanisms of action of drugs might suggest therapeutic benefits 
when used in combination. It can also be of value when a drug being developed is to be used in 
combination with an exisiting drug as part of a treatment regime.  
 
Evaluating the interactions between drugs is challenging, not least due to the complexitiy of 
biological systems. A review by Greco et al. categorized thirteen different approaches to 
model and evluate drug combinations (Greco et al., 1995). The most commonly used stategies 
and those employed in this study will be considered here. The various models and their 
limitations have most recently been presented in a complete review by Chou who has 
developed this field for the past 35 years (Chou, 2006).  
2.4.2.1  Summation method 
This basic evaluation of the interaction between two agents involves simply comparing the 
sum of the inhibitory effects of each drug alone to the observed effect. If the observed effect is 
greater than the expect sum of the effects of each drug alone, the drugs are considered to act 
synergistically (Equation 3). The limitations of this method can immediately be seen when 
considering drugs with high effects alone. 
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Equation 3 Summation of effects 
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2.4.2.2  Fractional product method 
An alternative to the summation method first described by Webb (Webb, 1963) is known as 
the fractional product or the survival fraction method (Chou & Talalay, 1984). It takes into 
account the potency of each drug alone (Equation 4), avoiding the problem of fractional 
inhibition which occurs in the evaluation of synergy by the summation of effects (Equation 3). 
However, it is only valid when the drugs assessed have hyperbolic curves (i.e. simple 
Michaelis-Menten kinetics). This is typically the case for simple systems such as enzymatic 
inhibition, but complex systems involving cellular or in vivo models more commonly have 
sigmoidal curves (Figure 16). Furthermore, it requires that the mechanisms of the drugs are 
mutually nonexclusive (i.e. that they act totally independently). 
   
Equation 4 Fractional product effect 
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Figure 16 Dose-response curves for two drugs with differing kinetics 
Examples of dose-response curves for two drugs. A: drug with a hyperbolic curve and an EC50 (Dm) value 
of 1µM. B: drug with a sigmoidal curve and an EC50 (Dm) value of 3.5µM. The effect of doubling the 
doses varies greatly between the two drugs due to their differing kinetics, highlighting the difficulty of 
estimating the ‘additive effect’ of the two drugs (Chou, 2006).  
 
2.4.2.3  Combination index and isobologram method 
The combination index (CI) and isobologram method is based on the concept that synergy is 
characterized by two agents ‘working together’, as opposed to antagonism where the agents 
‘work against’ each other. This implies the existence of a middle state where there is no 
interaction. This is referred to as the zone of ‘additivity’ or ‘zero interaction’. 
 
The region of zero interaction can be respresented graphically by an isobole joining points of 
isoeffective doses of the combination on a graph with axes for doses of each agent (Figure 17). 
At these doses, CI equals 1 (Equation 5). Synergistic combinations have a CI < 1 and map 
below the line of additivity while antagonistic combinations have a CI > 1 and are located 
above the isoeffective isobole. The classic isobologram method was introduced by Loewe in 
 
  67 
1928, and later refined by Chou and Talalay (Chou, 2006). Isobolograms representing 
Effective concentrations (EC) rather than percentages of inhibition effect are most commonly 
used to offer a more complete overview of the interaction between two agents (Figure 18). 
 
Equation 5 Combination index 
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Figure 17 A classic isobologram 
Isobolograms showing interactions between drug A and drug B. The dashed line indicates the zero 
interaction isobole i.e. the loci of combinations that would produce this effect if there was no interaction 
between the drugs. Combinations are plotted, e.g. E(dadb) at ×. Combinations that plot below the line of 
additivity are synergistic (CI<1, concave isobole, red line). Those that fall above the isoeffective line are 
antagonistic (CI>1, convex isobole, blue line). Based on figures in (Berenbaum, 1989).  
 68 
 
Figure 18 Isoeffective isoboles at varying effect levels  
Isoboles can be constructed for differing levels of effectiveness. Each dashed line represents zones of 
zero interaction at different effect levels (ECx) for drugs A and B. Based on a figure in (Chou, 2006). 
 
CIs calculated for varying levels of inhibition (EC%) can be plotted on a graph of CI against 
effect level, as the response for the same drugs can vary according to the doses and inhibition 
level (Figure 19). For infectious diseases and cancer therapies, synergy at high effect levels 
such as EC90-99 may be more therapeutically relevant than low levels. Although initially it is 
recommended to begin synergy studies with equipotent ratios (e.g. EC50 Da:EC50 Db) so that the 
contribution of each drug can be expected to be equal. However, this is not essential and 
indeed the ratios can be varied according to the requirements for particular drugs. For instance, 
the contribution of an agent may be deemphasized if it is known to induce severe toxiticity, 
has a narrow dose range, or if it exhibits limited availability due to source, price or solubility.  
 
 
Figure 19 Combination index plot 
Combination indices are calculated for each drug combination at varying inhibitory effect levels, 
according to Equation 5. Drugs typically demonstrate better synergy at higher effect levels. Based on a 
figure in (Chou, 2006).  
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2.4.2.4  Theoretical considerations for selecting an appropriate 
model 
The isobole method is generally considered the most valid as it is independent of the 
mechanism of action of the agents and their dose-response kinetics (Berenbaum, 1989). 
Computer software has been developed to simplify isobologram analyses. These include 
CalcuSyn and CompuSyn, the latter being the most recent (Chou, 1997; 2005). This program 
can handle data analysis of large scale drug combination studies and present data in 
publication-quality graphics with statistics.  
 
The use of other stategies will sometimes give different answers for the same drugs. For 
example, if two drugs give 50% inhibition alone, and 90% inhibition when combined, the 
summation method classifies this as antagonistic (100% inhibition expected) while using the 
fractional method it is synergistic (75% inhibition expected). However, the choice of analysis 
depends on the drugs to be investigated, as well as the time and resources available. 
Nevertheless, it is useful to bear the limitations of each method in mind when considering 
results reported in the literature. 
 
We chose to assess the interactions between Ad5 and phytochemicals by generating 
isobolograms and CIs (see Section 2.4.3), since this is the most robust method to determine 
synergy between two agents. Having established the occurance of synergy between Ad5 and 
selected phytochemicals at specific ratios, we went on to use the simpler combination assay to 
conduct a wider screening study with five phytochemicals (as detailed in Method Section 
2.4.4, see also Results Sections 3.1.3 and 3.1.4). Synergy between equol and resveratrol with 
Ad5 mutants was established using the isobologram and CI method using optimised ratios 
detailed in Section 2.4.3 (see also Results Section 3.5).  
 
2.4.3 Determination of synergy between Ad5 and phytochemicals 
Synergy assays were performed by combining 5-fold serially diluted phytochemicals (0.001-
500µM) and wild type or mutant Ad5 (0.004-100,000 particles per cell (ppc)) according to 
Chou and Talalay’s combination index method (see Section 2.4.2.3) (Chou & Talalay, 1984). 
Cells in 96-well plates were treated in triplicate with different fixed ratios of virus and 
phytochemical. The ratios tested for equol and genistein in the first study with wild-type Ad5 
were 1ppc:5nM, 1ppc:1nM, 1ppc:0.2nM and 1ppc:0.04nM (DU145 and 22Rv-1) or 
1ppc:10nM, 1ppc:2nM, 1ppc:0.4nM and 1ppc:0.08nM (LNCaP) (see Results Section 3.1.2). 
These ratios were based on effective ratios used previously in our lab to test for synergy 
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between Ad5 and chemotherapeutic drugs. In the second study of equol and resveratrol with 
adenoviral mutants, the ratios tested were lowered to emphasize the contribution of 
phytochemicals and take into account their low cytotoxicity. The ratios used in this study were 
1ppc:125nM, 1ppc:625nM, 1ppc:3125nM, 1ppc:15625nM (DU145 and PC-3) or 1ppc:250nM, 
1:1250nM, 1ppc:6250 and 1ppc:31250nM (22Rv-1) (see Results Section 3.5). Cellular 
viability was determined 6-days post-infection by MTS assay as described in Section 2.4.1. 
 
Dose-response data for each agent alone were compared to dose-response data for 
combinations at fixed concentration ratios (Figure 20 A and B). By plotting doses of each 
single agent which killed 50% of cells and connecting these two points by a straight line 
(Figure 20 C) representing theoretical additive effects, experimental results from combination 
dose-response EC50 values were plotted as coordinates on the isobologram. Data points below 
the line indicate a synergistic interaction between the agents at the respective combination 
ratio and those above the line indicate a subadditive/antagonistic effect. Synergistic 
interactions were also evaluated by determining combination indexes (CIs, Figure 20 D) 
according to Equation 6 and following a conservative version of Chou’s suggested CI ranges 
for categorizing interactions as synergistic, additive or antagonistic (Chou, 2006; Hallden et 
al., 2004).  
 
Equation 6 Combination index calculation 
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CI ≥ 1.2 sub-additive effect (antagonism) 
0.8 < CI < 1.2 additive effect 
CI ≤ 0.8 supra-additive effect (synergy) 
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Figure 20 Example of isobologram analysis of synergy 
PC-3 cells were treated with Ad5 and equol at four fixed combination ratios as detailed in Methods 
Section 2.4.3. Cell viability was determined 6 days post-infection by MTS assay. The isobologram 
analysis was performed as described above using Excel and Prism softwares to obtain combination 
indexes (CI) for each ratio.  
 
2.4.4 Combination assays 
Combination assays were performed by combining three fixed concentrations of 
phytochemicals with 5-fold serially diluted wild type Ad5 to generate Ad5 dose-response 
curves. The combinations selected were based on the dose-response curves and EC50 values in 
each cell line so that <40% of cells were killed by the phytochemicals alone. In the first study, 
Ad5 was serially-diluted ten times from 1×10-1-2×105ppc (PC-3) or 1×10-1-1×105ppc (22Rv-1). 
The concentrations of phytochemicals used were 5µM, 10µM, 30µM (PC-3) or 40µM  (22Rv-
1) for curcumin, 1µM (PC-3), 5µM, 10µM, 25µM (22Rv-1) for EGCG, 5µM, 50µM, 100µM 
for equol, 5µM, 50µM, 70µM (22Rv-1), 100µM and 150µM (PC-3) for genistein, 1µM, 10µM 
and 50µM for resveratrol. In the second study, equol was used at 10µM, 50µM and 100µM, 
resveratrol at 5µM, 10µM and 15µM with 5-6 serial dilutions of Ad5 (22Rv-1: 1×10-1-
6.4×101ppc; DU145: 2.56×10-1-1.6×102ppc; PC-3: 1.28×10-1-4×103ppc). Cells in 96-well 
plates were treated in triplicate and read by MTS assay 6-days post-treatments as described in 
Section 2.4.1. 
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2.5 Flow cytometry 
2.5.1  Infectability 
Cells were plated in 24-well plates at a density of 1×105 cells in 1ml/well. Cells were pre-
treated with equol (100µM) or resveratrol (10µM) or normal 10% FCS medium. After 24h the 
cells were infected in duplicate in 0% FCS medium (500µl/well) with a non-replicating Ad5-
GFP (22Rv-1: 25 ppc; DU145: 50 ppc, PC-3: 300ppc). Infection was allowed to proceed for 
2h, after which the infection medium was removed and replaced with normal or 
phytochemical-containing 2% FCS medium (1ml/well). Uninfected and untreated infected 
cells were used as controls. Cells were incubated at 37°C until harvesting for flow cytometry 
by trypsinisation. The cells were washed once with 3ml/sample of cold FACS buffer 
containing 1mM EDTA (Cancer Research UK Cell Services) and 0.1% BSA (Sigma) in PBS 
(Cancer Research UK Cell Services). Cells were spun at 1700rpm for 3min and resuspended in 
400-800µl FACS buffer. Cells were kept on ice and 2.5µg/ml propidium iodide (PI, 
Invitrogen) in PBS was added 5min before analysis by flow cytometry. Ten thousand events 
were acquired by flow cytometry on a FACScalibur cytometer (Becton Dickinson 
Immunocytometry Systems, Belgium) with CellQuest Pro Software version 4.0.2. The data 
was analysed by gating live cells on a PI (FL-3) vs. forward scatter (FSC) plot and then 
quantifying GFP+ cells on a plot of green fluorescence (FL-1) vs FSC and setting the marker 
to encompass <1% cells on the uninfected, untreated control.  
 
2.5.2 Surface expression levels of Ad5 receptors 
Cells (2×105 cells/well) were seeded in 6-well plates and allowed to adhere overnight. The 
following day, the medium was replaced with medium containing equol (100µM) or 
resveratrol (10µM) or no phytochemical. Cells were treated in duplicate wells. Following 24h 
incubation, cell surface receptors were detected using mouse monoclonal primary antibodies 
against CAR (American Type Cell Collection, Manassas, VA, USA, diluted 1:500), αVβ3 
integrin (Chemicon, USA, diluted 1:400) or αVβ5 integrin (Cancer Research UK Mab Services, 
diluted 1:520). Cells were incubated with the primary antibody in 5% goat serum 
(DakoCytomation, Glostrup, Denmark) at 4°C for 1h. The cells were then washed and 
incubated in the dark at 4°C for 1h with a secondary goat anti-mouse F(ab’)2 fluorescein 
isothiocyanate (FITC)-conjugated antibody (Dakocytomation, 1:30 dilution). All dilutions and 
washes were performed using 3ml/sample cold FACS buffer (composition detailed in Section 
2.5.1). To control for background fluorescence, cells were incubated without the primary 
  73 
antibody but labelled with the secondary antibody. Flow cytometry acquisition and analysis 
were performed as described in Section 2.5.1. 
 
2.5.3 Cell Cycle analysis 
Cells were seeded 24h before treatments in 6-well plates at a density of 2×105cells/well. Cells 
were infected in duplicate with Ad5 (100ppc) or mock infected. After 2h the infection medium 
was removed and replaced with 2% FCS medium with or without phytochemicals (equol 
100µM or resveratrol 10µM). At 24h and 48h after treatments, the cells were harvested by 
trypsinisation and fixed in 1ml 70% ethanol (Fisher Scientific, Loughborough, UK). To 
analyse DNA contents of the cells, the samples were washed twice with PBS (3ml/sample) and 
then stained with 10µg PI and 5µg RNase (Sigma, St. Louis, MO, USA) in a final volume of 
500µl PBS. Flow cytometry acquisition was performed as described in Section 2.5.1. A 
primary gate on forward scatter (FSC) vs. right angle side scatter (SSC) dot plot was used to 
exclude cell debris. A second gate on a dot plot of pulse-area (FL2-A) vs. pulse-width (FL2-
W) was used to exclude doublets. PI fluorescence (FL3-H) was then plotted against cell counts 
on a linear scale to distinguish between the different phases of the cell cycle. The G1 marker 
was set around the first peak at 2N DNA content, and the G2/S marker was set to encompass 
the second peak at 4N DNA content. The S phase marker included cells between 2N and 4N 
DNA content, while the sub-G1 marker counted cells with ≤2N DNA. 
 
2.5.4 Mitochondrial membrane potential depolarization 
Tetramethylrhodamine ethyl ester perchlorate (TMRE, 40nM) is a red fluorescent lipid cation 
which accumulates rapidly and reversibly in living cells. Loss of fluorescence intensity 
indicates mitochondrial membrane depolarization which is characteristic of apoptotic cells. 
Fluorescence can therefore be used as a measure of the mitochondrial potential difference 
(Δϕm) 
 
Cells were seeded 24h before treatments in 6-well plates at a density of 1-2×105cells/well. 
Cells were infected in duplicate with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc) for 2h 
and incubated with normal 2% FCS medium or phytochemical-containing medium. Treatment 
for 24h with the apoptosis-inducer staurosporine at 1µM/well (Calbiochem) was used as a 
positive control. Cells and media were harvested after 24-96h by trypsinisation, washed once 
with PBS (3ml/sample), then stained with TMRE (Invitrogen) by adding 40µL 1µM TMRE 
working stock to cells resuspended in 500µL PBS. Cells were incubated for 20min at 37°C in 
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the dark. Cells were washed with PBS, stained with 50µl 1µg DAPI (Polysciences, PA, USA) 
and flow cytometry performed as described in Section 2.5.1. The data were analysed by gating 
live cells on the FSC vs. SSC dot plot and then plotting DAPI fluorescence (FL-4) vs. TMRE 
fluorescence (FL-2). Results were shown as the percentage of cells that retained TMRE 
staining i.e. intact, active mitochondria but were negative for DAPI i.e. intact cellular 
membrane. 
 
2.5.5 Annexin-V detection of phosphatidylserine externalisation 
Cells were seeded and harvested as described in Section 2.5.4. Cells were stained for 30min at 
4°C in the dark with Alexa Fluor 488-conjugated Annexin-V in dH2O containing 10mM 
HEPES, 140mM NaCl and 2.5mM CaCl2. Cells were washed with PBS, stained with PI and 
flow cytometry performed as described in Section 2.5.1. The data were analysed by gating live 
cells on an FSC vs. SSC dot plot. Gated cells were then plotted on a PI fluorescence (FL-3) vs. 
Alexa 488-Annexin-V fluorescence (FL-1) graph with a quadrant to distinguish between live 
(PI-negative/Annexin-V-negative), apoptosing (PI-negative/Annexin-V-positive) and dead (PI-
positive/Annexin-V-positive) cells.  
 
2.5.6 Active caspase-3 detection 
Cells were seeded in 6-well plates at a density of 2×105cells/well. The following day, cells 
were infected with 100ppc Ad5 in serum-free medium. After 2h, the infection medium was 
aspirated and replaced with 2% FCS medium with or without equol (100µM) or resveratrol 
(10µM). At 48-96h post-infection, cells and media were harvested by trypsinisation, washed 
with PBS (3ml/sample) and labelled with a FITC-conjugated anti-active caspase-3 antibody 
according the the manufacturers’ instructions (Active caspase-3 FITC Mab apoptosis kit 1, BD 
Biosciences Pharmingen, San Diego, CA, USA). Cells were washed with PBS, stained with PI 
and flow cytometry performed as described in Section 2.5.1. The data were analysed by gating 
live cells on a PI (FL-3) vs. forward scatter (FSC) plot and then quantifying FITC+ cells on a 
plot of green fluorescence (FL-1) vs FSC and setting the marker to encompass <1% cells on 
the uninfected, untreated control.  
 
  75 
2.6 Viral replication  
2.6.1 Burst assay 
Viral replication was determined by performing burst assays in PCa cell lines followed by 
limiting dilution tissue culture infectious dose (TCID)50 assays in JH293 as described in 
Section 2.3.4. For the burst assay, cells were seeded at a density of 2×105 cells/well in 6-well 
plates. The following day, cells were infected with 100ppc of Ad5 in serum-free medium for 
2h. The infection medium was aspirated and replaced with 2% FCS media containing equol 
(100µM) or resveratrol (10µM) or no phytochemicals, each treatment in duplicate. At 24h, 48h 
and 72h post-infection, cells were detached by scraping and collected together with the media 
and stored at -80°C. Burst assay samples were freeze-thawed three times, diluted 100-1000-
fold and assayed by TCID50 as described in Section 2.3.4.  
 
2.6.2 Quantitative PCR 
Viral genome copies were quantified as an indirect measurement of viral replication. Cells 
were seeded in 6-well plates at a density of 2-4×105 cells/well. After adhering overnight, cells 
were infected in duplicate with 100ppc of Ad5 in 1ml/well serum-free medium for two hours. 
The infection medium was then removed and replaced with 2ml/well 2% FCS media 
containing equol (100µM) or resveratrol (10µM) or no phytochemicals. Samples were 
harvested at 3h, 24h, 48h and 72h post-infection by scraping cells into 200µl/well of PBS. 
DNA was extracted by adding 20µl/sample of proteinase K (Qiagen, UK) and using 
purification columns from the DNA Blood Mini Kit (Qiagen) following the manufacturer’s 
protocol. DNA concentrations were determined by Nanodrop (ThermoScientific) and adjusted 
to 5ng/µl with autoclaved ddH2O.  
 
Gene copy numbers of hexon were determined for each sample in triplicate using 0.6µl each of 
10µM forward and 10µM reverse primers (Table 9) with 10µl Power SYBR Green PCR 
MasterMix (Applied Biosystems, Warrington, Cheshire, UK) for 2µl DNA template with a 
total reaction volume of 20µl. The reactions were run on an ABI 7500 RealTime PCR System 
(Applied Biosystems).  
 
Gene copy numbers were determined as increase in SYBR-Green fluorescence and quantified 
against a standard curve generated by using Ad5 DNA 10-fold serially diluted from 5×108 
particles (V1) in ten steps. One Ad5 particle has a mass of 3.9×10-5pg, and consequently, the 
mass of the starting dilution of 5×108 viral genomes is equal to ≈9.8ng. The starting dilution to 
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make the standard curve can then be calculated as shown in Equation 7. The analysis was 
performed using the Sequence Detector Software version 1.9.1 (Applied Biosystems). 
 
Table 9 Hexon DNA primers 
Primer Sequence 
Forward 5’-GGACAGGCCTACCCTGCTAAC-3’ 
Reverse 5’-TGCTGTCAACTGCGGTCTTG-3’ 
 
Equation 7 Calculations to generate Ad5 standard curve 
Ad5 genome size × average base pair mass = mass of Ad5 genome 
35938bp × 1.096×10−21g/bp= 3.94×10−5pg/genome 
 
To make V1 = 5×108 genome copies: 
Mass of 5×108 genome copies = 5×108 genomes × 3.94×10−5pg/genome = 19694pg 
qPCR reaction volume: 2µl 
∴ 19694 ÷ 2 = 9847.012pg/µl 
 
To make 25µL of V1: (9847.012pg/µl × 25µl) ÷ stock DNA pg/µL = volume of stock DNA to use 
(µl) + (25µL –answer) dH2O 
 
2.7 Protein expression levels 
2.7.1 Preparation of protein lysates 
Cells were lysed in 1× Radio Immuno Precipitation Assay (RIPA) buffer containing protease 
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). RIPA buffer was made five-fold 
concentrated in dH2O with 0.75M NaCl, 5% NP40, 2.5% deoxycholic acid, 0.5% SDS and 
0.25M Tris pH8. One tablet of protease inhibitor cocktail containing inhibitors of serine-, 
cysteine- and metallo-proteases was used for 10ml 1× lysis buffer. Protein concentrations were 
determined by Bradford assay according to the manufacturer’s instructions (Bio-Rad, 
Philadelphia, PA, USA) using bovine serum albumin (BSA, Sigma) stock at 1µg/µl to make a 
standard curve from 0 to 5µg. Protein lysates were diluted to 1µg/µl in loading buffer and 
stored at -80°C. Loading buffer was made up five-fold concentrated in dH2O with 2% SDS, 
250mM Tris-HCl pH7.5, 5mM EDTA in 50% glycerol, bromophenol blue (0.25% w/v). β-
mercaptoethanol was added fresh (5% v/v) before diluting the samples.  
 
2.7.2 Western blotting 
Equal amounts of total protein (10-20µg) from the cell lysates were loaded onto 10-15% SDS 
reducing polyacrylamide gels made using the Hoefer SE-400 Western blot system (Amersham 
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Biosciences, UK). A PageRuler Prestained protein ladder (Fermentas, UK) was used to 
evaluate protein size. The samples and the ladder were separated by electrophoresis at 130V in 
a reducing running buffer containing 25mM Tris, 250mM glycine and 0.1% SDS. After 90min 
or until the bromophenol blue reached the bottom of the gel. The proteins were transferred 
from the gel onto polyvinylidene fluoride membranes (Invitrogen) using the iBlot transfer 
method according the manufacturer’s instructions (Invitrogen). Membranes were blocked with 
5% (w/v) dry milk (Marvel, Dublin, Ireland) in Tris-buffered saline Tween-20 buffer (TBS-T) 
containing 20mM Tris-HCl pH 7.4, 500mM NaCl and 0.05% Tween-20. The membranes were 
incubated overnight at 4°C with primary antibodies (Table 10) in 1.5% BSA (Sigma) in TBS-
T, washed and incubated with secondary antibodies conjugated to horseradish peroxidase 
(DakoCytomation) in TBS-T for 1h at room temperature. The membranes were washed three 
times for 10min with TBS-T after each antibody incubation. Protein bands were visualised on 
X-ray film (FujiFilm, Düsseldorf, Germany) using ECL Western Blot Detection Reagent (GE 
Healthcare, UK). 
 
Table 10 Primary antibodies used for Western blotting 
Protein Antibody Reference Company Dilution 
Actin Goat polyclonal sc1615 Santa Cruz 1:1000 
AR Rabbit polyclonal sc816 Santa Cruz 1:1000 
β-tubulin Mouse monoclonal T4026 Sigma 1:20,000 
Beclin-1 Rabbit polyclonal ab16998 Abcam 1:2000 
Active and pro caspase-3 Mouse monoclonal ab13585 Abcam 1:500 
Ad2/5 E1A (13S-5) Rabbit polyclonal sc430 Santa Cruz 1:1000 
LC3B Rabbit polyclonal ab51520 Abcam  1:2000 
Ad5 Hexon Rabbit polyclonal LF-PA0099 Autogen Bioclear 1:2000 
p53 Mouse monoclonal sc126 Santa Cruz 1:1000 
 
2.8 Visualisation of LC-3 cellular localization 
2.8.1 Creation of LC-3-GFP Stably transfected cell lines 
22Rv-1, DU145 and PC-3 cells were seeded in 6-well plates at a density of 2×105 cells/well 
and allowed to adhere overnight. The following day, cells were transfected with the pGFP-
LC3 plasmid constructed and kindly donated by Prof. Tamotsu Yoshimori (Osaka University, 
Japan) (Kabeya et al., 2000). The transfection was performed using JetPEI-RGD PolyPlus 
transfection reagent (Autogen Bioclear, Calne, UK) according to the manufacturer’s 
instructions by adding 2µg DNA in 100µl 150mM NaCl solution to 6µl JetPEI-RGD 
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transfection reagent in 100µl 150mM NaCl solution to each well. The transfection medium 
was removed after 24h and replaced with normal 10% FCS medium. Selection was started 
three days post-transfection using geneticin (Gibco, Paisley, UK) as a selection agent. A 
previous titration of geneticin (0.4-1.5mg/ml) identified the lowest concentrations of geneticin 
that killed non-resistant cells in each PCa cell line (Table 11). Medium with geneticin at these 
concentrations was replaced every 48-72h while transfected and geneticin-resistant cells grew 
out clonally for approximately 3 weeks. Cells were passaged to larger flasks and frozen stocks 
of 22Rv-1-GFP-LC3 and DU145-GFP-LC3 cells were made. The transfection efficiency in 
PC-3 cells was very low and cells did not retain GFP-LC3 expression, so no clones could be 
expanded, despite selective pressure.  
 
Table 11 Optimal concentrations of geneticin for selecting transfected cells 
Cell line Geneticin (mg/ml) 
22Rv-1 1.0 
DU145 0.5 
PC-3 0.8 
Cells were seeded in 24-well plates at a density of 105cells/well and exposed to increasing 
concentrations of geneticin (0.4-1.5mg/ml) in 10% FCS medium. Cells were observed for cell death every 
day for a week. The concentration selected was the lowest that killed the cells.  
 
2.8.2 Confocal microscopy 
Stably transfected 22Rv-1-GFP-LC3 or DU145-GFP-LC3 cells were seeded in 6-well plates 
with at least one glass coverslip per well at a density of 2×105 cells/well. The following day, 
cells were infected with Ad5 (100ppc) in 1ml/well for two hours or mock infected, incubated 
in 2ml/well with equol (100µM), resveratrol (10µM) or rapamycin (400nM) in 2% FCS 
medium, 0% FCS medium or normal 2% FCS medium for 3-48h. Cells were fixed with 
1ml/well 3.7% formalin in PBS (Sigma) for 10min at room temperature and permeabilised 
with 1ml/well 0.5% Triton-X (Sigma) at 4°C for 5min. Cells were washed once with 1ml/well 
PBS in between each step. Coverslips were mounted onto glass slides with ProLong Gold 
antifade with DAPI mounting medium (Invitrogen). Coverslips were allowed to dry at room 
temperature in the dark overnight before storage at 4°C. Cells were viewed using a confocal 
laser scanning microscope (LSM510 META, Carl Zeiss, Inc., Germany) with a 63×/1.4 NA 
Plan-Apochromat oil immersion objective. DAPI was excited with a 405nm blue diode laser 
and GFP with the 488nm line of an Argon laser. High quality (12bit, 1024 pixels) images were 
acquired using LSM 5 Software, version 3.2. 
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2.9  Experimental design 
The research described in this thesis was carried out following the four steps of the scientific 
method: formulation of the hypothesis, planning of the experiment, observing and collecting 
data and interpreting the results. One variable was investigated whilst keeping all others 
constant. Negative controls, including mock and vehicle controls, were used to ensure the 
relevance of the effects observed (minimizing false positives). Positive controls were included 
where possible to confirm the procedure was effective in observing the expected effect, thus 
minimizing false negatives. 
 
Experimental conditions were set up in duplicates or triplicates to reduce intra-experimental 
variability. Experiments were repeated wherever possible (at least twice but as indicated) to 
minimize inter-experimental variance and ensure reproducibility. Quantitative data were 
analysed statistically as described in Section 2.10. Representative studies are presented for 
qualitative data, as indicated in figure legends. 
 
2.10  Statistics 
Mean values were obtained from from at least two independent experiments in duplicates (i.e. 
a minimum of four sample data values). The scatter was estimated by calculating standard 
deviations which are represented on graphs by error bars (Equation 8). The standard error of 
the sample mean was calculated to determine how precisely the population mean is estimated 
from the sample mean (Equation 9). Approximately 95% of the values in this theortical 
sampling distribution of sample means lie within two standard errors of the population mean. 
The 95% confidence interval of a data set was estimated to evaluate the spread of the samples 
compared to the mean (Equation 10). These analyses were performed using GraphPad Prism 
version 4.0c for Macintosh (GraphPad Software, San Diego California, USA). 
 
Equation 8 Standard deviation to determine variability  
 
! 
s.d.=
(x
i
" x )2#
n "1
 
 
! 
s.d. = standard deviation 
! 
"  = sum of 
! 
x
i
= each sample 
! 
x = mean of the sample data set 
! 
n  = number of values in the data set 
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Equation 9 Standard error of the mean 
! 
s.e.=
s.d.
n
 
 
! 
s.d. = standard deviation 
! 
n  = number of values in the data set 
 
Equation 10 95% confidence intervals 
! 
CI = x " ( # t $ s.e.) to x + ( # t $ s.e.)  
 
! 
x = mean of the sample data set 
! 
" t = the 5% percentage point of the t distribution for the appropriate degrees of freedom 
! 
s.e. = standard error of the mean 
 
Statistical difference between data sets was evaluated for data obtained from at least two 
independent experiments with duplicates. Two-tailed unpaired t-tests and p-values were 
calculated to test the Null Hypothesis (H0), stating that any observed difference between 
sample means is due to sample variation (Equation 11). The Null Hypothesis was rejected 
when the t-value obtained was higher than the tabulated value for the percentage points of the t 
distribution for the corresponding degrees of freedom. This analysis was performed using 
GraphPad Prism version 4.0c for Macintosh (GraphPad Software, San Diego California, 
USA). Results were considered statistically significant when p < 0.05. 
 
Equation 11 t-test for statistical significance 
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s.e. = standard error of the differences 
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 = number of data values in set 2
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3 Results 
3.1 Synergistic interactions between Ad5 and phytochemicals 
3.1.1 Sensitivity of prostate cancer cell lines to Ad5 and five 
phytochemicals as single agents 
 
To determine whether phytochemicals might enhance antitumour efficiacy in combination 
with oncolytic adenoviruses in the treatment of PCa, we first assessed the cytotoxicity of five 
selected phytochemicals and Ad5 as single agents in two AR-positive (22Rv-1 and LNCaP) 
and two AR-negative (DU145 and PC-3) cell lines (Figure 21). The percentages of cell death 
were assessed six days post-infection and used to construct dose-response curves and 
determine the dose required to kill 50% of cells (Effective Concentration, EC50).   
 
All four human PCa cell lines were sensitive to Ad5-induced cell death to varying degrees. 
The AR-positive cell lines 22Rv-1 and LNCaP were the most sensitive, with EC50 values of 
5.6±4.3ppc and 11±2.8ppc respectively (Table 12). DU145 cells were moderately sensitive 
with an EC50 value of 14.1±6.3ppc and PC-3 cells were the least sensitive, with an EC50 value 
of 430±182ppc.  
 
Phytochemicals from soy (equol and genistein) were the least cytotoxic to the PCa cell lines, 
while curcumin and EGCG had a more potent effect, especially in the androgen-independent 
cell lines DU145 and PC-3. Equol had an EC50 between 139µM (PC-3) and 157µM (DU145) 
but 22Rv-1 cells were more resistant and had an EC50 of 182µM (Table 13). Resveratrol was 
less cytotoxic than curcumin and EGCG in AR-positive cell lines (22Rv-1 EC50 = 110µM, 
LNCaP EC50 = 95µM) whereas in androgen-independent cell lines it had a more significant 
effect (DU145 EC50 = 16µM, PC-3 EC50 = 41µM). 
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Figure 21 Sensitivity of PCa cell lines to Ad5 and phytochemicals 
Dose-response curves were generated by treating cells in triplicate wells with five-fold serially diluted 
phytochemicals (2.56×10-4−500µM) or Ad5 (1×10-2−2×104ppc). Results were obtained six days post-
infection by MTS cell viability assay. Results are shown as averages (±SD) from ≥2 experiments except 
for EGCG in LNCaP and DU145 cells, and resveratrol in LNCaP cells where N=1. 
 
Table 12 Effective concentrations killing 50% cells (EC50; ppc) for Ad5 in PCa cell lines 
Dose-response curves were generated by treating cells in triplicates with five-fold serial dilutions of Ad5         
(1×10-2−2×104ppc). Results were obtained 6 days post-infection by MTS cell viability assay. 
 
Table 13 Effective concentrations killing 50% cells (EC50, µM) for phytochemicals in PCa cell lines 
Mean SD N Mean SD N Mean SD N Mean SD N
Equol 219.9 75.9 11 149.5 3.5 2 156.8 20.2 6 138.7 21.9 9
Genistein 105.2 19.7 4 128.9 17.0 3 84.7 32.3 4 136.8 21.1 4
Curcumin 55.4 27.9 4 61.2 24.4 2 36.4 0.6 2 35.1 7.8 5
EGCG 38.6 18.9 5 27.4 0.0 1 25.9 0.0 1 34.3 11.5 4
Resveratrol 110.3 17.6 5 95.3 0.0 1 16.1 4.8 4 41.4 21.2 7
DU145 PC-322Rv-1 LNCaP
 
Dose-response curves were generated by treating cells in triplicates with five-fold serially diluted 
phytochemicals (2.56×10-4-500µM). Results were obtained six days post-infection by MTS cell viability 
assay. 
Mean SD N Mean SD N Mean SD N Mean SD N
5.60 4.30 16 11.40 2.80 2 14.05 6.27 8 440.74 216.83 15
DU14522Rv-1 LNCaP PC-3
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3.1.2 Synergistic effects on cell death by combination treatments 
of Ad5 and phytochemicals at fixed ratios 
 
To determine whether cell killing could be improved by combining Ad5 with phytochemicals, 
synergy studies were conducted in cell lines most sensitive to Ad5 (22Rv-1, DU145 and 
LNCaP). The two phytochemicals from soy, equol and genistein, were initially selected for 
testing as they were the least cytotoxic alone to PCa cell lines, despite their effects on a 
number of signalling pathways reported in the literature (Setchell et al., 2002; Surh, 2003). 
The EC50 values obtained for Ad5 alone in 22Rv-1 and DU145 cells for these two synergy 
experiments were much higher than the averages (Table 12). This may be due to the specific 
batch of cells and virus used. 
 
While the EC50 values for equol and genistein were decreased to very low levels at all 
combination ratios of Ad5, the changes in Ad5 EC50 values varied depending on the ratio 
(Figure 22 and Figure 23). The lowest combination ratios (22Rv-1 and DU145, 1ppc:5nM and 
LNCaP, 1 ppc:10nM) produced the lowest combination indexes (CI) with both equol and 
genistein in all three cell-lines, except equol in DU145 cells where this ratio produced a CI of 
1.83, indicating antagonism. In this cell line a 25ppc:1nM ratio of Ad5 to equol was 
synergistic (CI = 0.61), although this ratio was only additive in other cell lines (CI = 1.06 in 
22Rv-1 and 1.02 in LNCaP). Genistein also synergised with Ad5 at the lowest combination 
ratios in each cell line, and at a second ratio (1ppc:1nM, CI = 0.43) in DU145 cells. However, 
genistein also produced antagonistic effects at three ratios in 22Rv-1 cells (CI≥2), and at two 
ratios in LNCaP cells (1ppc:2nM, CI = 1.22 and 5 ppc:2nM, CI = 1.85).  
 
These experiments showed that phytochemicals could act synergistically with Ad5, indicating 
that the concept had potential. However, the study also highlighted the fact that the interactions 
could also be antagonistic at certain combination ratios. Therefore we next sought a method of 
screening the five selected phytochemicals over a range of concentrations and conditions.   
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Figure 22 Isobolograms and combination indexes for Ad5 with equol  
Cells were treated with four fixed combination ratios of Ad5 and equol and cell viability determined by 
MTS assay six days post-infection. Dose-response curves and EC50 values were used to construct 
isobolograms and calculate combination indexes (CI) for each ratio. Ratios are expressed as virus (ppc) 
to phytochemical (nM). A line is drawn connecting the EC50 values of the virus and phytochemical as a 
single agent. A ratio producing a CI≤0.8 is considered synergistic (CIs in green, below the line), CIs 
between 0.8-1.2 additive (black, on or near the line) and CI≥1.2 antagonistic (in red, above the line). One 
experiment shown as a representative of two. 
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Figure 23 Isobolograms and combination indexes for Ad5 with genistein  
Cells were treated with four fixed combination ratios of Ad5 and genistein and cell viability determined by 
MTS assay six days post-infection. Dose-response curves and EC50 values were used to construct 
isobolograms and calculate combination indexes (CI) for each ratio. Ratios are expressed as virus (ppc) 
to phytochemical (nM). A line is drawn connecting the EC50 values of the virus and phytochemical as a 
single agent. A ratio producing a CI≤0.8 is considered synergistic (CIs in green, below the line), CIs 
between 0.8-1.2 additive (black, on or near the line) and CI≥1.2 antagonistic (in red, above the line). One 
experiment shown as a representative of two. 
 
3.1.3 Fixed concentrations of phytochemicals decrease Ad5 EC50 
values 
 The phytochemicals were also screened for synergistic interactions with Ad5 on cell death by 
combining a fixed dose of phytochemical with a complete dose-response curve for Ad5. This 
method was chosen over synergy assays because it is easier and faster to perform, therefore 
allowing more reproducible data to be produced in less time. 22Rv-1 and PC-3 cells were 
selected for these experiments due to their differing androgen receptor status and sensitivities 
to Ad5-induced cell death.  
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Based on the EC50 values and dose-response curves for the phytochemicals, three doses of 
each phytochemical were selected to span a range of concentrations that killed <50% cells (as 
single agents) (Table 13). Control cells treated only with phytochemical were also included in 
each experiment to determine the proportion of cell death due to each agent alone. Dose-
response curves for Ad5 were corrected using these controls when cell death >10% (Table 14). 
Typically, this was required only for the highest doses of phytochemicals, except curcumin 
and equol which usually resulted in <10% cell death even at the highest concentrations used.  
 
Table 14 Cell death (%) induced by phytochemicals alone for combination assays 
Dose-response curves for the combination assays were adjusted to account for any significant level of 
cell death (>10%) induced by the phytochemicals alone after 6 days of treatment. Doses: curcumin: 5µM 
(low), 10µM (medium), 30µM (high, PC-3); EGCG: 1µM (low, PC-3), 5µM (low, 22Rv-1), 5µM (medium, 
PC-3), 10µM (medium, 22Rv-1; high, PC-3), 25µM (high, 22Rv-1); equol: 5µM (low), 50µM (medium), 
100µM (high); genistein: 50µM (medium), 100µM (high); resveratrol: 1µM (low), 5µM (medium), 50µM 
(high). −, no adjustment was necessary as cell death was <10%. Cell death percentages shown are from 
one experiment. Results of the combination assays are shown in Figure 24. 
 
The combination treatments were generally beneficial, with twenty-two out of twenty-eight 
combinations decreasing the Ad5 EC50 value (Figure 24). Genistein (50µM) reduced the Ad5 
EC50 value by more than 50% in both cell lines but, at a higher dose, genistein increased the 
Ad5 EC50 value (Figure 24). This correlates with the results from the synergy assay in 22Rv-1 
cells with genistein where one ratio was synergistic, but the other three were antagonistic 
(Figure 22).  
 
Curcumin and EGCG reduced Ad5 EC50 values at all concentrations in 22Rv-1 cells and at 
some concentrations in PC-3 cells (Figure 24). However, the decrease was moderate 
(maximum 40% decrease in 22Rv-1 by both curcumin and EGCG) and the responses were not 
dose-dependent over the concentrations tested. The greatest decreases in Ad5 EC50 value in 
both cell lines were observed in combinations with equol and resveratrol (Figure 24). In 
combination with 100µM equol, the Ad5 EC50 value was reduced to 8% (22Rv-1 cells) and 
40% (PC-3 cells). With 50µM resveratrol, the Ad5 EC50 value was reduced to 18% (22Rv-1) 
and 38% (PC-3).  
 
These effective reductions in Ad5 doses by the addition of equol and resveratrol can clearly be 
seen by the dose-response curves (Figure 25). The addition of increasing doses of equol and 
Dose low medium high low medium high
Curcumin - - - - - -
Equol - - 5.5 - - 10
EGCG - - 50 - 3.8 25
Genistein - 8 40 - - 18
Resveratrol - - 32 - - 37
22Rv-1 PC-3
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resveratrol to serially-diluted Ad5 shifted the viral dose-response curves to the left, indicating 
lower Ad5 EC50 values. The exposure of cells to equol or resveratrol caused higher 
percentages of cell death compared to the same viral dose without phytochemicals. For 
example, in DU145 cells, 6.4ppc Ad5 alone killed 16.5% cells, but in combination with 10µM, 
50µM and 100µM equol, the percentages of cell death increased to 55%, 78% and 90.4% 
respectively. Similarly, 6.4ppc Ad5 in combination with resveratrol increased cell death in this 
cell line from 32.3% to 59% (5µM), 83% (10µM) and 89% (15µM), respectively. Equol and 
resveratrol alone induced <10% cell death in these experiments. 
 
At the lowest doses, equol and resveratrol had no effect in 22Rv-1 cells (99% of the Ad5 EC50 
value with equol 5µM and 108% of the Ad5 EC50 value with resveratrol 1µM), and the 
interaction was slightly antagonistic in PC-3 cells (133% Ad5 EC50, resveratrol 1µM) (Figure 
24). The dose response curve for this combination was shifted to the right, compared to the 
dose-response for Ad5 alone, indicating a protective effect on cell death by resveratrol in PC-3 
cells under these conditions (Figure 25).  
 
These results showed that it was possible to significantly reduce the dose of Ad5 required to 
kill 50% cells by combining Ad5 with phytochemicals. Equol and resveratrol showed the 
greatest reductions in Ad5 EC50 at concentrations of 50µM (resveratrol) and 100µM (equol). 
At these concentrations, equol alone killed less than 10% cells and resveratrol alone killed 
32% (22Rv-1) to 37%  (PC-3) cells (Table 15).  
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Figure 24 Changes in sensitivity to Ad5-induced cell death in cells treated with phytochemicals 
Dose-response curves to Ad5 with and without three doses of phytochemicals were generated by 
determining cell death 6 days post-infection by MTS assay. Ad5 EC50 values were calculated for virus 
alone and in combination with each respective agent. When cell death due to phytochemical alone was 
>10%, cell death percentages were corrected as shown in Table 14. Data is expressed as the Ad5 EC50 
for each combination divided by the EC50 for Ad5 alone × 100%. Ad5 EC50 percentages below 100% 
indicate that 50% cells were killed by a lower dose of Ad5 in combination with phytochemical. Results 
shown as mean of at least two experiments ± SD. 
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Figure 25 Simultaneous addition of equol or resveratrol reduced Ad5 EC50 independently of AR 
status of PCa cell lines. 
Cells were infected with five-fold serially diluted Ad5 (black) with or without equol or resveratrol at three 
constant concentrations. Equol 10µM (light blue), 50µM (medium blue), 100µM (dark blue); resveratrol 
5µM (pink), 10µM (red), 15µM (purple). Cell death was assayed 6 days post-infection by MTS assay and 
is expressed as percentage relative to uninfected controls ± SEM. Cell death due to the phytochemicals 
alone was <10%, except in 22Rv-1 cells treated with 100µM equol (14% cell death) and PC-3 cells 
treated with 15µM resveratrol (26.7% cell death). N= 3.  
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Table 15 Reductions in Ad5 EC50 values by equol and resveratrol 
Ad5 EC50 (ppc)  Fold decrease Ad5 EC50 (ppc)  Fold decrease Ad5 EC50 (ppc)  Fold decrease
Ad5 1.41 9.58 461.00
Ad5 + equol 10 M 0.97 1.45 5.74 1.67 197.70 2.33
Ad5 + equol 50 M 0.55 2.54 2.35 4.07 111.30 4.14
Ad5 + equol 100 M 0.25 5.63 1.95 4.90 53.25 8.66
Ad5 4.15 8.04 461.00
Ad5 + resveratrol 5 M 3.62 1.15 5.50 1.46 583.70 0.79
Ad5 + resveratrol 10 M 1.85 2.24 2.79 2.89 535.10 0.86
Ad5 + resveratrol 15 M 1.26 3.30 1.07 7.51 27.30 16.89
22Rv-1 DU145 PC-3
 
Ad5 EC50 doses from the dose-response curves shown in Figure 21. Fold decreases were calculated by 
dividing  the Ad5 EC50 value as a single agent by the EC50 value of each combination. 
 
3.1.4 The timing of addition of phytochemicals affected virus-
induced cell death 
 
To determine whether the order of addition of each agent could further enhance cell death, PCa 
cells were treated with phytochemicals 24h prior to or after infection with Ad5. In 22Rv-1 
cells, pre-treatment for 24h with any of the phytochemicals did not further decrease the EC50 
values for Ad5 (Figure 26 and Table 16) compared to simultaneous addition for any of the five 
phytochemicals (Figure 24). In PC-3 cells, pre-treatment with equol, genistein and resveratrol 
decreased Ad5 EC50 values further, compared to simultaneous addition (Figure 24 and Figure 
26). However, in PC-3 cells pre-treated with curcumin and EGCG, Ad5 EC50 values were 
much higher than the EC50 for Ad5 alone. Under these conditions, exposure to low doses of 
curcumin and EGCG was actually protecting cells from Ad5-induced cell death rather than 
sensitising them.  
 
When PC-3 cells were treated with curcumin 24h after infection, no decrease in Ad5 EC50 was 
observed (Ad5 EC50 values around 110%). However, the delay in treatment with EGCG was 
beneficial in both cell lines, indicating that this phytochemical may inhibit the viral lifecycle at 
an early step but may enhance a later stage. 
 
The greatest increases in cell death for both cell lines were with equol and resveratrol. PC-3 
cells were more sensitised when pre-treated for 24h with these phytochemicals, compared to 
simultaneous addition. In 22Rv-1 cells, simultaneous addition produced the largest decreases 
in Ad5 EC50 with equol and resveratrol, except at the lowest dose of resveratrol where 
treatment with the phytochemical 24h post-infection further improved the effect on cell death.  
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Genistein at an intermediate dose also invariably reduced the Ad5 EC50 value to around 40% 
of the EC50 for Ad5 alone in both cell lines. This response was not significantly affected by the 
sequence of addition of the agents, suggesting that a highly specific interaction between the 
virus and this dose of genistein might be occuring, which inevitably leads to cell death. This 
effect disappeared at higher doses of genistein.  
 
In summary, each of the five phytochemicals was able to enhance Ad5-induced cell death 
under certain conditions. Out of the five phytochemicals tested, equol and resveratrol caused 
the largest decreases in Ad5 EC50 values without inducing high cytotoxicity at these doses 
when given alone. These synergistic effects were consistently observed at different sequences 
of addition although some cell line-dependent variability occurred with regard to the timing of 
phytochemical treatment relative to infection. Equol and resveratrol were selected for further 
study as the most promising phytochemicals in combination with Ad5. The largest decreases in 
Ad5 EC50 values with these phytochemicals were observed in simultaneously treated 22Rv-1 
cells and pre-treated PC-3 cells. 
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Figure 26 Changes in sensitivity to Ad5-induced cell death in cells treated with phytochemicals 
24h pre-infection or 24h post-infection. 
Cells were infected with 5-fold serially diluted Ad5 with or without phytochemicals. Cell death was 
assayed 6 days post-infection by MTS assay. Combination Ad5 EC50 values were obtained from dose-
response curves and expressed as percentages relative to Ad5 EC50 values in untreated cells, 
percentages below 100% indicate that 50% of cells were killed by a lower dose of Ad5 in combination 
with phytochemical. Results are shown as averages from 1-2 experiments ± SD. 
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Table 16 Percentage change in Ad5 EC50 values by the addition of phytochemicals at different 
time-points 
Cell line 24h pre- Simultaneous 24h post-
5 78.0 66.8 81.4
Curcumin 10 169.5 77.4 71.3
30 58.2 131.7
5 99.9 78.9 21.1
EGCG 10 98.6 67.8 52.3
25 110.6 66.9 47.4
5 136.9 98.8 170.2
Equol 50 57.3 17.3 17.5
100 61.6 8.2 20.1
5 99.5 - 64.9
Genistein 50 38.6 29.5 55.0
70 192.2 166.5 89.6
1 130.9 108.3 68.8
Resveratrol 10 81.8 70.3 244.2
50 58.8 18.0 50.3
5 188.0 84.5 125.0
Curcumin 10 130.0 72.0 102.8
30 91.8 82.5 110.6
2.5 565.0 121.5
EGCG 5 530.0 46.3 39.9
10 666.2 179.8 100.3
5 24.0 63.4 63.5
Equol 50 27.6 41.5 65.1
100 13.7 40.3 54.9
5 41.8 -
Genistein 50 24.1 37.0
150 33.9 142.0
1 86.2 132.7 94.8
Resveratrol 10 14.9 30.0 45.3
50 23.9 37.7 23.7
Phytochemical Ad5 EC50 (%, relative to Ad5 alone)
22
R
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Data from Figure 25 and Figure 26 with the percentage change in Ad5 EC50 for each combination 
compared to Ad5 alone. Reductions in Ad5 EC50 indicating a synergistic interaction (Ad5 EC50 < 60%) 
are highlighted in green. Antagonistic effects (Ad5 EC50 > 110%) are shown in red.  - : not done. 
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3.2 The effects of equol and resveratrol on the adenoviral 
lifecycle 
3.2.1 Equol and resveratrol increased the infectability of PCa cells 
Combination assays with Ad5 demonstrated a potent enhancement of cell death by the addition 
of equol or resveratrol. Since the phytochemicals alone caused cytotoxicity only at the higher 
concentrations tested, it seemed likely that the phytochemicals might be sensitising the cells to 
Ad5-mediated cell death. To understand the mechanism behind these interactions, the effects 
of the phytochemicals on various steps of the viral lifecycle were investigated. The first 
challenge the virus has to overcome during viral infection in vitro is entry into the host cell. As 
discussed in Section 1.2.3, the infectability of different cell lines is dependent on the cellular 
expression levels of adenoviral receptors, such as CAR which mediates viral docking to the 
cell. The possibility that the phytochemicals might be increasing cellular infectability via an 
upregulation of Ad5 receptors was considered.  
 
The infectability of four PCa cell lines was first determined in untreated cells using a non-
replicating GFP-expressing Ad5 mutant. PC-3 cells were the least infectible, with less than 1% 
infected after 48h infection with 100ppc (Figure 27). The most infectible cell line was 22Rv-1, 
with more than 50% cells infected by a dose of 100ppc. DU145 and LNCaP cells were of 
intermediate sensitivity to adenoviral infection. This pattern of infectability paralleled the 
observed sensitivity to Ad5-induced cell death (Figure 21).  
 
 
Figure 27 Infectability of PCa cell lines 
Cells were infected with Ad5-GFP (100ppc) for two hours. Cells were then incubated with normal 2% 
FCS medium for a further 48h, after which cells were harvested by trypsinisation and analysed by flow 
cytometry. Cells positive for GFP above background level were considered infected. Results shown are 
averages of duplicates from one experiment ± SD.  
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The effect of phytochemical treatment on infectability was determined in 22Rv-1, DU145 and 
PC-3 cells at concentrations shown to act synergistically with Ad5 (Figure 25). After infection 
with Ad5-GFP, both equol and resveratrol increased the percentage of GFP-positive cells in all 
three cell lines, indicating a greater proportion of infected cells (Figure 28, upper graphs). 
Resveratrol was slightly more potent than equol, except in PC-3 cells where equol induced a 
greater proportion of infected cells than resveratrol, although this trend was not statistically 
significant compared to untreated control cells (Figure 28, upper right graph).  
 
Median GFP fluorescence was also increased by both phytochemicals (Figure 28, lower 
graphs). The median GFP fluorescence represents the average viral load per cell. Equol was 
more potent than resveratrol and more than doubled the average viral load per cell in 22Rv-1 
and PC-3 cells.  
 
The increased Ad5-GFP uptake in response to treatment with equol and resveratrol was 
comparable to that observed in cells treated with trichostatin A (TSA, Figure 29). TSA is a 
well-known enhancer of adenoviral infectability via the upregulation of CAR expression in 
target cells (Hemminki et al., 2003).  
 
Increased viral uptake was also observed by measuring viral genome copies 3h post-infection 
with Ad5 (Figure 30). Equol doubled infectability in 22Rv-1 and DU145 cells, and increased 
the viral load in PC-3 cells from 72 to 96 viral copies/5ng DNA. Resveratrol doubled 
infectability in 22Rv-1 and PC-3 cells and increased the viral load in DU145 cells from 152 to 
215 viral copies/5ng DNA.  
 
Taken together, these results indicate that equol may sensitise a proportion of cells to Ad5, and 
that these cells become highly permissible to viral infection, resulting in a doubling of the 
average viral load per cell. On the other hand, exposure of cells to resveratrol enables a greater 
proportion of cells to become infected, although the average viral load per cell does not reach 
the levels achieved by treatment with equol. 
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Figure 28 The infectability of cells treated with phytochemicals 
Cells were incubated with equol (100µM) or resveratrol (10µM) or normal medium alone. After 24h 
exposure to the phytochemicals, the cells were infected with a non-replicating Ad5-GFP virus at doses 
determined to achieve around 30% infected cells (22Rv-1: 25 ppc; DU145: 50 ppc, PC-3: 300ppc). 
Infection was allowed to proceed for 2h, after which the infection medium was removed and replaced 
with normal or phytochemical-containing 2% FCS medium. Flow cytometry was performed 48h post-
infection. Upper panels show the proportion of GFP-positive cells. The lower panel represents the 
average viral load per cell, as measured by median GFP fluorescence. Results are presented as a mean 
of duplicates in at least two experiments ± SD. * = p < 0.05. 
 
 
Figure 29 The infectability of 22Rv-1 cells treated with equol, resveratrol or trichostatin A (TSA) 
22Rv-1 cells were infected with a non-replicating Ad5-GFP virus (30ppc) for 2h, after which the medium 
was removed and replaced with 2% FCS medium containing equol (50µM or 100µM), resveratrol (25µM 
or 50µM) or TSA (0.1µM or 0.5µM). Cells were harvested 48h post-infection and analysed by flow 
cytometry. The left panel show the percentage of GFP-positive cells. The right panel represents the 
average viral load per cell, as measured by median GFP fluorescence (arbitrary units). Results are 
expressed as the average of duplicates from one experiment ± SD.  
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Figure 30 Infectability of PCa cells detect by qPCR 
Cells were infected with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc) for 2h, after which the infection 
medium was removed and replaced with normal or phyochemical-containing (equol 100µM or resveratrol 
10µM) 2% FCS medium. Cells were harvested 3h after the beginning of the infection (i.e. the cells were 
exposed to phytochemicals for 1h). DNA was extracted, quantified and hexon gene copy numbers were 
determined in duplicate for each sample by qPCR as described in Methods Section 2.6.2. Results are 
shown as mean of one experiment ± SD. * = p < 0.05 compared to untreated cells. 
 
3.2.2 Equol and resveratrol enhanced the cellular expression of 
adenoviral receptors 
To determine whether the higher infectability observed in the presence of equol and resveratrol 
might be due to increased levels of cell surface receptors, the expression of three known 
adenoviral receptors, the integrins αVβ3 and αVβ5 and the Coxsackie Adenovirus Receptor 
(CAR), was analysed by flow cytometry. This was done in 22Rv-1, DU145 and PC-3 cells to 
support the infectability data, and LNCaP cells were also included.  
 
Untreated PC-3 cells expressed very low levels of all three adenoviral receptors. Integrins 
αVβ3, αVβ5  and CAR were present on only 4.8%, 6.5% and 2.9% of cells (Figure 31). This is 
likely to have contributed to the low infectability of this cell line (Figure 27) and has been 
previously described (Okegawa et al., 2000). DU145 cells expressed moderate to high levels 
of all three receptors with CAR present on 99% cells, 44% of cells expressing αVβ3 integrins 
and 11% of cells expressing αVβ5 integrins. In contrast, 22Rv-1 and LNCaP cells did not 
appear to express either class of integrin (<3% cells), although 66% (22Rv-1) and 88% 
(LNCaP) cells expressed CAR.  
 
The proportion of DU145 cells expressing αVβ3 integrins was increased from 44% to 58% by 
equol and to 67% by resveratrol. In PC-3 cells αVβ3 integrins were expressed on 4.8% cells 
and this was increased to 9% by equol and 13.3% by resveratrol. The proportion of cells 
expressing αVβ5 integrins was also increased in DU145 cells by equol from 11% baseline to 
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13.7% cells and by resveratrol to 29.3% cells. However, in PC-3 cells, equol caused a slight 
decrease in αVβ5 integrin expression from 6.5% to 4.6%, although resveratrol induced 
expression in 11.2% cells. Neither of the phytochemicals induced expression of these integrins 
in 22Rv-1 cells. 
 
CAR expression was already maximal in DU145 cells, so no increase was detectable in 
response to phytochemical exposure. However, phytochemical treatment increased the 
percentage of 22Rv-1 cells expressing CAR from 66% to 71% by equol and 73% by 
resveratrol. This effect was not seen in PC-3 cells where CAR expression remained <4%. In 
LNCaP cells, the percentage cells expressing CAR was decreased by equol from 88% to 63% 
while resveratrol had no effect.  
 
Considering the level of expression of all three adenoviral receptors, DU145 cells would be 
predicted to be the most, and PC-3 cells the least permissive cell line to Ad5 infection, since 
very few of those cells express any of the receptors. PC-3 cells were indeed the most resistant 
to Ad5 infection (Figure 27). However, the most infectible cell line was not DU145 but 22Rv-
1 cells. This may indicate that additional factors, such as unidentified adenoviral receptors, 
could be involved in the infection process. Alternatively, this could be due to differences in 
transcription efficiency from the CMV promoter which controls GFP expression. 
 
In summary, both equol and resveratrol increased the expression of one or more of the three 
known adenoviral receptors in three PCa cell lines, 22Rv-1, DU145 and PC-3 cells, but not in 
LNCaP cells.   
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Figure 31 Cellular surface expression levels of three Ad5 receptors, CAR and the integrins αVβ3 
and αVβ5 
Cells were treated with equol (100µM) or resveratrol (10µM) or left untreated. After 24h, the proportion of 
receptor-positive cells was determined by flow cytometry. Results are presented as a mean of duplicates 
in two experiments ± SD. * = p < 0.05 compared to untreated cells.  
 
3.2.3 The effect of phytochemicals on viral replication 
To determine whether the increased infectability of cells treated with phytochemicals was 
paralleled by enhanced viral replication, viral titres were determined in cells treated with equol 
or resveratrol. These experiments were performed in 22Rv-1, DU145 and PC-3 cells to follow 
up on the data obtained from the infectability experiments described in Results Section 3.2.1.  
 
In all three cell lines, viral titres increased up to 48h and plateaued at 72h (Figure 32). DU145 
cells supported the highest levels of replication, with 1.57×104±5.3×103 pfu/cell after 72h. 
Despite the higher infectability of 22Rv-1 cells, viral replication in this cell line was 
significantly lower than in DU145, with 1.9×103±7.1×102 pfu/cell at 72h. PC-3 cells supported 
the lowest levels of viral replication, with titres of 1.1×103±4.1×102 pfu/cell, which was also 
significantly lower than in DU145 cells. The levels of replication at 72h in 22Rv-1 and PC-3 
cells were not statistically different (p = 0.06).   
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Viral replication in DU145 and PC-3 cells treated with equol or resveratrol was significantly 
reduced from 24h to 72h post-infection. Resveratrol reduced viral titres in both cell lines 10-
fold. A smaller decrease was detected in resveratrol-treated 22Rv-1 cells which was 
statistically significant at 72h post-infection.  
 
 
Figure 32 Viral replication over time determined by TCID50 assay  
Cells were infected with Ad5 (100ppc) and cultured in medium without (black lines) or with equol (100µM, 
blue) or resveratrol (10µM, pink). Cells and media were harvested at 24h, 48h and 72h post-infection and 
viral titres were determined by TCID50 assay as described in Methods Section 2.6.1. One experiment, 
representative of 2-3. Results shown as mean of triplicates ± SD. * = p < 0.05 for viral titres in 
phytochemical-treated cells compared to untreated cells. NS = not statistically significant (p > 0.05) for 
treated cells compared to untreated cells. 
 
To verify that the decreased viral titres were not simply due to a reduction in the proportion of 
viable cells, cell death under the conditions tested in the TCID50 assay was determined over 
time (Figure 33 and Table 17). At 72h, there was a significant amount of cell death in cells 
treated with combinations, although virus alone did not induce any cytotoxicity. At this time-
point, Ad5 and 100µM equol killed nearly 70% DU145 cells and 15% PC-3 cells, while Ad5 
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with 10µM resveratrol killed around 50% DU145 cells and 32% PC-3 cells. However, there 
was less than 6% cell death under all conditions up to 48h in all three cell lines.  
 
This demonstrates that the observed reductions in viral titres up to 48h were likely due to 
inhibitory effects on replication by the phytochemicals. At 72h, the high levels of cell death in 
response to combination treatments probably also contributed to the reduced replication in 
DU145 and PC-3 cells. The decreased replication due to resveratrol in 22Rv-1 cells after 72h 
may also be due to a reduced viability of the cells (14% cell death under these conditions).  
 
 
Figure 33 Cell death due to combination treatments under the conditions used for viral replication 
assays 
Cells were seeded in 96-well plates and infected in triplicate with 100ppc (22Rv-1 and DU145) or 300ppc 
(PC-3) in 50µl serum-free medium. After 2h, the infection medium was replaced with normal or 
phytochemical-containing 2% FCS medium. Cell viability was assessed 24h, 48h and 72h post-infection 
by MTS assay. N=1. 
 
 
 
 
 
 
 102 
Table 17 Cell death due to combination treatments under the conditions used for viral replication 
assays 
Time (h) Untreated
24 3.63 -8.52 8.68 0.83 2.29
48 2.37 -17.67 16.36 -0.83 15.61
72 -2.87 -0.39 35.49 6.37 36.65
168 2.04 38.27 65.7 43.13
Time (h) Ad5
24 -5.83 -15.11 1.43 -10.99 -9.97
48 -9.66 -18.98 6.45 -17.77 0.85
72 -13.63 -1.81 28.37 -10.71 14.29
168 80.6 97.37 98.09 95.85 82.54
Time (h) Untreated
24 0.33 0.8 0.71 0.09 -0.1
48 0.23 1.41 3.25 1.09 1.42
72 -0.17 6.87 55.51 5.49 30.98
168 -0.04 14.57 83.95 98.3
Time (h) Ad5
24 0.6 1.16 1.17 0.53 0.63
48 0.66 2.25 4.39 1.58 2.16
72 0.94 18.53 68.61 13.38 50.71
168 95.65 98.71 99.07 98.97 96.44
Time (h) Untreated
24 1.36 -1.28 -0.59 -0.92 -0.77
48 0.61 -1.7 2.89 -0.64 3.3
72 -1.44 1.97 8.63 14.7 24.67
168 -0.61 22.31 54.85 34.3
Time (h) Ad5
24 3.41 0.28 0.73 1.4 1.09
48 3.04 0.24 5.29 2.04 6.1
72 -0.53 4.71 14.86 18.26 32.09
168 5.46 69.29 84.83 68.51
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Data from Figure 33 with percentage cell death (% compared to untreated and uninfected control cells) at 
each condition for each time-point. In red are the combination treatments of Ad5 with phytochemicals 
after 48h and 72h. Those causing significant levels of cell death are highlighted in bold. 
 
Viral replication was also assayed by flow cytometry using a replicating adenovirus expressing 
GFP (Figure 34). Replication as detected by FACS appeared to increase steadily over 24-72h. 
By 72h resveratrol caused a statistically significant reduction in the proportion GFP-positive 
cells in both DU145 and PC-3 cells. These findings are in agreement with the TCID50 assay 
results (Figure 32).  
 
However, in contrast to the TCID50 assay results, resveratrol increased the percentage of GFP-
positive 22Rv-1 cells at 72h. As expected from the TCID50 assays, equol increased viral 
replication in 22Rv-1, but surprisingly, also in PC-3 cells. The higher infection load used for 
PC-3 for FACS (300ppc, three times the dose used in the TCID50 assay) could have had an 
impact on the results, the high dose overcoming inhibition by equol but not by resveratrol.  
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Figure 34 Flow cytometric detection of a replication-competent GFP-expressing Ad5 in 
phytochemical-treated cells  
After 24h pre-treatment with equol (100µM) or resveratrol (10µM), cells were infected with a replicating 
Ad5-GFP virus (22Rv-1: 25ppc, DU145: 50ppc, PC-3: 300ppc). After 2h, the infection medium was 
removed and replaced with normal or phytochemical-containing (equol 100µM, resveratrol 10µM) 2% 
FCS medium. Cells were analysed by flow cytometry at 24h, 48h and 72h post-infection. Results are 
shown as mean of three experiments ± SD. * = p < 0.05 compared to untreated cells. 
 
To resolve the differences between the results obtained from the TCID50 assay with those from 
the data obtained by flow cytometry on cells infected with the replicating Ad5-GFP virus, viral 
genome amplification was assessed by qPCR under the same conditions.  
 
Resveratrol significantly reduced hexon gene copy numbers in all three cell lines, although the 
effect was minor in 22Rv-1 cells (Figure 35). Gene copy numbers were also greatly reduced by 
equol in DU145 and PC-3 cells. However, 22Rv-1 cells treated with equol showed an increase 
in genome copy numbers, although the trend was not statistically significant at 72h. This may 
be due to reduced cell viability at this later time point (28% cell death at 72h., Table 17). 
Quantification of hexon gene amplification by qPCR therefore confirmed the trends shown by 
the TCID50 assays (Figure 32). 
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Figure 35 Ad5 DNA amplification measured by quantification of hexon gene copy numbers by 
qPCR  
Cells were infected with Ad5 100ppc for 2h, after which the infection medium was removed and replaced 
with normal or phyochemical-containing (equol 100µM or resveratrol 10µM) 2% FCS medium. Cells were 
harvested at 3h, 24h, 48h and 72h post-infection. DNA was extracted, quantified and hexon gene copy 
numbers were determined in duplicate for each sample by qPCR as described in Methods Section 2.6.2. 
Results shown as means from one experiment ± SD. * = p < 0.05 compared to untreated cells. 
 
Since E1A is essential for the initiation of viral replication, the expression levels of this protein 
in phytochemical-treated cells were also assessed to verify the replication data. Western blots 
showed that E1A expression in 22Rv-1 cells was affected by neither equol nor by resveratrol 
(Figure 36). However, in DU145 cells, there was a decrease in E1A protein levels in cells 
treated with resveratrol for 18-24h. By 48h, E1A expression in resveratrol-treated cells had 
recovered to levels similar to those observed in untreated cells. Equol had no effect in DU145 
cells. In PC-3 cells, treatment with resveratrol decreased E1A expression at 24h and 48h and 
equol caused a slight decrease. These results indicate that equol had no effect on E1A 
expression levels, while resveratrol caused a decrease in E1A expression in DU145 and PC-3 
cells. This paralleled the decrease in viral replication. E1A expression in 22Rv-1 cells 
appeared to be unaffected by phytochemical treatment which supports the replication data 
showing that the phytochemicals do not have significant effects on viral replication in this cell 
line.  
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Figure 36 E1A expression in phytochemical-treated PCa cells 
Cells were infected with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc). After 2h, the infection medium 
was removed and replaced with phytochemical-containing medium (equol 100µM or resveratrol 10µM). 
Cell lysates were harvested at the indicated times and used to blot for E1A as described in Methods 
section 2.7. One blot representative of three independent experiments. 
 
Taken together, these results indicate that the effects of phytochemical treatment on viral 
replication were cell line dependent. Equol and resveratrol reduced viral replication in the AR-
negative cell lines, particularly in DU145 cells. Ad5 replication in 22Rv-1 cells seemed 
relatively unaffected and titres were possibly increased by treatment with equol at 48h post-
treatment, but not with resveratrol.  
 
3.2.4 Effect of phytochemicals on cell cycle progression 
The main function of the early viral proteins is to induce S phase to enable viral DNA 
synthesis and amplification. The cell cycle was analysed to determine whether treatment with 
phytochemicals might induce changes that could explain the synergistic interaction with Ad5 
and/or the different responses of the cell lines in terms of viral replication. 
 
Cell cycle progression was monitored by flow cytometry for 72h after treatment and infection 
(Figure 37, Figure 38, Figure 39). The distribution of cells was similar between 24h and 48h. 
Resveratrol treatment caused an increase in the proportion of cells in S phase (Figure 40). This 
effect was detected in all three cell lines and at both time points. Infection with Ad5 also 
stimulated S phase in 22Rv-1 and DU145 cells. Viral-induced S phase was not detected in  
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PC-3 cells at this dose of Ad5 (100ppc), probably due to the lower infectability of this cell line 
(Figure 27). Exposure of infected cells to resveratrol increased the proportion of cycling cells 
above the level induced by Ad5 (Figure 40). By 72h, phytochemical treatment increased the 
proportion of cells in sub-G1, indicating the possible induction of apoptosis (Figure 41). This 
pattern was further enhanced by infection with Ad5. Equol slightly increased the proportion of 
PC-3 cells in G2/M, while it increased the proportion of DU145 cells in S phase and had little 
effect in 22Rv-1 cells. There was an increase in sub-G1 cells by 72h in 22Rv-1 and DU145 
cells treated with equol (Figure 41 and Table 18). The increased viral replication in equol-
treated 22Rv-1 cells and the decrease in equol- or resveratrol-treated DU145 and PC-3 cells 
therefore could not be explained by differences in cell cycle progression. The induction of S 
phase is presumably beneficial for viral replication, so resveratrol must interfere at a later step 
to attenuate replication.  
 
Untreated DU145 cells had the highest proportion of cells going through S phase, reflecting 
the high proliferative index of this cell line. This might explain why this cell-line supported the 
highest levels of viral replication (Figure 32). In contrast, both slow-growing cells, 22Rv-1 and 
PC-3 cells, had fewer cells undergoing S phase, which correlates with the lower viral titres 
produced by these cell lines. 
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Figure 37 The effect of equol and resveratrol on cell cycle progression in 22Rv-1 cells 
Cells were infected with Ad5 (100ppc) or mock infected. After 2h the infection medium was removed and 
replaced with 2% FCS medium with or without phytochemicals (equol, 100µM or resveratrol, 10µM). Cell 
cycle analysis was performed at 24-72h post-infection by flow cytometry. One experiment representative 
of two. 
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Figure 38 The effect of equol and resveratrol on cell cycle progression in DU145 cells 
Cells were infected with Ad5 (100ppc) or mock infected. After 2h the infection medium was removed and 
replaced with 2% FCS medium with or without phytochemicals (equol, 100µM or resveratrol, 10µM). Cell 
cycle analysis was performed at 24-72h post-infection by flow cytometry. One experiment representative 
of two. 
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Figure 39 The effect of equol and resveratrol on cell cycle progression in PC-3 cells 
Cells were infected with Ad5 (100ppc) or mock infected. After 2h the infection medium was removed and 
replaced with 2% FCS medium with or without phytochemicals (equol, 100µM or resveratrol, 10µM). Cell 
cycle analysis was performed at 24h post-infection by flow cytometry. One experiment representative of 
two. 
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Figure 40 Proportion of cells in S phase in response to Ad5 infection and phytochemical 
treatment 
Cells were infected with Ad5 (100ppc) or mock infected. After 2h the infection medium was removed and 
replaced with 2% FCS medium with or without phytochemicals (equol, 100µM or resveratrol, 10µM). Cell 
cycle analysis was performed at 24h post-infection by flow cytometry. Results are shown as the mean of 
duplicates in two experiments ± SD. * = p <0.05 compared to uninfected and untreated cells, # = p< 0.05 
compared to infected and untreated cells, % = p <0.05 compared to uninfected treated cells. 
 
 
Figure 41 Proportion of cells in sub-G1 after 72h treatments 
Data from Figure 37 and Figure 38. Average of duplicates from one experiment ± SD. 
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Table 18 Percentage (%) of cells in sub-G1 after 72h treatments  
22Rv1 DU145
Untreated 1.1 1.0
Equol 4.2 14.8
Resveratrol 11.3 10.8
Ad5 7.1 3.9
Ad5 Equol 5.1 21.9
Ad5 Resveratrol 5.6 19.9  
Data from Figure 37 and Figure 38. Average of duplicates from one experiment ± SD. 
 
Table 19 Cell cycle distribution in treated and infected PCa cells 
Data from Figure 37, Figure 38 and Figure 39. Results are shown as mean of duplicates in two 
experiments ± SD. Changes in the proportion of cells in S phase are highlighted in blue (uninfected cells) 
and red (infected cells). Changes in the proportion of cells in G2/M are highlighted in green. 
Mean SD Mean SD Mean SD Mean SD
Untreated 0.3 0.2 63.4 4.3 11.0 0.6 22.9 1.9
Equol 0.7 0.7 62.6 5.8 11.2 0.4 23.4 4.1
Resveratrol 0.6 0.4 57.9 6.9 21.3 1.9 17.3 3.0
Ad5 0.2 0.2 57.5 11.1 16.4 5.3 22.4 2.7
Ad5 + equol 0.3 0.2 59.0 8.3 14.1 4.6 24.3 2.0
Ad5 + res 0.4 0.3 52.7 11.2 25.5 6.2 18.8 3.3
Untreated 1.0 0.3 61.3 1.3 12.7 0.5 24.3 1.0
Equol 2.0 0.8 61.1 2.1 11.2 0.9 24.9 0.6
Resveratrol 5.6 2.9 46.4 4.2 22.7 0.8 24.1 0.6
Ad5 1.0 0.5 40.9 9.4 23.6 3.8 31.0 3.5
Ad5 + equol 1.2 0.6 42.8 2.9 25.0 2.5 27.7 1.0
Ad5 + res 1.9 0.2 31.4 5.1 28.3 3.9 34.8 0.7
Untreated 0.1 0.1 52.4 0.5 13.4 2.9 31.3 0.4
Equol 0.3 0.1 53.0 2.7 15.4 0.8 28.1 0.4
Resveratrol 0.2 0.1 46.5 0.9 23.9 0.5 25.9 2.9
Ad5 0.1 0.1 46.5 3.3 20.9 0.1 27.9 0.9
Ad5 + equol 0.2 0.0 50.5 1.9 18.3 0.5 26.9 1.1
Ad5 + res 0.2 0.1 42.7 1.1 26.0 1.7 27.1 2.3
Untreated 0.4 0.2 60.8 4.0 11.5 2.5 26.8 1.5
Equol 2.4 2.0 54.8 1.3 14.1 1.0 28.0 0.8
Resveratrol 2.0 1.5 44.9 5.4 23.7 2.0 28.4 2.2
Ad5 0.6 0.3 50.8 0.5 16.6 0.7 30.8 1.3
Ad5 + equol 2.8 2.3 44.2 7.4 22.7 5.2 29.0 0.8
Ad5 + res 2.2 1.7 32.5 8.1 27.3 4.7 36.1 2.5
Untreated 0.2 0.1 61.4 2.2 11.0 1.7 25.7 1.2
Equol 0.2 0.1 55.1 2.9 12.7 0.6 30.1 4.7
Resveratrol 0.4 0.1 45.1 2.7 25.0 1.9 27.3 5.8
Ad5 0.3 0.1 62.1 1.9 11.6 1.3 24.1 2.0
Ad5 + equol 0.3 0.1 55.0 3.8 12.2 1.2 30.8 5.6
Ad5 + res 0.5 0.3 43.8 3.2 23.7 2.0 29.8 6.6
Untreated 0.4 0.1 64.2 0.6 9.8 0.6 24.3 1.4
Equol 0.3 0.1 61.7 1.9 8.7 1.4 27.9 1.6
Resveratrol 0.5 0.1 50.8 4.4 16.9 1.0 29.4 1.8
Ad5 0.4 0.2 57.6 3.8 11.7 0.7 27.1 0.6
Ad5 + equol 0.5 0.2 58.0 2.3 12.1 1.4 26.2 1.5
Ad5 + res 1.6 0.5 45.3 9.1 19.1 3.0 30.2 2.7
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3.3 The role of apoptosis in cell death induced by 
phytochemicals  
 
We next sought to determine whether the synergistic interactions between Ad5 and the 
phytochemicals could be due to the induction of apoptosis. Although viral cell death is non-
apoptotic (Abou El Hassan et al., 2004; Baird et al., 2008), chemotherapeutic drugs, such as 
docetaxel, mitoxantrone and cisplatin, cause toxicity by apoptosis. Combinations of apoptosis-
inducing chemodrugs with oncolytic adenoviral mutants have been shown to improve 
anticancer potency both in vitro and in vivo and potentiate drug-induced cell death (Heise et 
al., 2000b; Heise et al., 1997; Leitner et al., 2009; Yoon et al., 2006; Yu et al., 2001). Equol 
and resveratrol have also been reported to induce apoptosis in certain cell types (Choi et al., 
2009; Mahyar-Roemer et al., 2001; Mohan et al., 2006). We therefore hypothesised that the 
synergistic enhancement of cell death by the phytochemicals and Ad5 might be due to the 
induction of apoptosis.  
 
3.3.1 Depolarization of the mitochondrial membrane 
One of the characteristics of apoptosis is a loss in mitochondrial membrane polarity, 
accompanied by release of cytochrome c into the cytoplasm. We therefore determined changes 
in mitochondrial membrane polarization (Δϕm) in response to virus, phytochemicals and 
combination treatments.  
 
In DU145, Ad5 alone did not affect Δϕm (Figure 42), indicating that adenoviral cell death was 
not apoptotic, in agreement with previous reports. Decreases in Δϕm were observed in response 
to all other treatments in DU145 cells from 48h to 96h. By 96h, in uninfected cells treated with 
phytochemicals, the proportion of cells with intact Δϕm was lowered from 80% (untreated 
cells) to 26% by equol and 31% by resveratrol. Infection of phytochemical-treated cells with 
Ad5 reduced the proportion of cells with intact Δϕm further to 19% by equol and 15% by 
resveratrol. These effects were greater than those observed in uninfected cells treated with 
phytochemicals although the differences were not statistically significant. 
 
In PC-3 cells, exposure to phytochemicals depolarized the mitochondrial membrane after 72h 
but the largest differences between different treatments were observed after 96h incubation. At 
this time-point, Δϕm was intact in 89% cells treated with Ad5 alone, in 57% equol-treated 
uninfected cells and 51% resveratrol-treated uninfected cells. When infected cells were treated 
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with equol or resveratrol, only 34% and 29% of cells treated displayed intact Δϕm. The 
differences between infected and uninfected treated cells were not statistically significant.  
 
In untreated 22Rv-1 cells, only 75% of cells had intact Δϕm, indicating compromised viability, 
even without treatments (Figure 42). Further decreases due to treatments were observed from 
48h, although differences between treatments only became apparent at 72h and 96h. 
Surprisingly, Ad5 in combination with equol or resveratrol caused less of a decrease in Δϕm 
than the phytochemicals alone. The proportion of cells with intact Δϕm at 96h was higher in 
cells treated with combinations of Ad5 and equol (41%) or resveratrol (52%) compared to 
uninfected cells treated with equol (24%) or resveratrol (28%) alone. This protective effect of 
Ad5 can also be seen when comparing Ad5 alone (69% cells with intact Δϕm) to untreated 
cells (53%), the latter showing fewer live cells than Ad5 alone at 72h and 96h.  
 
In conclusion, this study showed that mitochondrial membrane depolarization was induced by 
both equol and resveratrol in PCa cell lines. However, the proportion of cells with depolarized 
mitochondrial membrane was not significantly increased by the combination treatments 
compared to phytochemicals alone. Ad5 seems to have a protective effect in 22Rv-1 cells as 
viral infection reduced the phytochemical-induced depolarization of the mitochondrial 
membrane.  
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Figure 42 Changes in Δϕm in response to phytochemical treatment and Ad5 infection 
Cells were infected with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc) for 2h and then incubated with 
normal 2% FCS medium or phytochemical-containing medium. Cells were harvested for flow cytometry 
analysis after 24-96h as indicated. Cells were stained with TMRE and DAPI and analysed by flow 
cytometry as described in Methods Section 2.5.4. Cells that retained TMRE staining (i.e. intact, active 
mitochondria) whilst remaining negative for DAPI (i.e. intact cellular membrane) were considered ‘live’. 
Results are shown as the means of duplicates from three separate experiments ± SD. * = p < 0.05 
compared to uninfected and untreated cells, # = p < 0.05 compared to infected and untreated cells, % = p 
< 0.05 compared to uninfected treated cells. Statistical significance was calculated for the 96h time-point. 
 
3.3.2 Activation of caspase-3 
To characterise the apoptotic response further, the activation of caspase-3, which is 
downstream of mitochondrial changes, was also monitored. The relative activation levels of 
caspase-3 varied between cell lines.  
 
Although PC-3 cells seemed to undergo mitochondrial membrane depolarization readily in 
response to phytochemical and combination stimuli, active caspase-3 levels remained quite 
low (Figure 43). As expected, Ad5 alone did not induce activation of caspase-3 (maximum 4% 
of cells at 96h post-infection). Equol alone at the highest dose (100µM) induced caspase-3 
activation in 7.7% of uninfected cells and in 11.7% infected cells. Treatment of PC-3 cells 
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with resveratrol caused slightly higher levels of caspase-3 activation compared to equol. In 
addition, the induction peaked earlier, at 72h. At 96h however, the differences between 
resveratrol-treated uninfected and infected cells were greater. At this time-point, 9.0% of 
uninfected cells treated with 5µM resveratrol had activated caspase-3, while up to 13.3% 
infected cells had active caspase-3. 
 
Caspase-3 activation in DU145 cells was induced to higher levels than in PC-3 cells. Ad5 
alone did not induce a significant degree of apoptosis until 96h infection when 28% cells had 
active caspase-3. The phytochemicals induced caspase-3 activation from 72h after treatment. 
At 96h, 41.6% cells treated with equol and 55% cells treated with resveratrol had active 
caspase-3. By 96h, there were notable differences between uninfected and infected cells 
exposed to phytochemicals. Surprisingly, the largest differences were between combinations 
with the lower doses of phytochemicals. While 18.5% cells treated with 50µM equol had 
active caspase-3, this was increased to 66.8% in infected cells exposed to equol. Similarly, 
35% uninfected cells exposed to 5µM resveratrol for 96h had active caspase-3 and this was 
increased to 70% of cells in those also infected with Ad5.  
 
The proportion of 22Rv-1 cells with active caspase 3 was very low. The maximum percentage 
of cells with active caspase-3 was 9.7% in cells treated with Ad5 and resveratrol 96h post-
infection. This reluctance to undergo apoptosis might explain why 22Rv-1 cells were the least 
sensitive to phytochemical cytotoxicity (Figure 21). After 96h infection, Ad5 caused caspase-3 
activation in 10.1% cells but the addition of 100µM equol reduced this to 5.9%. This 
protective effect was similar to the results observed in TMRE-stained cells (Figure 42). 
Treatment of infected cells with 10µM resveratrol caused caspase-3 activation in 9.7% cells 
and had no effect on the proportion of cells with active caspase-3 compared to single 
treatments. 
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Figure 43 Active caspase-3 in PCa cells treated with phytochemicals and Ad5 
Cells were infected with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc) for 2h and then incubated with 
normal 2% FCS medium or phytochemical-containing medium. Cells were harvested for flow cytometry 
analysis after 24-96h as indicated. Cells were permeabilized and incubated with a FITC-tagged antibody 
specific for activated caspase-3. Results shown are averages (±SD) of one experiment representative of 
3 independent experiments showing the same trend. 
 
3.3.3 Loss of cellular membrane phospholipid asymmetry  
The exposure of phosphatidylserine (PS) on the outer leaflet of the cellular membrane is a 
characteristic feature of apoptosis downstream of mitochondrial depolarization and caspase 
activation. Exposed PS acts as a tag for recognition by macrophages phagocytosing apoptotic 
bodies. PS exposure can be detected by staining with Annexin V, which is membrane 
impermeable and has a high affinity for PS in the presence of calcium. PS exposure was 
monitored in DU145 and PC-3 cells but it could not be assessed in 22Rv-1 cells due to 
cytotoxicity of the calcium-binding buffer in this cell line.  
 
B 
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Cells were co-stained with FITC-labelled annexin V (to label apoptotic cells) and the 
membrane-impermeable DNA dye propidium iodide (to detect cells with compromised 
membranes, indicating necrotic or advanced apoptotic death). Cells were analysed by flow 
cytometry and those negative for both dyes were determined as live cells. The results obtained 
were similar to the patterns observed for caspase-3 activation, with a delay of about 24h.  
 
Ad5 infection did not induce PS exposure except in DU145 cells at the final 120h time-point 
(Figure 44). At this time point, 59% cells demonstrated PS exposure. In DU145 cells, equol 
and resveratrol alone did not increase the proportion of cells with exposed PS, except at the 
highest concentrations (100µM equol, 10µM resveratrol) between 72-120h. At these higher 
doses, the phytochemicals in combination with Ad5 did not increase the proportion of cells 
with PS exposure above that caused by single agent treatments. However, in combination with 
Ad5, 50µM equol decreased live cells from 86.5% (equol alone) and 82.7% (Ad5 alone) to 
46.7% at 96h post-infection. In combination with 5µM resveratrol Ad5 did not increase the 
proportion of cells with exposed PS further than Ad5 alone.  
 
In PC-3 cells, equol (50µM and 100µM) and resveratrol (5µM) in combination with Ad5 did 
trigger PS exposure in a higher proportion of infected cells compared to uninfected treated 
cells. After 120h, the percentage live cells dropped from 73.4% and 69.5% (equol 50µM and 
100µM alone) to 52.9% and 40.7% (equol 50µM and 100µM with Ad5). Resveratrol at the 
highest dose (10µM) caused a significant drop in live cells from 72h. The combination at this 
dose with Ad5 did not further decrease live cells until 120h post-infection where live cells 
dropped from 22.8% (resveratrol 10µM alone) to 11.5% (resveratrol 10µM with Ad5).  
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Figure 44 Exposure of phosphatidylserine (PS) in dying cells exposed to combination treatments 
Cells were infected with Ad5 (22Rv-1 and DU145: 100ppc, PC-3: 300ppc) for 2h and then incubated with 
normal 2% FCS medium or phytochemical-containing medium. Cells were harvested for flow cytometry 
analysis after 24-96h as indicated. Cells were stained with Alexa fluor 488-conjugated annexin V and 
propidium iodide. Annexin-V negative and PI-negative cells were plotted as live cells under each 
condition. Results are means of duplicates from 1-4 experiments ± SD.  
 
3.3.4 Inhibition of apoptosis reduced phytochemical-induced cell 
death  
To evaluate the role of apoptosis in cell death induced by equol and resveratrol with and 
without Ad5, a pan-caspase-inhibitor, zVAD-fmk, was used in cell viability assays. Cell death 
was evaluated six days post-treatment with 50-100µM equol or 5-10µM resveratrol. These 
doses were found to initiate apoptosis at 48h-120h in previous experiments (Figure 42, Figure 
43 and Figure 44), although treatments did not cause cytotoxicity before 72-96h, depending on 
the cell line (Figure 33). The dose of zVAD-fmk was selected based on previous experiments 
in our lab, although it could have been optimized for PC-3 cells which showed 15% cell death 
in response to treatment with 25µM zVAd-fmk alone. 
 
The lower dose of equol (50µM) did not cause any cytotoxicity in DU145 cells at any time-
point, but 100µM equol caused cell death that was reduced by the addition of the caspase 
inhibitor from 52.2% to 21.7% (Figure 45). Similarly, no cell death induction was observed in 
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response to 5µM resveratrol, while exposure of DU145 cells to 10µM resveratrol resulted in 
58% cell death which was reduced by zVAD-fmk to 20.9%. 
 
Lower levels of cytotoxicity were seen in 22Rv-1 cells and the reductions by caspase 
inhibition were also less in this cell line. The addition of zVAD-fmk to cells treated with 
100µM equol reduced cell death from 33% to 27% respectively (Figure 45). At a lower dose, 
equol (50µM) induced 10.7% cell death and this was decreased by caspase inhibition to 5.8%. 
The lower dose of resveratrol (5µM) did not cause any cytotoxicity, but at the higher dose 
(10µM), 17.2% cell death was reduced by zVAD-fmk to 8.2%. 
 
PC-3 cells were more sensitive to treatment with the pan-caspase inhibitor which caused 6.7% 
(5µM) and 15.3% (25µM) cell death respectively. Surprisingly, the addition of zVAD-fmk to 
the phytochemicals increased cytotoxicity additively, except for equol at 50µM which did not 
induce cell death alone or in combination with the inhibitor. The highest dose of equol 
(100µM), caused <5% cell death, but in combination with zVAD-fmk, cell death increased to 
20.1%. When resveratrol was combined with zVAD-fmk, cell death was increased from 4.7% 
to 15.9% (5µM) and from 16.7% to 28.9% (10µM). This could be due to an enhancement of 
alternative cell death pathways, such as necrosis. 
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Figure 45 Effect of the pan-caspase inhibitor zVAD-fmk on phytochemical-induced cell death 
Cells were treated with equol (50µM or 100µM) or resveratrol (5µM or 10µM), with or without zVAD-fmk 
at two concentrations (5µM or 25µM). Cell viability was assessed 6 days post-treatment by MTS assay. 
Results are shown as means of triplicates in one experiment ± SD.  
 
Cell death induced by Ad5 infection was not significantly affected by caspase inhibition in 
DU145 cells, as is demonstrated by the overlapping dose-response curves (Figure 46). 
Nevertheless, there was a reduction in the Ad5 EC50 value with the highest dose of zVAD-fmk 
(25µM), from 10.6ppc to 6.7ppc, indicating a slight sensitization effect in the presence of 
zVAD-fmk (Table 20). The pan-caspase inhibitor had little effect on cell death induced by 
Ad5 in combination with 50µM equol in DU145 cells and in combinations with equol 100µM 
cell death was only slightly decreased by zVAD-fmk (Figure 45). A greater yet still modest 
protective effect was observed with resveratrol when combined with Ad5 and the caspase 
inhibitor. The Ad5 EC50 value increased from 3.4ppc to 5.3ppc (1.4-fold) in cells treated with a 
combination of 5µM resveratrol and Ad5, with and without the caspase inhibitor. In cells 
treated with combinations of Ad5 and the higher dose of resveratrol (10µM) zVAD-fmk also 
appeared to have a small protective effect.  
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In 22Rv-1 cells, there was a small decrease in the Ad5 EC50 value, from 14.8ppc to 9.6ppc, by 
the addition of zVAD-fmk at the highest concentration (Figure 47). Caspase-inhibition had a 
sensitising effect in infected 22Rv-1 cells treated with equol. With the highest dose of caspase 
inhibitor (25µM), the Ad5 EC50 values were reduced from 5.2ppc to 3ppc (equol 50µM) and 
from 3.7ppc to 0.8ppc (equol 100µM) (Table 20). In resveratrol-treated 22Rv-1 cells infected 
with Ad5, zVAD-fmk had opposite effects depending on the dose of phytochemical. With 
5µM resveratrol, Ad5 EC50 was increased 1.7-fold from 9ppc to 15.8ppc. However, at a higher 
dose (10µM) the inhibition of caspases had a sensitising effect, with Ad5 EC50 value reduced 
by 40% from 16ppc to 9.7ppc.  
 
Caspase inhibition also had a sensitising effect in PC-3 cells where the Ad5 EC50 value for 
Ad5 alone was reduced 2-fold from 1167ppc to 560.2ppc by 5µM zVAD-fmk (Figure 48 and 
Table 20). The inhibition of caspases in infected PC-3 cells treated with equol was highly 
protective. Cell death was clearly decreased, resulting in a shift of dose-response curves to the 
right. Cells treated with Ad5 and equol showed increases in Ad5 EC50 values from 165.5ppc to 
505.2ppc (equol 50µM) and from 57.6ppc to 197ppc (equol 100µM). Caspase inhibition also 
protected resveratrol-treated PC-3 cells from Ad5-induced cell death (Figure 48). The highest 
dose of zVAD-fmk increased Ad5 EC50 values 1.6-fold, from 344ppc to 553ppc with 5µM 
resveratrol, and 8-fold from 83ppc to 662ppc with 10µM resveratrol.  
 
These results indicate that the role of apoptotic cell death in combination treatments with 
phytochemicals may be cell line- and dose-dependent. A requirement for apoptosis and 
caspase-3 activation was most obvious in PC-3 cells, despite these cells showing significant 
increased cell death in response to addition of zVAD-fmk to equol- or resveratrol-treated 
uninfected cells. 
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Figure 46 Effects of apoptosis inhibition on cell death in DU145 cells 
Cells were infected with 5-fold serially diluted Ad5 (0.256-800ppc), with or without zVAD-FMK at two 
concentrations (5µM or 25µM), with or without equol (50µM or 100µM) or resveratrol (5µM or 10µM). Cell 
viability was assessed 6 days post-infection by MTS assay. Results are shown as means of triplicates 
from three independent experiments ± SD.  
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Figure 47 Effects of apoptosis inhibition on cell death in 22Rv-1 cells 
Cells were infected with 5-fold serially diluted Ad5 (0.128-400ppc), with or without zVAD-fmk at two 
concentrations (5µM or 25µM), with or without equol (50µM or 100µM) or resveratrol (5µM or 10µM) in a 
final volume of 100µl/well. Cell viability was assessed 6 days post-infection by MTS assay. Results are 
shown as means triplicates from one experiment ± SD.  
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Figure 48 Effect of apoptosis inhibition on cell death in PC-3 cells 
Cells were infected with 5-fold serially diluted Ad5 (0.256-800ppc), with or without zVAD-fmk at two 
concentrations (5µM or 25µM), with or without equol (50µM or 100µM) or resveratrol (5µM or 10µM). Cell 
viability was assessed six days post-infection by MTS assay. Results were corrected for cell death 
caused by the caspase inhibitor alone (Figure 45). Results are shown as means of triplicates ± SD from 
one experiment representative of two.  
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Table 20 Ad5 EC50 values for combination-treated cells with and without caspase inhibitor 
Treatments 22Rv-1 DU145 PC-3
Ad5 14.81 10.6 1167
17.54 9.5 560.2
9.6 6.7 695.6
5.16 2.75 165.5
4.22 2.57 109.8
2.99 2.78 505.2
3.71 57.55
2.9 69.95
0.81 197
9.16 3.41 343.9
14.02 3.69 536
15.75 5.26 552.9
16.11 82.67
10.75 324.1
9.65 661.9  
Data from experiments shown in Figure 46, Figure 47 and Figure 48. Reductions are shown in green, 
increases in red. Ad5 EC50 values could not be determined for combinations with the highest doses of 
equol (100µM) and resveratrol (10µM) in DU145 cells due to high levels of cell death.  
 
3.3.5 Summary of apoptotic cell death studies 
Taken together, these results indicate that the level of apoptosis induced by the phytochemicals 
and by the combinations with Ad5 is cell line-dependent. Both equol and resveratrol induced 
apoptosis in a dose-responsive manner, as detected by mitochondrial membrane 
depolarization, caspase-3 activation and externalization of PS on the cell membrane. The 
strongest responses were in DU145 cells. Cell death caused by equol or resveratrol alone was 
reduced using a pan-caspase inhibitor, except in PC-3 cells where zVAD-fmk unexpectedly 
increased phytochemical cytotoxicity in an additive fashion.  
 
Ad5 alone did not cause any of the classical features of apoptosis, although low levels of 
active caspase-3 and PS externalization were detected 96-120h post-infection in DU145 cells. 
This may indicate an indirect effect of Ad5 infection that results in a general stress response in 
these cells at late time-points. Caspase-inhibition in Ad5-infected cells caused a small 
sensitising effect, suggesting cross-talk between apoptosis and the viral-induced mode of cell 
death. 
 
Combination treatments of phytochemicals with Ad5 in DU145 and PC-3 cells induced higher 
levels of caspase-3 activation and PS externalization, but differences between combination and 
single treatments on mitochondrial membrane depolarization could only be seen in PC-3 cells. 
Caspase inhibition was protective against combination-induced cell death in DU145 and PC-3 
cells, confirming the involvement of an apoptotic mechanism of cell death in these cell lines in 
response to combination treatment. The strong effect of zVAD-fmk in PC-3 cells is surprising, 
considering this cell line lacks p53 and it did not exhibit high levels of active caspase-3.  
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In contrast, the percentages of combination-treated 22Rv-1 cells with active caspase-3 and 
depolarized mitochondrial membrane were lower compared to cells exposed to single agents. 
Ad5 appears to have a protective effect in this cell line, reducing apoptosis induction by the 
phytochemicals despite clear sensitization at specific Ad5-phytochemical ratios. Caspase-
inhibition sensitised 22Rv-1 cells to combinations of equol and Ad5, although zVAD-fmk was 
protective against combinations of resveratrol with Ad5.  
 
In conclusion, apoptosis seemed to play a significant role in cell death caused by combinations 
of Ad5 and phytochemicals in DU145 and PC-3 cells. However, apoptosis remained very low 
in 22Rv-1 cells, despite evidence of strong synergistic induction of cell death by combinations 
of Ad5 and phytochemicals (Figure 25). 
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3.4 Autophagy is a survival mechanism induced by 
combination treatments 
 
Although apoptosis seemed to be induced and play a role in cell death induced by 
combinations of phytochemicals with Ad5 in DU145 and PC-3 cells, additional mechanisms 
must play a role in 22Rv-1 cells to cause the supra-additive effects in this cell line. 
Furthermore, the protective effect of zVAD-fmk in DU145 and PC-3 cells did not completely 
desensitise cells to the synergistic combination-induced cell death.  
 
Autophagy induction in response to Ad5 has been reported in some cell lines (Ito et al., 2006; 
Jiang et al., 2007), and by resveratrol in ovarian (Kueck et al., 2007), breast (Scarlatti et al., 
2008) and lung (Ohshiro et al., 2007) cancer cells. As discussed in Section 1.4.3.2.2, 
autophagy can serve as both a survival and a cell death mechanism. 
 
Autophagy induction was evaluated in 22Rv-1 to determine whether this pathway might be 
functioning as a cell death mechanism in this cell line in response to combination treatment. 
PC-3 cells were used as a comparative cell line in which zVAD-fmk was protective against 
combination-induced cell death and autophagy was therefore expected to have less 
involvement in the cell death mechanism.  
 
3.4.1 Expression levels of LC3: a protein marker of autophagy 
Autophagy induction was assessed by monitoring LC3 expression in cells treated with the 
autophagy inducer rapamycin (Kabeya et al., 2000). LC3-II is an essential structural protein of 
the autophagosome membrane and is normally localized to the cytoplasm in its precusor form, 
LC3-I. Upon autophagy induction, LC3-I (18kDa) is converted to LC3-II (16kDa) by post-
translational modification. LC3-II is incorporated in the autophagosome membrane and the 
amount present correlates with the extent of autophagosome formation. After 48h treatments, 
the induction of LC3-II was detected in response to 1nM (PC-3 cells) and 10nM (22Rv-1 cells) 
rapamycin (Figure 49). Untreated PC-3 cells also expressed LC3-II, indicating that autophagy 
might be induced under regular cell culture conditions (2% FCS medium) in these cells. 
However, the level of LC3-II expression in untreated cells varied since only LC3-I was 
detected in a subsequent experiment (Figure 51). This variability was also noted in untreated 
22Rv-1 cells (Figure 50 and Figure 51). 
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Figure 49 Induction of LC3 expression by rapamycin 
22Rv-1 and PC-3 cells were treated with increasing doses of rapamycin (1nM-400nM) for 48h. Lysates 
were harvested and blotted for LC3 expression as detailed in Methods Section 2.7. Actin was used as a 
loading control. N=1.   
 
Western blot analysis of phytochemical-treated cells showed that equol induced LC3-II 
expression in both 22Rv-1 and PC-3 cells (Figure 50). This effect was strongest with 100µM 
equol and appears to be dose-dependent. Both concentrations of resveratrol also induced   
LC3-II expression, especially in PC-3 cells. A decrease was observed in rapamycin-treated 
cells with 100µM equol in both cell lines and with 10µM resveratrol in PC-3 cells. Ad5 
infection seemed to repress   LC3-II expression in 22Rv-1 cells, but this was overcome by the 
addition of either equol or resveratrol (Figure 51). The trend was similar in PC-3 cells except 
Ad5 seemed to repress resveratrol-induced LC3-II expression. 
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Figure 50 LC3 expression in phytochemical-treated cells with and without rapamycin 
Cells were treated with equol (50µM or 100µM) or resveratrol (5µM or 10µM) and with or without 
rapamycin (100nM). Cell lysates were harvest 48h post-treatment and LC3 detected by western blotting 
as described in Methods Section 2.7.  
 
 
Figure 51 LC3 expression in Ad5-infected cells with and without phytochemicals 
Cells were infected with Ad5 (100ppc) or left uninfected. After 2h, the medium was removed and 
replaced with normal or phytochemical-containing 2% FCS medium (equol 50µM, resveratrol 5µM). 
Lysates were harvested 48h post-infection and blotted for LC3 and actin as described in Methods 
Section 2.7.  
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3.4.2 Subcellular localization of LC3 
Autophagy was also assessed by monitoring the cellular localization of LC3 in phytochemical-
treated cells. This was done by creating stably transfected cells expressing GFP-tagged LC3, 
as described in Methods Section 2.8.1, and determining the localization of this protein by 
confocal microscopy.  
 
In untreated, stably transfected 22Rv-1-LC3-GFP cells, LC3 remained cytosolic and the cells 
therefore appear homogeneously and diffusely green (Figure 52 A and B). A few cells in 
untreated samples displayed signs of autophagy. This correlates with the Western blot analyses 
which indicated basal levels of autophagy in untreated cells. Cells undergoing autophagy 
should display a punctate pattern of green, indicating relocalisation of LC3 to 
autophagosomes. Cells were treated with rapamycin (up to 400nM for 48h) or were serum-
starved to obtain a positive control (Figure 52 C and D). A proportion of these cells did show a 
punctate green appearance although the phenotype was not as striking as expected. This was 
surprising since LC3-II expression was highly upregulated in 22Rv-1 cells treated with 
rapamycin, as determined by Western blotting (Figure 50).  
 
Ad5 alone did not induce relocalization of LC3 to autophagosomes (Figure 53 B). This is 
consistent with LC3-II expression detected by Western blot (Figure 51). Cells treated with 
equol showed punctate patterns of green in some cells that were reduced by Ad5 (Figure 53 C 
and D). A trend towards autophagy was also observed in resveratrol-treated 22Rv-1 cells that 
was not prevented by Ad5 (Figure 53 E and F). LC3-GFP localization to autophagosomes was 
also visible in cells exposed to resveratrol after shorter treatments of 3-6h (Figure 54). 
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Figure 52 Autophagy-induced localization of LC3-GFP in 22Rv-1-LC3 -GFP cells viewed by 
confocal microscopy 
Stably transfected 22Rv-1-LC3-GFP cells were seeded on glass coverslips in duplicate 6-well plates and 
allowed to adhere overnight. Cells were incubated for 48h with 2% FCS medium (A and B), with 
rapamycin (400nM, C) or with 0% FCS (D). Cells were fixed, permeabilised and mounted as described in 
Methods Section 2.8.2 for viewing by confocal microscopy. Arrows indicate cells with punctate green 
indicating LC3 localization to autophagosomes. Images are of representative fields of cells viewed on 
duplicate coverslips. Scale bars, 10µM. N=2. 
 
A. Untreated B. Untreated 
 
C. Rapamycin 
 
D. 0% FCS 
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Figure 53 LC3 localization in phytochemical-treated 22Rv-1-LC3-GFP cells 
Stably transfected 22Rv-1-LC3-GFP cells were seeded on glass coverslips in duplicate 6-well plates and 
allowed to adhere overnight. Cells were left uninfected or infected with Ad5 (100ppc) for two hours, then 
incubated with equol (100µM) or resveratrol (10µM) in 2% FCS. Cells were fixed, permeabilised and 
mounted as described in Methods Section 2.8.2 48h post-infection. A, Uninfected, untreated; B, Ad5; C, 
Equol; D, Ad5 and equol; E, Resveratrol; F, Ad5 and resveratrol. Images are of representative fields of 
cells viewed on duplicate coverslips. Scale bars, 10µM. N=2. 
B. Ad5 
 
 
A. Untreated 
 
 
C. Equol 
 
 
 
 
 
 
 
 
D. Ad5 + equol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. Resveratrol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F. Ad5 + resveratrol 
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 Figure 54 LC3 localisation in 22Rv-1-LC3-GFP cells treated with resveratrol at early time-points 
Stably transfected 22Rv-1-LC3-GFP cells were seeded on glass coverslips in duplicate 6-well plates. The 
following day cells were treated with resveratrol (10µM) in 2% FCS or left untreated (A). Cells were fixed, 
permeabilised and mounted as described in Methods Section 2.8.2 after 1h (B), 3h (C), 4h (D and E) and 
6h (F). Images are of representative fields of cells viewed on duplicate coverslips. Scale bars, 10µM. 
N=1. 
A. Untreated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Resveratrol 1h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Resveratrol 3h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. Resveratrol 4h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F. Resveratrol 6h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. Resveratrol 4h  
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3.4.3 Inhibition of autophagy enhances cell death 
To determine whether the observed induction of autophagy might play a role in the synergistic 
enhancement of cell death in response to the combination treatments of Ad5 with 
phytochemicals, two autophagy inhibitors were used in MTS cell viability assays. 3-
methyladenine (3-MA) inhibits autophagy induction by binding to class III PI3K (Petiot et al., 
2000; Seglen & Gordon, 1982), whereas bafilomycin A1 inhibits autophagy further 
downstream by preventing the fusion of the autophagosomes with lysosomes (Yamamoto et 
al., 1998). 
 
In cells treated with phytochemicals alone, the inhibition of autophagy increased cell death, 
although the effect was mostly additive (Figure 55). For example, in 22Rv-1 cells, cytotoxicity 
due to equol 50µM was increased from 38.6% to 47.7% by bafilomycin A1 and to 56.1% by 3-
MA. Similarly, resveratrol-induced (10µM) cell death increased from 27.3% to 40.7% with 
bafilomycin A1 and to 44.6% 3-MA. In DU145 cells 3-MA increased cell death in response to 
100µM equol from 44.8% to 65.9% and in response to 10µM resveratrol from 16.6% to 
60.9%. In PC-3 cells, 3-MA increased cell death induced by 5µM resveratrol from 9.8% to 
21.8%, although there was little effect on equol-induced cell death. However, there was a 
striking induction of cell death by the combination of equol with bafilomycin A1, cell death 
levels reaching 74.9% (equol 50µM) and 85.4% (equol 100µM).  
 
In PC-3 cells, rapamycin alone caused 47.9% cell death. This was not affected by the addition 
of resveratrol, however, equol reduced rapamycin-induced cytotoxicity to less than 2% cell 
death. The induction of autophagy by rapamycin in DU145 reduced cell death caused by the 
highest concentrations of phytocehmicals from 44.8% (equol 100µM) and 16.7% (resveratrol 
10µM) to less than 2%. In contrast to the AR-negative cell lines, in 22Rv-1 cells, rapamycin in 
combination with the phytochemicals induced higher cytotoxicity levels additively. With 
100µM equol, rapamycin increased cell death from 61.6% to 76.3% and with 10µM, from 
27.3% to 47.4%. Rapamycin alone caused 14.7% cell death in this cell line.  
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Figure 55 The effect of autophagy inhibitors on phytochemical-treated cells 
Cells were treated in triplicate with phytochemicals (equol 50µM or 100µM, resveratrol 5µM or 10µM) 
with or without the autophagy inhibitors, 3-methyladenine (3MA, 22Rv-1 and PC-3: 2mM, DU145: 10mM) 
or bafilomycin-A1 (BafA1, 22Rv-1: 0.5nM, PC-3: 2nM), or with the autophagy inducer, rapamycin (Rapa, 
10nM). Cell viability was determined 6 days post-treatments by MTS assay. Results show as the average 
percentages of cell death for triplicates from one experiment ± SD, representative of 1-3 experiments.  
 
In infected 22Rv-1 and PC-3 cells, the inhibition of autophagy induction by 3-MA had a 
sensitising effect while, conversely, the addition of rapamycin had a protective effect (Figure 
56). The effect was most noticeable in PC-3 cells where 3-MA reduced the Ad5 EC50 value 
more than 5-fold, from 388.1ppc to 72.6ppc. On the other hand, in this cell line, rapamycin 
increased the Ad5 EC50 value 2.6-fold, to 1011.0ppc. While 10nM rapamycin caused about 
50% cell death in PC-3 cells, treatment with Ad5 seemed to reduce this cytotoxicity The 
inhibition of autophagosome fusion with lysosomes by bafilomycin A1 did not have a 
significant effect in 22Rv-1 nor PC-3 cells (this inhibitor was not tested in DU145 cells). In 
DU145 cells, both rapamycin and 3-MA were protective, as they increased the Ad5 EC50 value 
from 12.9ppc to 33.8ppc (rapamycin) and 44.2ppc (3-MA) respectively.  
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Figure 56 The effect of autophagy inhibition and stimulation on Ad5-induced cell death 
Cells were infected with serially diluted Ad5 (22Rv-1, 0.128-400ppc, DU145, 0.256-800ppc, PC-3, 1.28-
4000ppc) and treated with 3-methyladenine (22Rv-1 and PC-3, 0.5mM, DU145, 5mM), bafilomycin-A1 
(22Rv-1, 0.5nM, PC-3, 2nM) or rapamycin (10nM). Cell viability was determined 6 days post-infection by 
MTS assay. Results shown as the average percentage cell death of triplicates from one experiment ± 
SD, representative of 2-3 experiments (except for rapamycin where N=1).  
 
In cells treated with combinations of Ad5 and phytochemicals, 3-MA also sensitised 22Rv-1 
cells to equol-induced cell death in combination with Ad5 (Figure 57), as observed when 3-
MA was combined with equol (Figure 55). Inhibition of the fusion of autophagosomes with 
lysosomes by bafilomycin-A1 was not as potent, although Ad5 EC50 with equol 50µM was 
reduced from 2.59ppc to 1.85ppc (Table 21). 3-MA had a protective effect in PC-3 cells, 
where it increased Ad5 EC50 with 100µM equol from 8.3ppc to 22.2ppc. This is in keeping 
with the small protective effect of 3-MA on cell death induced by equol alone (Figure 55). 
Bafilomycin A1 greatly sensitised PC-3 cells to cell death induced by combinations of Ad5 
and equol, similarly to its effect with equol alone in this cell line (Figure 55). 3-MA was also 
protective against combination-induced cell death with equol in DU145 cells, particularly at 
the lower concentration (50µM) of phytochemical.  
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The effect of rapamycin on cell death induced by Ad5 and equol was clearly protective in PC-
3 cells, as in DU145 cells, although the results were less pronounced in the latter cell line. 
Unexpectedly, in 22Rv-1 cells, rapamycin appeared to be sensitising, particularly for 
combinations with equol 100µM. The induction of autophagy by rapamycin had no effect on 
cell death caused by combinations with resveratrol in 22Rv-1 cells, although in PC-3 cells it 
was clearly protective, increasing the Ad5 EC50 value 4.5-fold (Figure 58 and Table 21). 
 
In DU145 cells, 3-MA was protective against combination-induced cell death with the lower 
dose of resveratrol (5µM) but at the higher dose (10µM), 3-MA was highly sensitising. The 
inhibition of autophagy signalling by 3-MA was sensitising in both 22Rv-1 and PC-3 cells 
treated with combinations of Ad5 and resveratrol. The effect of inhibiting autophagy at a 
downstream step by bafilomycin-A1 also sensitised these cell lines, although it was less potent 
than 3-MA.  
 
These results showed that the modulation of autophagy using various chemical inhibitors could 
greatly impact the potency of combination treatments with Ad5. The induction of autophagy 
by rapamycin decreased Ad5-induced cell death so its stimulation may not be beneficial for 
adenovirus-based oncolytic virotherapy, at least in these cell lines. Rapamycin increased Ad5 
EC50 values in combination-treated cells, except with 100µM equol in infected 22Rv-1 cells.  
 
The inhibition of autophagy was found to sensitise the cells to combination treatments with 
Ad5 and phytochemicals in most instances, although the step at which autophagy was inhibited 
was important and the outcome varied between cell lines. The most responsive cell line to 
autophagy modulation was PC-3 cells.  
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Figure 57 The effects on cell death by autophagy inhibition and stimulation when Ad5 is 
combined with equol 
Cells were infected with serially diluted Ad5 (22Rv-1, 0.128-400ppc, DU145, 0.256-800ppc, PC-3, 1.28-
4000ppc) and treated with or without equol (50µM or 100µM) and 3-methyladenine (22Rv-1 and PC-3, 
0.5mM, DU145, 5mM), bafilomycin-A1 (22Rv-1, 0.5nM, PC-3, 2nM) or rapamycin (10nM). Cell viability 
was determined 6 days post-infection by MTS assay. Results shown as the average percentage cell 
death of triplicates from one experiment ± SD, representative of 2-3 experiments (except for rapamycin 
where N=1).  
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Figure 58 The effect of autophagy inhibition and stimulation on combination-induced cell death 
with resveratrol 
Cells were infected with serially diluted Ad5 (22Rv-1, 0.128-400ppc, DU145, 0.256-800ppc, PC-3, 1.28-
4000ppc) and treated with or without resveratrol (5µM or 10µM) and 3-methyladenine (22Rv-1 and PC-3, 
0.5mM, DU145, 5mM), bafilomycin-A1 (22Rv-1, 0.5nM, PC-3, 2nM) or rapamycin (10nM). Cell viability 
was determined 6 days post-infection by MTS assay. Results shown as the average percentage cell 
death of triplicates from one experiment ± SD, representative of 2-3 experiments (except for rapamycin 
where N=1).  
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Table 21 Ad5 EC50 values in phytochemical-treated cells with two autophagy inhibitors and one 
inducer  
22Rv1
Ad5 alone 11.35 13.44 16.10 6.50
2.59 1.85 2.43 1.07
1.38 1.65 N/A N/A
14.49 8.51 13.94 3.74
8.96 6.25 8.63 4.05
DU145
Ad5 alone 12.90 33.84 44.15
3.94 5.99 16.49
2.66 2.96 3.98
6.13 27.11 28.51
1.93 19.87 N/A
PC-3
Ad5 alone 388.1 360.5 1011.0 72.6
58.2 N/A 487.5 98.9
8.3 N/A 261.3 22.2
172.3 214.2 1800.0 204.7
201.9 164.4 907.0 99.6
3-Methyladenine
Untreated Rapamycin 3-Methyladenine
Untreated Bafilomycin-A1 Rapamycin
Untreated Bafilomycin-A1 Rapamycin 3-Methyladenine
 
Representative data from experiments shown in Figure 56 Figure 57 and Figure 58. Results are shown 
as Ad5 EC50 values (ppc) for each combination treatment and inhibitor/inducer. N/A = Ad5 EC50 value not 
determined due to a lack of dose response curve, resulting from high cell death.  
 
To determine whether the inhibition of autophagy increased cell death through the apoptotic 
pathway, caspase-3 expression levels were verified in bafilomycin-A1-treated cells (Figure 59 
and Figure 60). Caspase-3 activation was detected in both 22Rv-1 and DU145 cells treated 
with equol or resveratrol. Treatment with bafilomycin-A1 caused an accumulation of LC3-II, 
as expected since the degradation of the autophagosome is inhibited by this compound. The 
addition of equol or resveratrol to 22Rv-1 and DU145 cells treated with the autophagy 
inhibitor increased the level of LC3-II. Treatment of DU145 cells with phytochemicals and 
bafilomycin-A1 induced higher expression levels of caspase-3, indicating that the induction of 
apoptosis was enhanced by the repression of autophagy. In both 22Rv-1 and DU145 cells, 
caspase-3 activation was abrogated by Ad5, although combination-treated cells expressed low 
levels of cleaved caspase-3. In 22Rv-1 cells bafilomycin-A1 had little effect on caspase-3 
activation in Ad5-infected cell, indicating that the enhanced cell death detected in 
combination-treated cells when autophagy is inhibited may not be due to apoptosis. However, 
these data correlate with the limited changes in Ad5 EC50 caused by bafilomycin A1 detected 
in this cell line (Table 21). Use of the more potent autophagy inhibitor, 3-MA, could reveal 
differential caspase-3 expression. In combination-treated DU145 cells exposed to bafilomycin-
A1, there was a small level of active caspase-3 expression, indicating that apoptosis might play 
a role in combination-induced cell death when autophagy is inhibited in this cell line. The 
effect of bafilomycin-A1 on combination-induced cell death in DU145 cells remains to be 
determined.  
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Figure 59 Caspase-3 expression in bafilomycin-A1-treated 22Rv-1 cells 
Cells were infected with Ad5 (100ppc) for 2h or left uninfected. Cells were then treated with equol 100µM 
or resveratrol 5µM), with or without bafilomycin-A1 (1nM). Cell lysates were harvested 48h after nfection 
and used for western blot detection of capase-3 as detailed in Methods Section 2.7.2. Blots shown are 
representative of two independent experiments.  
 
 
 
Figure 60 Caspase-3 expression in bafilomycin-A1-treated DU145 cells 
Cells were infected with Ad5 (100ppc) for 2h or left uninfected. Cells were then treated with equol 100µM 
or resveratrol 5µM), with or without bafilomycin-A1 (1nM). Cell lysates were harvested 48h after infection 
and used for Western blot detection of capase-3 as detailed in Methods Section 2.7.2. N=1. 
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3.5 Synergy of phytochemicals with replication-selective 
oncolytic Ad5 mutants 
 
We sought to determine whether the synergistic enhancement of adenovirus-induced cell death 
by equol and resveratrol could also be achieved with replication-selective oncolytic deletion 
mutants and to further investigate the mechanisms for the enhanced cell death with the 
phytochemicals. We therefore tested equol and resveratrol with several Ad5 mutants designed 
in our lab which are currently being evaluated preclinically. This was done by screening 
different combination ratios of adenoviral mutants and phytochemicals. Higher combination 
ratios were selected since the earlier synergy study showed that they seemed to give better 
results (Figure 22 and Figure 23). Isobolograms were constructed from the EC50 doses for each 
combination ratio and combination indexes (CIs) were determined.  
 
PC-3 cells, which had previously been shown to be the most resistant to Ad5-induced cell 
death (Figure 21), were the most responsive cells to combination treatments. This cell line 
showed very few antagonistic results with any of the adenoviral mutants tested (Table 22). As 
expected, the majority of responses with wild type virus and equol were synergistic (77% 
responses with Ad5, 100% responses with Ad5tg, the wild type backbone from which our 
other mutants are constructed; see Methods Section 2.3.1). With resveratrol, 56% of the 
interactions with Ad5 were found to be synergistic, the rest being additive, and with Ad5tg 
80% of the responses were additive and the others were synergistic. 
 
The other replicating adenoviral mutants also acted synergistically with equol in PC-3 cells. 
The best CI (0.24) was obtained with AdΔΔ at the highest ratio (1ppc:15625nM) (Table 23). 
However, both AdΔCR2 (best CI=0.8) and AdΔΔ (best CI=0.78) were mostly additive with 
resveratrol and AdΔE1B-19K was antagonistic with this phytochemical (CIs between 1.34-
2.6). The non-replicating AdE1A-12S mutant, that has been shown to sensitise cells to 
chemotherapeutic drug-induced apoptosis, gave four out of four antagonistic responses, 
although the average CI was less than 1.3, indicating only mild antagonism. However, this 
observation supports the conclusion that the synergistic interaction of phytochemicals with 
adenoviruses does not solely rely on the induction of apoptosis. No effects could be 
determined in combination with the non-replicating dl312 mutant in PC-3 cells since this virus 
killed <10% cells (2×105ppc) so the EC50 value could not be determined. 
 
Despite clear synergy with Ad5 in combination experiments with DU145 cells (Figure 25), 
Ad5 in this cell line produced 48% antagonistic responses with equol and nearly a third 
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interactions with resveratrol (Table 22). Average CIs showed that the antagonism occurs 
especially at the lowest combination ratios (1ppc:125nM and 1ppc:625nM, Table 24). The 
highest ratio (1ppc:15625nM) gave consistent additive results with Ad5 and synergy with 
Ad5tg.  
 
The replicating deletion mutants also acted synergistically at the highest ratio with equol and 
additively with resveratrol in DU145 cells. The most synergistic mutant with equol was 
Ad5ΔE1B-19K (9/12 synergistic interactions), followed by AdΔCR2 (5/8). Surprisingly, most 
responses with AdΔΔ were antagonistic (5/8), although at the highest combination ratio, it was 
synergistic with both equol (average CI=0.68) and resveratrol (average CI=0.8).  
 
The non-replicating mutants showed good responses in DU145 cells, nearly all interactions 
being synergistic or additive. Ad5-Hey1, which expresses the AR co-repressor Hey1, produced 
5 out of 8 synergistic responses with equol (CIs between 0.6-0.94) although this cell line does 
not express the androgen receptor. dl312 acted additively in DU145 cells. AdE1A-12S was 
synergistic with equol at the lowest ratio (average CI=0.6) and additive at other combination 
ratios with equol and resveratrol.  
 
Interactions of the deletion mutants were not studied as extensively in 22Rv-1 cells since the 
results with wild type Ad5 were not as promising as for other cell lines. The majority of 
responses were only additive and for each phytochemical, 3 out of 8 interactions were found to 
be antagonistic (Table 25). One point of synergy was detected with Ad5 and resveratrol at the 
highest combination ratio (average CI=0.6, Table 25). The non-replicating Ad5-Hey1 mutant 
was also synergistic with equol at this ratio (average CI=0.65) although it was additive (3/8 
responses) or antagonistic (5/8) with resveratrol. 
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Table 22 Summary of interactions between equol and resveratrol with Ad5 mutants 
Synergy assays were performed with replicating and non-replicating Ad5 mutants with equol and 
resveratrol. The interactions were analysed by constructing isobolograms and determining combination 
indices (CIs) for combination ratios of each mutant and phytochemicals, as described in Methods Section 
Error! Reference source not found.. The results were summarized by counting the number of 
synergistic (CI≤0.8), additive (CI 0.8-1.2) and antagonistic (CI≥1.2) ratios from independent experiments 
repeated >2 times. Results for the double-deleted AdΔΔ mutant are shown in red. Results for non-
replicating mutants are shown in green. 
 
Table 23 Combination indices for adenoviral mutants with equol or resveratrol in PC-3 cells 
PC-3
Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol
1:125 0.35 0.43 0.34 0.89 0.39 2.59 0.49 0.87 0.49 1.03
1:625 0.27 0.46 0.28 0.77 0.30 1.34 0.48 0.83 0.32 0.85
1:3125 0.82 0.48 0.31 1.04 0.35 1.55 0.47 0.83 0.27 0.83
1:15625 0.92 0.54 0.34 1.04 0.39 1.49 0.52 0.85 0.24 0.78
Equol Resveratrol Equol Resveratrol
1.18 N/A N/A
1.03 N/A N/A
1.95 N/A N/A
1.30 1.33 N/A N/A
Ad5 pTG3602
AdE1A-12S dl312
Average combination indices from >2 experiments (except where N=1, numbers in italics) shown in Table 
22. The most effective ratio indices are highlighted in purple.  
 
 
 
 
 
 
PC-3
Synergistic Additive Antagonistic Total Synergistic Additive Antagonistic Total
Ad5 10 3 0 13 5 4 0 9
Ad5tg 5 0 0 5 1 4 0 5
10 1 0 11 2 5 0 4
9 0 0 9 1 3 0 5
5 0 0 5 1 4 0 5
AdE1A-12S 0 4 2 6 0 1 1 2
dl312
DU145
Synergistic Additive Antagonistic Total Synergistic Additive Antagonistic Total
Ad5 6 5 10 21 2 9 5 16
Ad5tg 1 1 2 4 1 1 2 4
2 1 5 8 1 2 5 8
9 2 1 12 4 2 2 8
5 2 1 8 0 5 3 8
AdE1A-12S 4 3 1 8 4 0 0 4
Ad5-Hey1 5 3 0 8 1 7 0 8
dl312 1 3 0 4 1 3 0 4
22Rv1
Synergistic Additive Antagonistic Total Synergistic Additive Antagonistic Total
Ad5 0 5 3 8 1 4 3 8
Ad5tg 0 1 0 1 1 0 0 1
0 1 0 1 0 1 0 1
AdE1A-12S 0 1 0 1 0 1 1 1
Ad5-Hey1 2 5 1 8 0 3 5 8
Equol Resveratrol
Equol Resveratrol
N/A (no EC50 for dl312 alone)
Equol Resveratrol
N/A (no EC50 for dl312 alone)
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Table 24 Combination indices for adenoviral mutants with equol or resveratrol in DU145 cells 
DU145
Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol
1:125 1.34 1.35 2.13 2.56 0.90 1.27 0.88 1.40 1.71 1.60
1:625 1.02 1.39 2.15 1.80 0.82 1.14 0.72 2.24 1.67 1.56
1:3125 0.93 1.14 0.91 1.16 0.56 0.91 0.63 1.12 1.28 1.18
1:15625 0.90 1.08 0.69 0.71 0.53 0.90 0.43 1.01 0.68 0.80
Equol Resveratrol Equol Resveratrol Equol Resveratrol
0.88 0.91 0.82 1.04 0.94 0.99
0.80 0.88 0.74 0.93 0.66 0.84
1.03 0.94 1.01 0.93 0.60 0.96
0.59 0.84 1.05 0.96 0.79 1.07
Ad5 Ad5tg
AdE1A-12S dl312 Ad5-Hey1
 
Average combination indices from >2 experiments (except where N=1, numbers in italics) shown in Table 
22. The most effective ratio indices are highlighted in purple.  
 
Table 25 Combination indices for adenoviral mutants with equol or resveratrol in 22Rv-1 cells 
22Rv-1
Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol Equol Resveratrol
1:250 1.81 1.25 1.06 1.20
1:1250 1.24 1.23 1.05 1.23
1:6250 0.95 1.16 1.14 1.26
1:31250 0.84 0.60 0.97 0.77 1.14 0.85 1.19 0.83 0.65 1.26
Ad5 Ad5tg AdE1A-12S Ad5-Hey1
 
Average combination indices from >2 experiments (except where N=1, numbers in italics) shown in Table 
22. The most effective ratio indices are highlighted in purple.  
 
In conclusion, these synergy studies highlighted that PC-3 cells were the most easily 
sensitised, as they produced the most synergistic interactions, compared to 22Rv-1 and DU145 
cells. The lowest average CI was obtained in PC-3 cells with AdΔΔ (ratio 1ppc:15625nM, 
CI=0.24). Equol induced a greater number of synergistic responses compared to resveratrol. 
Most notably, equol acted synergistically with the non-replicative mutant Ad5-Hey1 in both 
22Rv-1 and DU145 (not tested in PC-3 cells). 
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4 Discussion 
 
Selectively replicating Ad5 mutants are attractive anti-cancer therapeutics currently being 
developed for use in the clinic. However, their efficacy as a single modality has been limited. 
Combining Ad5 oncolytic vectors with chemotherapeutic drugs, as well as radiation, has 
proven successful in enhancing the anti-tumour potency, whilst still retaining cancer 
selectivity.  
 
In view of the demonstrated anticancer benefits of phytochemicals, we hypothesized that these 
non-toxic compounds might also enhance tumour cell killing in combination with Ad5. This 
could pave the way for the development of therapeutic phytochemicals for oral administration 
to patients treated with oncolytic adenoviruses, avoiding systemic side-effects from non-
targeted chemo- and radiotherapies. Specifically, we conceived that phytochemicals which 
inhibit the MAPK pathway might be able to enhance the expression of CAR, a well-known 
Ad5 receptor, enabling greater adenoviral infectability and enhancing cell death. We found an 
increase in viral uptake and a striking synergistic induction of cell death in cells treated with 
equol or resveratrol and Ad5. Curcumin, EGCG and genistein could also sensitise PCa cells to 
Ad5-induced cell death although the effects were more modest. We therefore decided to focus 
on equol and resveratrol to determine the underlying mechanism for synergy with Ad5.  
 
We found that equol and resveratrol induced apoptosis in DU145 cells, and to a lower extent in 
PC-3 cells, and that the addition of Ad5 enhanced the apoptotic response in these cell lines. 
Apoptosis levels in 22Rv-1 cells remained very low, so we considered whether additional cell 
death mechanisms might be involved in combination-induced cell death. Equol and resveratrol 
alone induced autophagy in 22Rv-1 and PC-3 cells, while Ad5 alone seemed to repress 
autophagy. Cell viability data using pharmacological autophagy modulators suggest that 
autophagy may perform a survival function in these cells rather than acting as a cell death 
mechanism. The execution of cell death in response to combination treatments is cell line-
dependent and appears to involve apoptotic, autophagic and most certainly additional 
pathways. 
 
Synergy studies with replication-selective mutants demonstrated the in vitro potential of using 
equol and resveratrol for specific targeting of cancer cells. Combinations with equol 
demonstrated the most encouraging results in DU145 cells with AdΔE1B-19K and with AdΔΔ 
in PC-3 cells. The potency of these combinations remains to be verified in vivo. 
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4.1 Curcumin, EGCG and genistein are antagonistic with Ad5 
under certain conditions 
Combination assays showed that curcumin and EGCG treatment could enhance, but also 
decrease, cell death with Ad5. Ad5 EC50 values were increased more than 6-fold in PC-3 cells 
pretreated with EGCG, and to a lesser extent when the phytochemical was added 
simultaneously or 24h after infection. One reason for this could be the reported inhibitory 
effect of EGCG on the adenoviral protease (Weber et al., 2003). As described in Section 
1.2.3.8, the viral protease is instrumental in allowing Ad5 escape from the endosome and 
delivery to the nucleus, as well as for viral packaging later in the viral life-cycle. EGCG-
mediated inhibition of the viral protease could therefore contribute to the antagonistic effect 
observed with Ad5, although the IC50 for the protease was reported to be 109µM which is 
higher than any of the concentrations used in our combination assays (<25µM). 
 
EGCG was also the most cytotoxic phytochemical out of the five tested in this study. We 
observed the largest antagonistic effects with Ad5 when cells were pre-treated for 24h before 
infection. EGCG may therefore induce apoptosis which could block cell cycle progression, 
preventing viral replication and causing cell death before the virus is able to hijack the cellular 
machinery and express viral proteins required for the synergistic effect.  
 
Although we found few synergistic interactions between Ad5 and EGCG, this phytochemical 
has previously been found to enhance cell death in PCa cells synergistically with other 
cytotoxic agents such as TRAIL (Siddiqui et al., 2008). LNCaP cells, which are naturally 
resistant to TRAIL, were shown to be sensitised by EGCG-mediated Akt inhibition that blocks 
prosurvival signalling, lowering the sensitivity threshold of the cells for TRAIL and inducing 
apoptosis. This may indicate that combining EGCG with Ad5 causes a different response in 
the cells compared to death-inducing TRAIL. 
 
Curcumin also antagonised cell death with Ad5 in cells treated both 24h before or after 
infection. There were fewer antagonistic responses in 22Rv-1 cells, but none of the conditions 
could significantly enhance cell death. Li et al. showed that curcumin induces apoptosis via the 
inhibition of Akt and the downregulation of the MDM2 oncogene in PCa and breast cancer 
cell lines (Li et al., 2007). Furthermore, in LNCaP and PC-3 cells, curcumin has been found to 
cause growth arrest, blocking the cell cycle by preventing the G1/S transition by upregulating 
p21 and p27 expression and inhibiting the expression of cyclins D and E (Srivastava et al., 
2007). This inhibition of cell cycle progression beyond G1, in addition to the premature 
induction of apoptotic cell death, could explain the negative effects of curcumin we observed 
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with Ad5 on cell death since the prevention of S-phase induction would block viral gene 
expression and subsequent viral replication. In addition, it is well known that cyclin E is 
required for efficient viral replication (Zheng et al., 2008).  
 
We also chose to discard genistein as a potential enhancer of cell death with Ad5 because 
although this phytochemical showed some potent reductions in Ad5 EC50 values, the responses 
were not dose-dependent: the higher doses of genistein tested actually caused antagonism in 
both 22Rv-1 and PC-3 cells. A number of epidemiological and in vivo studies suggest that 
genistein consumption may be chemopreventive (Magee & Rowland, 2004). However, a 
biphasic effect on cell growth by this phytochemical has been observed in a number of breast 
cancer cell lines and immortalized nontumorigenic prostate epithelial cells (Wang et al., 2006). 
Furthermore, transgenic adenocarcinoma of the mouse prostate (TRAMP) mice which 
consumed low doses of genistein suffered from an aggressive progression of PCa (El Touny & 
Banerjee, 2009). In vitro, El Touny et al. found that the equivalent concentration of genistein 
increased PC-3 cell proliferation and invasion via estrogen and PI3K signalling. These 
observations highlight the potential risk of detrimental effects by genistein. The situation in 
vivo in combination with Ad5 might be different, depending on the balance of beneficial and 
unfavourable systemic effects, but this was beyond the scope of the project. 
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4.2 Equol and resveratrol act synergistically with Ad5 
 
Equol and resveratrol were found to act synergistically with Ad5 on cell death in both AR-
positive and negative cell lines. Ad5 EC50 values were reduced 9-fold by equol and 17-fold by 
resveratrol in PC-3 cells which are the most resistant to the virus. In more permissive cell 
lines, equol reduced Ad5 EC50 values 6-fold (22Rv-1) and 5-fold (DU145), while resveratrol 
reduced Ad5 EC50 values 3-fold (22Rv-1) and 8-fold (DU145). The largest reductions in Ad5 
EC50 values were observed in cells treated simultaneously with phytochemical and Ad5.  
 
4.2.1 Equol and resveratrol enhance the permissivity of PCa cells 
to Ad5 infection 
Equol and resveratrol enhanced the infectability of the cell lines, both in terms of the 
percentage of cells infected and the average viral load per cell. However, the increase in viral 
uptake was not reflected in the levels of viral replication. In fact, both phytochemicals 
repressed viral replication in DU145 and PC-3 cells. No major effects on viral replication were 
detected in 22Rv-1 cells that were the least sensitive to the phytochemicals. The mechanism 
behind the decrease in viral replication does not involve phytochemical-mediated cell cycle 
arrest, since equol and resveratrol allowed and even enhanced the induction of S phase which 
is required for viral replication.  
 
We deduced that the synergy observed between Ad5 and these phytochemicals could be due to 
greater permissivity of the cell lines to viral infection, perhaps enhancing early viral gene 
expression and thereby increasing the sensitivity of cells to combination-induced cell death. 
The synergistic interaction is likely to require E1A to transactivate the expression of other viral 
proteins that might be involved in combination-induced cell death. For example, E4-orf4 has 
been proposed to induce cell death via mitotic arrest and remodelling of the actin cytoskeleton 
(Robert et al., 2006). E3-11.6K encodes the adenovirus death protein (ADP) which could also 
be involved in the combination-induced cell death mechanism (Tollefson et al., 1996). The 
involement of these proteins in combination-induced cell death could be investigated further 
by characterising their expression. The adenoviral cell death mechanism is discussed futher in 
Section 4.3.  
 
Based on our findings, a key factor in the synergistic enhancement of cell death appears to be 
the permissivity of cells to Ad5 infection, which was enhanced by equol and resveratrol. It has 
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been recognised that insufficient tumour transduction by oncolytic adenoviruses is an 
important factor limiting the antitumoral efficacy of therapeutic mutants (Krasnykh et al., 
2000; Kruyt & Curiel, 2002). Efforts to improve transduction have centred on retargeting 
mutants to alternative receptors, such as αV integrins, or enhancing the expression of the 
adenoviral receptor, CAR (Glasgow et al., 2006; Mathis et al., 2005).  
 
A number of chemotherapeutic drugs, in particular histone deacetylase (HDAC) inhibitors, 
were reported to enhance CAR expression, enabling improved transduction of a variety of 
cancer cell types (Goldsmith et al., 2003; Hemminki et al., 2003; Kitazono et al., 2002; 
Okegawa et al., 2005). A subsequent investigation also identified phytochemicals which 
upregulate CAR expression in human bladder cancer cells (Pong et al., 2006). Most notably, 
this study identified genistein as the most potent CAR inducer out of a screen of 58 
phytochemicals. Genistein was also found to dramatically synergise with the HDAC inhibitor 
FR901228 to heighten CAR expression. Pong et al.’s study demonstrated the potential of 
phytochemicals to induce viral uptake although their study did not include equol or resveratrol.  
 
We monitored Ad5 transduction of cells using a replication-defective mutant expressing GFP 
from a CMV promoter replacing the E1 genes. Kim et al. recently showed that the cytotoxic 
drug doxorubicin could enhance transgene expression from the CMV promoter by 
upregulating the NFκB transcription factor that binds to and transactivates the CMV promoter 
(Kim et al., 2007). CMV promoter activity has also been demonstrated to be increased by 
DNA-damaging agents such as cisplatin and by UV exposure in the context of adenoviral-
mediated transgene delivery (Zacal et al., 2005). Despite these considerations, we are 
confident that the increase in GFP-positive cells and the median fluorescence observed were 
not simply due to enhanced transcription from the CMV promoter as the increased infectability 
was also observed in phytochemical-treated cells by qPCR measuring viral genome copy 
numbers 3h post-infection. In addition, we can probably rule out effects via NFκB since both 
equol and resveratrol have been reported to inhibit NFκB activation (Estrov et al., 2003; Kang 
et al., 2005). Finally, equol and resveratrol do not induce DNA-damage at the low 
concentrations used in our studies, so would not function in a similar way to cisplatin or UV.  
 
Initially we hypothesised that the phytochemicals might be able to mediate enhanced cellular 
infectability by inhibiting the MAPK pathway, leading to an increase in CAR expression. This 
has been demonstrated in a panel of cell lines using pharmacological inhibitors (Anders et al., 
2003a). Although statistically significant increases in CAR cell surface expression were 
detected in 22Rv-1 cells treated with phytochemicals, the increases were small. In PC-3 cells, 
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CAR levels remained extremely low while CAR expression was already maximal in DU145 
cells. Consequently, the increases in viral uptake and enhanced cytotoxicity could not be 
explained by increased cell surface expression levels of CAR alone.  
 
CAR expression was also monitored in LNCaP cells where resveratrol had no effect and equol 
actually reduced the percentage of cells expressing the receptor. The use of this cell line in 
further studies was hampered by difficulties in growing these cells and their variability 
between different clones, passages and source. Nevertheless, it would have been interesting to 
analyse the infectability of LNCaP cells in response to phytochemical treatment to determine 
whether the decreased CAR expression in response to equol also reduced permissivity to Ad5 
infection.  
 
Nevertheless, our results support the notion that the infectability of cell lines is not determined 
solely by CAR expression, but also internalization receptors (integrins αVβ3 and αVβ5), 
alternative receptors such as HS-GAGs, and additional unidentified factors (Dechecchi et al., 
2001). The expression of HS-GAGs in untreated and phytochemical-treated PCa cells is 
unknown. It is possible that other unidentified adenoviral receptors might also be present that 
could be upregulated by equol and resveratrol. 
 
Furthermore, based on the analysis of αVβ3 and αVβ5 integrins and CAR expression, DU145 
cells would be expected to be the most permissive cell line to Ad5 infectability. However, 
instead, we found that both 22Rv-1 and LNCaP cells were more infectable than DU145 cells, 
although the former two cell lines showed low levels of integrins and high (but lower than 
DU145!) levels of CAR. This suggests that there may be additional receptors present on 22Rv-
1 and LNCaP cells which render these cells more permissive to Ad5 infection.  
 
In accordance with our data, Okegawa et al. detected the highest levels of CAR in DU145 
(82% cells CAR-positive), intermediate levels in LNCaP (63% cells CAR-positive) and the 
lowest levels in PC-3 (35% cells CAR-positive) (Okegawa et al., 2000). However, in contrast 
to our observations, using a replication deficient adenovirus expressing CMV-βgal, they found 
that DU145 cells were the most infectible. Another study found that at an MOI of 30, only 
24% of DU145 cells were infected with a non-replicating GFP-expressing virus, while 78% of 
LNCaP cells and 5% of PC-3 cells were GFP-positive (Pandha et al., 2003). These results 
correlate better with our results. Although our data clearly showed a correlation between the 
levels of expression of CAR and both αV-integrins in PC-3 cells and the low transduction rate 
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of these cells, no clear correlation was observed in DU145, 22Rv-1 and LNCaP cells. This 
suggests that additional adenoviral receptors are likely to be involved in the infection process.  
 
Whether the increased infectability imparted by phytochemical treatment in vitro can also be 
observed in vivo remains to be determined. In vivo biodistribution following systemic 
administration of Ad5 vectors is reported to be independent of CAR expression on target 
tissues (Alemany & Curiel, 2001; Fechner et al., 1999). As described in Section 1.3.2.3, in 
humans, Ad5 binds to erythrocytes in the blood via CAR or CR1 (Carlisle et al., 2009). This 
interaction is absent in mice, since murine erythrocytes lack CAR. In these animals, i.v. 
injection of Ad5 results in liver infection mediated via binding of Ad5 hexon with blood 
coagulation factors, in particular Factor X (Waddington et al., 2008). In addition, the specific 
interaction of Ad5 with Kupffer cells has recently been suggested to be mediated via 
Scavenger Receptor-A (SR-A) (Xu et al., 2008). These macrophage receptors function as part 
of the immune system and recognise conserved motifs on pathogens and negatively-charged 
material, including the Ad5 capsid. Haisma et al. demonstrated that Ad5-resistant Chinese 
Hamster Ovary (CHO) cells could be transduced by transfecting them with SR-A and that this 
interaction can be abolished by polyinosinic acid, an SR-A ligand (Haisma et al., 2009). The 
authors suggest that SR-A binding of Ad5 could trigger a defense mechanism, as they noted 
that Ad5 is sequestered in autophagosome-like vesicles in these cells, which subsequently 
fused with lysosomes. This pathway could therefore represent another route for degradation of 
Ad5. To avoid these ‘Ad5 traps’, we plan to first conduct in vivo experiments delivering Ad5 
i.t. in mouse xenograft models.  
 
4.2.2 Equol and resveratrol-induced cell death 
Equol and resveratrol lowered Ad5 EC50 values in three PCa cell-lines, independently of their 
AR status. We observed an enhanced induction of apoptosis in DU145 and PC-3 cells infected 
with Ad5 and treated with phytochemicals. Inhibition of the caspases using the 
pharmacological inhibitor zVAD-fmk reduced phytochemical-induced cytotoxicity in DU145 
cells by about 50%. However, in PC-3 cells, caspase inhibition did not decrease cell death 
caused by equol and resveratrol alone. In 22Rv-1 cells, the phytochemicals alone induced a 
modest apoptotic response which was slightly decreased by zVAD-fmk. 
 
Both PC-3 and DU145 cell lines have defective apoptotic signalling. PC-3 cells have a 
homozygous mutation in p53 which generates a premature stop codon so the cells lack p53, 
and DU145 cells harbour a mutated form of p53 (Isaacs et al., 1991). 22Rv-1 cells express 
wild type p53 although immunohistochemistry staining has shown that its expression is 
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restricted to only 10% cells (van Bokhoven et al., 2003). However, members of our lab have 
detected strong p53 expression in this cell line by Western blot.  
 
Marcelli et al. saw that there was a loss in mitochondrial membrane potential in both DU145 
and PC-3 cells in response to the apoptosis inducer staurosporine (STS) although downstream 
events including caspase activation and PARP cleaveage were absent in PC-3 cells and 
delayed in DU145 cells (Marcelli et al., 2000b). These findings correlate with our observations 
that both cell lines display loss of mitochondrial membrane potential in response to 
phytochemical treatment and only DU145 cells showed significant levels of caspase-3 
activation. Marcelli et al. propose that STS-treated DU145 and PC-3 cells die by a necrotic-
like process, based mostly on morphological studies.  
 
The PCa cell lines also exhibit enhanced activation of antiapoptotic and cell survival pathways 
which might contribute to resistance to chemotherapy. For instance, DU145 and PC-3 cells 
express the inhibitor of apoptosis protein (IAP) survivin (Tamm et al., 1998). Bcl-XL is present 
in both cell lines, at higher levels in PC-3 cells, and both DU145 and PC-3 cell lines appear to 
express Bcl-2, while DU145 cells lack proapoptotic Bax (Marcelli et al., 2000b; Skjoth & 
Issinger, 2006). 22Rv-1 cells also have high levels of Bcl-2 (Skjoth & Issinger, 2006). These 
aberrations might explain the resistance of these cells to some chemotherapeutic drugs, as well 
as to phytochemical-induced cytotoxicity.  
 
Resveratrol influences a variety of genes and proteins involved in cell cycle control and 
apoptosis, as described in Section 1.4. However, its ability to trigger apoptosis alone is 
reported to be modest, although it can potentiate the induction of apoptotsis by cytokines and 
chemotherapeutic agents (Gatz & Wiesmuller, 2008). Resveratrol has been shown to sensitise 
DU145 and PC-3 cells to cell death induced by death receptor-targeting agents, such as 
TRAIL, Fas and TNFα, but was less effective with compounds inducing apoptosis via 
alternative signalling pathways, such as etoposide, paclitaxel, etc. (Gill et al., 2007; Shankar et 
al., 2007). Gill et al. found that PC-3 cells may be less sensitive to resveratrol than DU145 
cells due to the constitutively active status of Akt in PC-3 cells which promotes survival. Fulda 
et al. identified cell cycle arrest in S-phase and survivin upregulation as key mechanisms by 
which resveratrol could sensitise a panel of carcinoma cell lines to chemodrug-induced 
apotosis, independently of p53 status (Fulda & Debatin, 2004). We also observed an increase 
in the proportion of cells in S phase in response to resveratrol treatment in all three PCa cell 
lines tested. This may enhance Ad5 gene expression and play a role in combination-induced 
cell death.  
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Intruigingly, one study has shown that the induction of apoptosis mediated by resveratrol in 
colorectal cancer cells was autophagy-dependent (Trincheri et al., 2008). The authors suggest 
that autophagy is initially rapidly and reversibly induced as a survival response, but that 
prolonged exposure to resveratrol triggers a switch to apoptotic cell death. A panel of ovarian 
cancer cell lines were also found to undergo a mixed type of cell death in response to 
resveratrol, regardless of the levels of Bcl-2 and Bcl-XL proteins they harboured (Opipari et 
al., 2004). Cells showed characteristic features of apoptosis, including release of cytochrome c 
and caspase activation, but ultrastructural changes were indicative of autophagic cell death. 
Our results are in agreement with the involvement of both apoptotic and autophagic pathways 
observed in PCa cells treated with resveratrol alone and in combination with Ad5, since 
caspase inhibition reduced resveratrol-induced cytotoxicity by half, and resveratrol activated 
LC3 and caused its relocation to autophagosomes. To further investigate the requirement of 
autophagy in resveratrol-mediated cytotoxicity we used the pharmacological inhibitors 3-MA 
and bafilomycin-A although the results did not provide clear evidence to elucidate this 
problem. Additional insights might be gained by interfering with autophagy using a more 
direct approach, such as with siRNA targeting of Atg5. 
 
The mechanisms responsible for equol-induced cytotoxicity are less well known. Hedlund et 
al. found that equol causes benign human prostatic epithelial cells (PrEC) to arrest in G1, but 
cell cycle progression in malignant PCa cell lines was not investigated, although their 
sensitivity to equol was established (Hedlund et al., 2003). A recent study found that equol 
induced cytochrome c release and downstream activation of caspase-3, -6, -7 and -9 in human 
breast cancer cells, supporting a role for apoptotis in equol-induced cell death (Choi et al., 
2009). The effect of equol on autophagy has not been reported. 
 
We did not find a significant effect on cell cycle progression in PCa cells after 24-48h 
treatments with equol, although we did observe an increase in the proportion of cells in sub-G1 
after 72h indicative of apoptosis. Equol also caused decreased mitochondrial membrane 
potential, caspase-3 activation and PS externalization, and caspase inhibition by zVAD-fmk 
protected PCa cells from equol-induced cytotoxicity. Our results therefore provide evidence of 
an induction of apoptosis, the level of which varied with the ability of each cell lines to 
undergo apoptosis. Autophagy was induced by equol but, similarly to resveratrol, its 
involvement in cell death remains unclear.  
 
Additional cell death mechanism may also be involved in phytochemical-induced cell death. 
For instance, it is possible that our inhibition of caspases using zVAD-fmk depresses necrotic 
cell death which contributes to phytochemical-induced cell death. Apoptosis has been found to 
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have a negative feedback on necrois, possibly via caspase-8 which has been shown to cleave 
the necrosis mediator RIP-1 (Vandenabeele et al., 2006). RIP1 is a serine/threonine kinase 
downstream of death receptors, such as TNF-R and TRAIL, and is thought to regulate necrosis 
(Festjens et al., 2007).  
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4.3 Ad5 induced cell death is neither apoptotic nor 
autophagic 
 
Although determining the adenoviral-induced mechanism of cell death was not an aim of this 
project, our experimental results allow us to confirm previously established findings and draw 
a number of additional conclusions described below.  
 
4.3.1 Ad5-infected cells are not rescued by caspase-inhibition 
Pan-caspase inhibition using the pharmacological inhibitor zVAD-fmk did not decrease Ad5-
induced cell death. This observation confirms the non-apoptotic nature of cell death induced 
by Ad5 (Abou El Hassan et al., 2004; Baird et al., 2008; Ito et al., 2006). However, 
surprisingly, at the highest dose, zVAD-fmk actually increased cell death with Ad5 in all three 
PCa cell lines while the inhibitor alone did not cause significant cell death, indicating 
sensitisation to non-apoptotic cell death. This has also been reported in other models where 
cell death is caused by autophagy or necrosis (Vandenabeele et al., 2006). The possible role of 
these pathways in Ad5-induced cell death is discussed below.  
 
4.3.2 Ad5 represses autophagy 
We found no evidence that adenoviral-induced cell death was autophagy-dependent in our 
studies with 22Rv-1, DU145 and PC-3 cells. Confocal microscopy showed that Ad5 did not 
cause relocalization of GFP-LC3 to autophagosomes and expression of the activated form of 
LC-3 (LC3-II), detected by Western blotting, was not induced by adenoviral infection. In fact, 
Ad5 reduced LC3-II expression induced by the phytochemicals.  
 
These results suggest that Ad5 might be able to repress the induction of autophagy. One 
possibility is that Ad5 mediates this through the activation of mTOR which has previously 
been reported to be induced (and necessary) during viral replication (O'Shea et al., 2005a). 
O’Shea et al. found that PI3K inhibition using the pharmacological inhibitor LY294002 or 
blocking mTOR directly by rapamycin abolished the activation of the mTOR effector p70S6K 
and decreased viral replication. p70S6K initiates translation by recruiting eIF4B to the pre-
initiation complex and enhances the RNA helicase acitivty of eIF4A which facilitates 40S 
ribosomal binding for translation initiation (Ma & Blenis, 2009). O’Shea et al. also found that 
another downstream target of mTOR, 4EBP1, was inactivated by Ad5, allowing eIF4E and 
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eIF4G translation initiation. The activation of mTOR was found to be mediated by E4-orf4, in 
cooperation with E4-orf1, which activates PI3K (O'Shea et al., 2005a). The expression and 
functioning of these viral proteins was postulated to mimic growth signals, maintaining mTOR 
activation, even under nutrient-poor conditions, to ensure the translation of viral proteins.  
 
This hypothesis is supported by earlier observations that 4EBP1 and 4EBP2 were 
hyperphosphorylated as early as 30min post-infection with wild-type Ad5 (Gingras & 
Sonenberg, 1997). 4EBP1 binds to and prevents the activity of eIF4E, a core-component of the 
eIF4F cap-binding protein complex required for translation initiation. In its 
hyperphosphorylated state, 4EBP1 cannot bind eIF4E and is therefore unable to inhibit cap-
dependent translation initiation. This is probably beneficial for Ad5 since early genes are 
translated in a cap-dependent fashion. The upregulation of cap-dependent translation during 
the early stage of infection is mediated by E1A-CR1 and it has been shown to be inhibited by 
rapamycin (Feigenblum & Schneider, 1996). During the late stage of the adenoviral infection, 
cap-dependent translation is inhibited by L4-100K to selectively repress cellular mRNA 
translation while ribosome shunting allows the translation of viral mRNAs containing a 
tripartite leader sequence (see Introduction Section 1.2.3.8).  
 
As discussed in Section 1.4.3.2.2, mTOR is also a major modulator of autophagy. In 
Saccharomyces cerevisiae, active TOR represses autophagy by preventing the initiation of 
autophagosome formation via Atg13 phosphorylation (Chang & Neufeld, 2009). Our finding 
that Ad5 seems to repress autophagy could therefore be a side-effect of viral mTOR activation. 
We also found that the autophagy inhibitor bafilomycin-A1 had no effect on the level of viral-
induced cell death. Since this inhibitor blocks the fusion of the autophagosome with the 
lysosome downstream of mTOR, this suggests that the modulation of signalling upstream of 
autophagy may be more important to Ad5 than the final stage of autophagy. Another inhibitor 
of the fusion of the autophagosome with the lysosome, such as chloroquine, could be used to 
confirm this hypothesis (Boya et al., 2005).  
 
In addition to ensuring translation of viral proteins, inhibiting autophagy could protect Ad5 
from the host immune system, since autophagy has been postulated to play a role in the anti-
viral response, and could therefore be detrimental to Ad5. Toll-like receptors which recognise 
foreign genomic material have been shown to activate autophagy in vitro. Similarly, protein 
kinase R (PKR), a potent inducer of the antiviral interferon response, can induce autophagy 
(Talloczy et al., 2002). A number of viruses have therefore evolved mechanisms counteracting 
the induction of autophagy and even hijacking the process to their own ends (Shoji-Kawata & 
Levine, 2009). For example, the herpes simplex virus (HSV)-1 infected cell protein 34.5 
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(ICP34.5) blocks autophagy by repressing PKR and inhibiting Beclin-1 (Talloczy et al., 2006). 
Similarly, the adenovirus VA RNAs are known to block PKR and the interferon pathway 
(Ghadge et al., 1994; Mathews & Shenk, 1991). Results from our lab show that VA1 can also 
inhibit autophagy (C. Binny et al, manuscript in preparation). The importance of autophagy in 
clearing adenoviral infections in vivo has not been investigated.  
 
Ad5 may also have evolved mechanisms to block autophagy to ensure progression to S phase. 
Autophagy has also recently been identified as an effector mechanism triggering senescence, a 
stable form of cell cycle arrest that functions to limit the proliferation of damaged cells (Young 
et al., 2009). This could be unfavourable to Ad5 as it would restrict cell cycle progression, 
which is necessary for productive infection.  
 
4.3.3 The effect of autophagy modulation on Ad5 cytotoxicity 
The induction of autophagy using rapamycin significantly increased Ad5 EC50 values in all 
cell lines, while, conversely, except in DU145 cells, repression of autophagy with 3-MA (an 
inhibitor of class III PI3K) had a sensitising effect and reduced Ad5 EC50 values. This indicates 
that, in 22RV-1 and PC-3 cells, autophagy probably functions as a protective cellular 
mechanism. The effect of autophagy inhibition on viral replication in these cells needs to be 
investigated to further characterize this protective effect.  
 
Our conclusion that autophagy can protect PCa cells against adenoviral-induced cell death is in 
contrast to two other reports. These studies found that combinations of a telomerase-driven 
adenoviral mutant and temozolomide, an autophagy-inducing chemodrug, or an E1A-CR2 
deletion mutant and RAD001, a derivative of rapamycin, induced autophagy and enhanced the 
anticancer effect in glioma cell lines (Alonso et al., 2008; Yokoyama et al., 2008).  
 
Based on these observations, Jiang et al have proposed a model whereby, during the late stages 
of infection, autophagosomes disrupt cellular membranes and promote the release of viral 
progeny (Jiang et al., 2008). Our data is not supportive of such a general and fundamental role 
for autophagy in adenoviral infection which might be cell line-specific. Nevertheless, this 
mechanism could possibly be occurring in our DU145 cells which were protected by 3-MA-
mediated autophagy inhibition. However, we speculate that the protective effect of 3-MA 
observed in DU145 cells may not be due to the prevention of autophagic cell death, since the 
induction of autophagy by rapamycin in DU145 was also protective. We hypothesise that the 
increased Ad5 EC50 value in DU145 cells treated with 3-MA might instead be due to 
unidentified off-targets effects of 3-MA. 
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It should be noted that the observations on which Jiang’s et al. model is based were made in 
glioblastoma cell lines. These cells are relatively resistant to apoptosis but readily undergo 
autophagic cell death (Furnari et al., 2007; Lefranc et al., 2007). Furthermore, E1A has been 
implicated in the regulation of viral protein translation, via 4EBP1 phosphorylation as well as 
p70S6K induction, hence its deletion in the mutants used could explain why autophagic cell 
death was observed under those conditions (Feigenblum & Schneider, 1996). Finally, both  
chemotherapeutic drugs used in combination with the adenoviral mutants have additional 
biological effects other than induction of autophagy which could play a role in the enhanced 
anticancer effects observed by the combination treatments. RAD001 is antiangiogenic and 
immunosuppressive, while the primary action of temozolomide is to induce DNA alkylation.  
 
Our data from studies in three PCa cell lines suggest that combining oncolytic adenoviral 
mutants with chemodrugs which act only by inducing mTOR and autophagy could hamper 
viral replication. The use of RAD001 or similar drugs with oncolytic adenoviral mutants 
should be investigated further to determine their effect on a wider range of cell lines as well as 
in vivo. In fact, the immunosuppressant and antiangiogenic effects of RAD001 may delay 
tumour growth such that the net spread of virus throughout the tumour might be improved. 
Therefore, overall, combining RAD001 with adenoviral mutants may be beneficial if the 
timing of addition is optimized (Homicsko et al., 2005). 
 
4.3.4 Adenoviral-induced cell death: a novel mechanism 
Having excluded apoptosis and autophagy as cell death pathways induced by Ad5 in PCa cell 
lines, we hypothesise that the adenoviral mode of cell death may involve an unidentified and 
mostly uncharacterised form of cell death.  
 
The inhibition of apoptosis has been reported to result in caspase-independent modes of cell 
death, such as autophagy and necrosis, which may function as ‘back-up’ cell death 
mechanisms in case apoptosis fails (Vandenabeele et al., 2006). Contrary to prior status as a 
basic, unregulated form of cell death, necrosis has recently been reclassified as a type of 
programmed cell death, as its regulation by specific transduction pathways is gradually being 
uncovered (Kroemer et al., 2009). Necrosis, now also known as necroptosis, is characterised 
by morphological features, such as cell swelling and loss of plasma membrane integrity, and 
the activity of receptor interactive protein 1 (RIP1). Apoptosis-deficient cells have been shown 
to be sensitised to metabolic stress and necrosis by the inhibition of autophagy (Degenhardt et 
al., 2006).  
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Since the PCa cells used in this study have deregulated apoptotic pathways, and Ad5 can 
prevent apoptosis and also downregulate autophagy in these cells, adenoviral infection may be 
forcing cells down an alternative mode of cell death such as necrosis. Indeed, necrosis has 
been postulated to function as part of the innate immune response against the invasion of 
foreign organisms, with viral inhibition of apoptosis serving as a signal to the host of the 
danger of infection.  
 
The molecular pathways involved in necrosis have recently been investigated in a genome-
wide siRNA screen (Hitomi et al., 2008). A key regulator of necrosis is RIP1, a 
serine/threonine kinase downstream of death receptors such as TNF-R and TRAIL. The TLR 
pathway, which has been reported to induce RIP1, was also found to be involved in necrosis 
signalling. Activation of RIP1 can lead to downstream inflammatory signalling, via NFκB, and 
cell death, perhaps by the induction of mitochondrial ROS production (Festjens et al., 2007).  
 
In contrast to apoptosis and autophagy that lead to the shutdown of protein synthesis, 
translation of mRNAs is allowed to proceed during necrosis (Saelens et al., 2005). If induced 
in host cells, this form of cell death would therefore not prevent Ad5 replication and would 
allow efficient release of progeny virions. However, investigating the involvement of necrosis 
in Ad5-induced cell death is hampered by the lack of specific positive markers of necrosis. 
Apart from distinct morphological features such as increased cell volume (oncosis) and 
organelle swelling, necrosis is characterised by decreased concentration of ATP, high mobility 
group box-1 (HMGB1) release, and the presence of an inflammatory response (Kroemer et al., 
2009). Although Ad5-infected cells do appear swollen, this is most likely a direct result of 
partial detachment and the accumulation of progeny virions due to viral replication. 
Furthermore, our colleagues found that ATP levels increased, rather than decreased, in 
response to infection with dl922-947 in ovarian carcinoma cells, and concluded that pure 
necrosis was not the Ad5-induced mode of cell death (Baird et al., 2008). Necrosis may be 
restricted by viral TNF-inhibitory mechanisms (discussed in Section 1.2.3.6), which would 
preclude the activation of RIP1 by this pathway. To assess the role of necrosis in adenoviral-
induced cell death under our conditions in PCa cells, the expression levels of RIP1 could be 
determined as a preliminary indicator of the activation of this pathway.  
 
Perhaps a more likely cell death mechanism in response to adenoviral infection (which is not 
mutually exclusive with necrois) is mitotic catastrophe. Cell cycle analyses with dl1520 
(Onyx-015, deleted in E1B-55K) determined that infected human umbilical vein endothelial 
cells (HUVEC) are able to overcome not only the G1/S, but also the G2/M checkpoint 
(Cherubini et al., 2006). Ad5 was shown to modulate the DNA damage response by blocking 
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the Mre11-Rad50-NBS1 (MRN) complex and ataxia-telangectasia-mutated (ATM) protein. 
While Ad5-infection caused deregulation of the cell cycle and induced cell death within 72h, 
the E1B-55K deletion mutant accumulated cells in G2/M, causing the generation of polyploid 
cells which died due to mitotic catastrophe. In addition to E1B-55K, the E4 proteins are 
implicated in cell cycle control beyond S phase. Cherubini et al showed that a mutant lacking 
the E4 region caused cells to accumulate in G2/M but did not generate >4N cells. E4-orf4 has 
recently been shown to upregulate cyclin E, which normally induces S phase, and caused an 
accumulation of >4N cells in a G1-like phase, resulting in mitotic catastrophe (Li et al., 2009). 
To determine whether this type of cell death might be induced in our cells, the expression 
levels of cyclin E could be monitored at late time-points as an indicator of unrestricted cell 
cycle progression beyond M, although we did not observe any significant >4N cell population 
24-72h post-infection.  
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4.4 Combination-induced cell death is cell line-dependent 
4.4.1 The response of AR-negative cell lines may differ according 
to PI3K/Akt/mTOR activation 
PC-3 cells were particularly sensitive to treatment with rapamycin, whereas no cytotoxicity 
was detected in DU145 cells, although exact EC50 values were not determined. Rapamycin 
blocks protein translation and cell growth, causing G1 cell cycle arrest and apoptosis. The 
sensitivity of different tumours to CCI-779, an ester of rapamycin, has previously been shown 
to be related to PTEN status (Neshat et al., 2001). PTEN is a tumour suppressive lipid 
phosphatase which modulates Akt activation and has a negative effect on mTOR. As discussed 
in Section 1.1.5, the loss of PTEN is critical in PCa tumorigenesis. Acquired mutations in 
PTEN have been found in 30-60% PCa tumours and correlate with advanced tumour stage and 
chemotherapeutic resistance (McMenamin et al., 1999). The action of PTEN in the PI3K 
pathway is illustrated in Figure 13.  
 
A number of studies have demonstrated that PC-3 cells are PTEN-null, whereas DU145 cells 
have retained PTEN expression (Grunwald et al., 2002; McMenamin et al., 1999; Neshat et 
al., 2001). The lack of PTEN in PC-3 cells may have led to the evolution of hyperactive 
mTOR and ‘addiction’ to activation of the PI3K pathway for growth, rendering PC-3 cells 
vulnerable to mTOR inhibition. DU145 cells may not be as sensitive to rapamycin since they 
are PTEN-positive and do not have constitutively activated Akt (Nakatani et al., 1999). DU145 
cells are probably not as dependent on the PI3K pathway and may instead require alternative 
proliferation pathways, which are not blocked by rapamycin. Resistance to rapamycin has also 
been observed in tumours where negative feedback loops involving the activation of MAPK 
and PI3K signalling cascades (Carracedo et al., 2008). This could be occurring in DU145 cells. 
However, Neshat et al. have found that, in comparison to other cell lines expressing intact 
PTEN, the IC50 of DU145 cells for CCI-779 is still relatively low (Neshat et al., 2001). DU145 
cells have been shown to have an activated mTOR, which could explain why this cell line 
shows some sensitivity to rapamycin, despite its independence from PI3K pathway activation 
(Sekulic et al., 2000). These observations and hypotheses are somewhat speculative since our 
results are based on experiments which need to be repeated to demonstrate reproducibility. The 
activation of upstream signalling proteins such as Akt and PI3K also needs to be examined. 
 
We observed no further sensitisation of (uninfected) PC-3 cells by rapamycin to resveratrol-
induced cell death, and co-treatment with equol actually repressed rapamycin cytotoxicity. 
This is in contrast to findings by Gründwald et al. who showed that resistance of PC-3 cells to 
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the topoisomerase II inhibitor doxorubicin can be reversed by rapamycin-mediated mTOR 
inhibition (Grunwald et al., 2002). Similarly, Wu et al. found that sensitivity to mitoxantrone 
or docetaxel could be increased additively by CCI-779 in DU145 and PC-3 xenograft 
experiments (Wu et al., 2005). The mTOR inhibitor RAD001 has also been shown to sensitise 
PCa cells to radiotherapy and induce autophagy, particularly in PTEN-null cells (Cao et al., 
2006). The discrepancy of our data with these studies highlights the need for others to repeat 
these experiments. Nevertheless, if proven reproducible, these results would indicate that the 
phytochemicals in combination with rapamycin function differently to highly cytotoxic agents 
such as DNA-damaging chemodrugs and radiation. Equol could be counteracting rapamycin-
mediated cytotoxicity directly, by enabling mTOR activation, or indirectly, but maintaining 
PI3K pathway activation, but this has not yet been shown. 
 
In Ad5-infected cells, rapamycin treatment was highly protective, with and without 
phytochemicals, in both DU145 and especially in PC-3 cells. The highest Ad5 EC50 values 
were obtained in rapamycin-treated infected cells with the lower doses of phytochemcials, 
rather than higher doses which are apoptosis-inducing. The protective effect of rapamycin in 
combination-treated cells could be due to the viral inhibitory effect of rapamycin discussed in 
Section 4.3.3. This could be studied by assaying viral replication in combination-treated cells 
with and without rapamycin, and by monitoring upstream signalling mediators such as Akt, 
mTOR and p70S6K. Another possibility is that the protective effect of rapamycin is viral-
replication independent, and rather delays onset of death by inducting autophagy which 
functions as a cell survival mechanism.  
 
In PC-3 cells, the inhibition of apoptosis using the pan-caspase inhibitor zVAD-fmk also 
imparted significant protection against combination-induced cell death, increasing Ad5 EC50 
values. PC-3 cells showed moderate levels of apoptosis induction in response to combination 
treatments in a phytochemical dose-responsive manner. This suggests that apoptosis may play 
a role in the cytotoxicity caused by the highest doses of phytochemicals in Ad5-infected cells. 
DU145 cells showed stronger induction of apoptosis but inhibition of caspase activity in this 
cell line had a smaller protective effect.  
 
Overall, cell death in DU145 and PC-3 cells is therefore probably due to a combination of 
pathways induced by Ad5 and the phytochemicals which results in overwhelming stress and 
cellular death. Further investigation into the expression and activation levels of upstream 
signalling proteins and cell death modulators is required to understand the mechanism in 
greater detail.  
 
 164 
4.4.2 The sensitivity of 22Rv-1 cells to autophagy modulation may 
be AR-dependent 
In contrast to the other two PCa cell lines, we found that the effect of rapamycin in 22Rv-1 
cells treated with combinations of Ad5 and phytochemicals was not protective. Rapamycin had 
no effect on Ad5 EC50 values except in infected cells treated with 100µM equol where it 
increased cell death (Figure 57 and Table 21). This sensitising effect was similar to the higher 
cytotoxicity observed in uninfected cells treated with rapamycin and equol (Figure 55). This 
effect, which was not observed in DU145 nor PC-3 cells, could be due to modulation of AR 
signalling by rapamycin.  
 
Rapamycin has been reported to stimulate AR expression and transcriptional activity via Akt 
and mTOR, enabling AR-positive cells to develop resistance and escape the growth-inhibitory 
effects of rapamycin (Wang et al., 2008b). However, the authors of this study also demonstrate 
that bicalutamide, a competitive inhibitor of AR ligand binding commonly used in the clinic 
(see Introduction Section 1.1.4), can sensitise AR-positive cells to rapamycin-induced 
cytotoxicity and overcome resistance. Wang et al. demonstrate that bicalutamide causes 
apoptosis by preventing the induction of the AR cell survival pathway, which is triggered by 
rapamycin. 
 
In our system, the enhanced cytotoxicity observed in 22Rv-1 cells treated with both equol and 
rapamycin could be due to the anti-androgenic effect of equol sensitising the cells to 
rapamycin-induced cytotoxicity. Equol has been reported to inhibit DHT, sequestering the 
ligand from the AR (Lund et al., 2004). Equol could therefore be acting similarly to 
bicalutamide and sensitising these cells to rapamycin. We are currently verifying whether, as 
in Wang et al.’s model, 22Rv-1 cells treated with equol and rapamycin undergo apoptosis. 
 
Resveratrol has also been shown to have a negative effect on AR signalling (Mitchell et al., 
1999). Resveratrol is thought to block AR signalling by inhibition of MEK which activates the 
AR by phosphorylation (Gao et al., 2004). Resveratrol may also be inhibiting AR signalling 
via the upregulation of Sirt1 which represses AR activity (Fu et al., 2006; Howitz et al., 2003). 
The different AR inhibitory mechanism of the phytochemicals may explain why the 
combination of rapamycin with resveratrol in Ad5-infected 22Rv-1 cells was not as sensitising 
as the combination with equol, although resveratrol was sufficient to prevent the protective 
effect of rapamycin.  
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Ad5 has been reported to down-regulate AR expression and transcriptional activity, an effect 
that has also been observed by us (S. Cheong et al., manuscript in preparation) and others 
(Hoti et al., 2007). Höti et al. suggest that the effect of Ad5 on AR is mediated by E1A 
competition for common transcriptional coactivators, although the region of E1A required for 
this response has not yet been identified. The suppression of AR by Ad5 and downstream 
survival pathways could explain why the effect of rapamycin in infected cells is not as 
protective as in AR-negative cell lines. Furthermore, the addition of two AR-repressive agents, 
Ad5 and equol, could act synergistically in sensitising cells to rapamycin-induced cell death. 
 
In AR-negative cell lines, this effect obviously does not occur, since DU145 and PC-3 cells 
lack the AR and are insensitive to growth stimulation by androgens. Rapamycin therefore 
principally acts as an autophagy-inducer in these cells. As discussed in Section 4.3.3, this is 
probably detrimental to Ad5 since rapamycin can abolish translation and induce senescence. 
This could explain the protective effect of rapamycin in DU145 and PC-3 cells infected with 
Ad5, with and without phytochemicals. This hypothesis will be verified by determining 
whether rapamycin also blocks viral replication in these cells.  
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4.5 Future directions 
 
Oncolytic adenoviral mutants are currently being developed and tested in the clinic for PCa 
(Freytag et al., 2007). It has been established that the anti-cancer effect of replication-selective 
Ad5 vectors can be significantly enhanced by multimodal treatments with chemo- or 
radiotherapy (Heise et al., 2000b; Kirn, 2001). However, these agents can lead to tumour 
resistance, and also cause significant side-effects. The work described in this thesis presents an 
alternative, novel and promising stategy to improve oncolytic efficacy in PCa cells using non-
toxic phytochemicals.  
  
In the future, we plan to verify the efficacy of combining equol and resveratrol with 
replication-selective Ad5 mutants in vivo using mouse xenograft models. We have developed 
suitable in vivo mouse xenograft models for all three PCa cell lines used in this thesis. Initial 
experiments to validate the concept will be performed using i.p. delivery of the 
phytochemicals and i.t. delivery of the virus. Once proof of concept is established, we hope to 
extend the studies using oral delivery of the phytochemicals, with the caveat that mouse 
metabolism of phytochemicals differs from human metabolism.  
 
The molecular interactions of the AdΔΔ mutant in combination with equol and resveratrol are 
currently being characterized. A number of encouraging in vivo studies have been conducted in 
our lab demonstrating the efficacy of this virus in both PCa and pancreatic cancer models 
(Öberg et al., submitted; Cherubini et al, unpublished data). Additional synergy assays will be 
performed to verify the supra-additive interaction between AdΔΔ and equol and resveratrol in 
PCa cells. The effect of combining phytochemicals with the non-replicating Ad5-Hey1 mutant, 
which expresses the AR co-repressor Hey1 under the control of the CMV promoter will also 
be tested, since combination treatment of both AR-positive and -negative cells in vitro has 
shown promising results.  
 
The selectivity of phytochemical enhancement of cell death with Ad5 also remains to be 
examined. We observed an increased viral uptake in cells treated with equol or resveratrol but 
we anticipate that this will not occur in non-tumourigenic cells and that tumour selectivity will 
be maintained in the presence of phytochemicals. The sensitivity of normal PrEC cells to 
combination treatments will be tested in vitro by assaying cell viability, viral uptake and viral 
replication. The selectivity and biodistribution of oncolytic mutants will be determined in vivo.  
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We established that equol and resveratrol can act synergistically with Ad5 to enhance PCa cell 
death, despite decreasing viral replication in DU145 and PC-3 cells. This is counter-intuitive. 
To understand the mechanisms responsible for the inhibition of viral progeny production in 
phytochemical-treated cells, the expression of E1A and additional viral proteins, such as 
hexon, protease or L4-100K, could be characterized, both in terms of expression levels and the 
timing of their expression. This could help identify which step of the viral replication cycle is 
blocked by the phytochemicals, causing decreased viral titres. The effect of rapamycin on Ad5 
replication in PCa cell lines will also be determined.  
 
A more in-depth study of changes in cell cycle progression in response to combination 
treatments is also warranted. This will be done by staining cells with bromodeoxyuridine 
(BrdU) to distinguish between cell populations in G2 and M. The expression patterns of cell 
cycle proteins, including cyclins B and E and cdc25a will be analysed.  
 
Further investigations into the combination-induced cell death mechanism are needed to gain a 
greater understanding of the synergy observed between Ad5 and equol and resveratrol. As 
discussed in Section 4.2, viral proteins such as E1A, ADP and E4-orf4 could be involved. 
Additional insights might also be gained from observing cellular morphology at the 
ultrastructural level. The expression of LC3-II and caspase-3 will be verified under the 
conditions tested. 
 
Currently, our observations suggest that autophagy functions as a survival mechanism in 
response to combination treatments. The autophagic response will be quantified in 
combination-treated cells by flow cytometry on cells stained with acridine orange, a dye 
specific for acidic cellular compartments. The expression of upstream signalling proteins 
involved in regulating the induction of autophagy, including Akt, PI3K and mTOR, will be 
analysed. Clarification of the role of autophagy in phytochemical-, Ad5- and combination-
induced cell death will be sought by determining the effect of specific inhibition of autophagy 
using siRNA to knock down the essential autophagy protein Atg5.  
 
The differential response observed in 22Rv-1 cells treated with rapamycin compared to the 
protective effect seen in DU145 and PC-3 cells will also be elucidated. The effect of 
rapamycin on autophagy and AR signalling, with and without phytochemicals, will be 
delineated by detecting the expression levels of LC3 and AR activity. Upstream signalling via 
Akt and the PI3K pathway will be analysed and the effect of inducting autophagy in 
combination-treated 22Rv-1 cells will be verified using alternative autophagy inducers to 
rapamycin. 
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Finally, the cross-talk between apoptosis, autophagy and necrosis will be explored by 
examining the role of caspase-8 and RIP1 which are thought to be at the interface of the two 
pathways (Vandenabeele et al., 2006). A greater understanding of cell death mechanisms 
induced by Ad5 and phytochemicals will pave the way to designing improved anticancer 
therapeutic options.  
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